

Editor: M J Davies Associate Editors: Peter Mills, H G Just

Assistant Editors: R Gordon Murray (general cardiology), Janet M McComb (electrophysiology),  
John L Gibbs (paediatric cardiology) Statistical Advisor: Ian Ford

Technical Editor: Jane Dawson Editorial Assistant: Samantha Shaul

## International Advisory Board

Antonio Bayes de Luna (Barcelona, Spain)  
George A Beller (Charlottesville, USA)  
Nicholas A Boon (Edinburgh)  
Roger M Boyle (York)  
Jean-Paul Broustet (Bordeaux, France)  
John G F Cleland (Glasgow)  
Stuart M Cobbe (Glasgow)  
Peter Cummins (Birmingham)  
Henry J Dargie (Glasgow)  
Pim J de Feyter (Rotterdam, The Netherlands)  
Carlo di Mario (Milan, Italy)  
Yoshinori L Doi (Kochi, Japan)  
Roberto Ferrari (Brescia, Italy)  
Clifford J Garratt (Leicester)

Bernard J Gersh (Washington, DC, USA)  
Roger Hall (Cardiff)  
Stephen C Hammill (Rochester, USA)  
Axel Haverich (Kiel, Germany)  
Otto M Hess (Zürich, Switzerland)  
Alan B Houston (Glasgow)  
Stewart Hunter (Newcastle upon Tyne)  
Barry Keeton (Southampton)  
Paul Klugfield (New York, USA)  
Wolfgang Kübler (Heidelberg, Germany)  
Paul M McKeigue (London)  
Bernhard Meier (Bern, Switzerland)  
Richard L Popp (Stanford, USA)  
Nina Rehnqvist (Stockholm, Sweden)

Edward Rowland (London)  
John Sanderson (Hong Kong)  
Iain A Simpson (Southampton)  
Jordi Soler-Soler (Barcelona, Spain)  
Giuseppe Specchia (Pavia, Italy)  
Eric Topol (Cleveland, USA)  
Tom Treasure (London)  
Sylvan Lee Weinberg (Dayton, USA)  
Harvey White (Auckland, New Zealand)  
Peter Wilde (Bristol)

Editor: BMJ

Editor Emeritus: Dennis M Krikler

## Guidance on publishing in *Heart*

### Scope

*Heart* is an international journal of cardiology. Though clinical cardiology is its central theme *Heart* also publishes basic science papers with a clear clinical application. Please see *Heart* 1996;75:1-2 for guidance on the main categories of papers and their word limits.

### Ethical standards

The study must comply with the Declaration of Helsinki. The research protocol must have been approved by the locally appointed ethics committee and informed consent must have been obtained from the subjects (or their parents).

### Submitting a paper

Intending authors should send four paper copies of their text (including tables) and figures and, where practicable, one electronic copy to: Editor, *Heart*, 9 Fitzroy Square, London W1P 5AH.

**Papers and disks must be prepared in accordance with the guidelines printed in the January issue (*Heart* 1996;75: 103-5) and be accompanied by a covering letter that addresses the following points:**

#### AUTHORSHIP

- A covering letter (where possible giving telephone, fax and e-mail details of the corresponding author) must be signed by all authors stating that they have read and approved the paper and that the work has not been, and will not be published elsewhere.
- We want authors to assure us that all authors included on a paper fulfil the criteria for authorship (International Committee of Medical Journal Editors. *Uniform requirements for manuscripts submitted to biomedical journals*. Philadelphia: ICMJE, 1993). In addition we need assurance that all those who fulfil the criteria have been included as authors.

#### CONFLICT OF INTEREST

Please inform us of any grant, business interest, or consultancy that could lead to a conflict of interest.

#### COPYRIGHT

- All authors will be required to transfer copyright of their articles to the journal before publication.
- You must send *Heart* written permission from publishers and authors to reproduce or adapt previously published illustrations, tables, or extensive quotations.

#### HELPING THE REVIEW PROCESS

- You may suggest three suitable reviewers for your paper.
- We encourage authors to send copies of any previous referees' reports on their research and indicate how these comments have helped the authors to improve the submitted paper. This may be helpful to our editors and reviewers.
- If you have papers (published or submitted elsewhere) that overlap with the present submission, send us copies of them and indicate if there are patients common to both studies.

#### Receipt and return of typescripts

We acknowledge receipt of all new papers. The reference number given on the acknowledgement letter should be quoted on all subsequent correspondence and in telephone inquiries. Typescripts of papers that are not accepted for publication will not be returned. We will endeavour to return original artwork and floppy disks for rejected papers.

#### Queries

If you have any queries about the journal's requirements please contact the editorial office:

Tel: +44 171 383 4006

Fax: +44 171 388 0323

e-mail: 100536.2733@compuserve.com

## NOTICE TO SUBSCRIBERS

*Heart* is published monthly. The annual subscription rates are £207.00 (USA \$325.00). Orders should be sent to the Subscription Manager, *Heart*, BMJ Publishing Group, BMA House, Tavistock Square, London WC1H 9JR. Orders can also be placed with any leading subscription agent or bookseller. Subscribers may pay for their subscriptions by Access, Visa, or American Express by quoting on their order the credit or charge card preferred together with the appropriate personal account number and the expiry date of the card. (For the convenience of readers in the USA subscription orders with or without payment may also be sent to British Medical Journal, PO Box 408, Franklin, MA 02038, USA. All inquiries, however, must be addressed to the Publisher in London.) **All copies are despatched by air-speed.** First class rates available on request.

## NOTICE TO ADVERTISERS

Applications for advertisement space and for rates should be addressed to the Advertisement Manager, *Heart*, BMA House, Tavistock Square, London WC1H 9JR (0171 383 6330).

COPYRIGHT © 1996 by *Heart*. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of *Heart*.

ISSN 1355-6037

Published by the  
BMJ Publishing Group and printed in England by  
Thanet Press Limited, Margate, Kent

# ANNUAL MEETING OF THE BRITISH CARDIAC SOCIETY

Scottish Exhibition and Conference Centre, Glasgow

7-9 May 1996

## PROGRAMME AND ABSTRACTS OF PAPERS

- ★ The **Meeting** will be held in Halls 1 and 2 of the SECC as well as the Castle 1/2 Suite and the Argyll Suite in the Moat House Hotel.
- ★ **Posters** will be presented in the Exhibition Hall (Hall 4) of the SECC during the coffee, lunch and tea breaks.
- ★ Together with the posters, **moderated posters** will be on display throughout the meeting in the Exhibition Hall (Hall 4).
- ★ **Catering** facilities are situated at three points in the Exhibition Hall (Hall 4).
- ★ A **location plan** of the meeting rooms and exhibition hall is printed on the inside back cover of the programme.
- ★ The **contact telephone number** for the duration of the meeting is 0141 275 6229.
- ★ The **exhibitors** are thanked for their support of the meeting. All those attending the meeting are encouraged to visit the exhibition.
- ★ The Society thanks Bayer UK for the provision of the conference bags.



The Society gratefully acknowledges financial support from  
Glasgow District Council and Strathclyde Regional Council



### BRITISH CARDIAC SOCIETY

#### OFFICERS:

Dr R Balcon	President	(1995-97)
Prof R W F Campbell	President Elect	(1995-97)
Dr I Hutton	Honorary Treasurer	(1995-97)
Dr J G F Cleland	Honorary Secretary	(1994-96)
Dr N Brooks	Assistant Secretary	(1994-96)

#### COUNCIL: 1995-96

Prof A A J Adgey	Prof D de Bono
Dr N A Boon	Prof R Hall
Dr R M Boyle	Dr S Hunter
Dr P Cummins	Mr H O'Kane
Prof H J Dargie	Dr M F Shiu
Prof M J Davies	Dr R H Swanton

**Please remember to bring this supplement  
with you to the Meeting**

British Cardiac Society  
9 Fitzroy Square  
London, W1P 5AH

Telephone: 0171-383 3887  
Fax: 0171-388 0903

---

**BRITISH CARDIAC SOCIETY**


---

**NINE AFFILIATED GROUPS**

1. **British Pacing & Electrophysiology Group (BPEG)**  
**President:** Dr R Charles, Liverpool Cardiothoracic Trust (0151 228 1616)  
**Treasurer:** Dr D Cunningham, Glasgow Royal Infirmary (0141 330 4643)  
**Secretary:** Dr A Nathan, St Bartholomew's Hospital (0171 601 8708)
2. **British Cardiovascular Intervention Society (BCIS)**  
**Chairman:** Dr J Perrins, Leeds General Infirmary (0113 2316072)  
**Treasurer:** Dr T R D Shaw, Western General Infirmary, Edinburgh (0131 537 1843)  
**Secretary:** Dr M Norell, Hull Royal Infirmary (01482 674224)
3. **British Nuclear Cardiology Group (BNCG)**  
**President:** Dr D Pennell, Royal Brompton Hospital (0171 351 8810)  
**Treasurer:** Dr E Prvulovich, Nuclear Medicine, Middlesex Hospital (0171 380 9419)  
**Secretary:** Dr M Metcalfe, Aberdeen Royal Infirmary (01224 681818 ext 52532)
4. **British Society of Echocardiography (BSE)**  
**President:** Dr G Williams, Killingbeck Hospital, Leeds (0113 2648164)  
**Treasurer:** Dr D Springs, Northampton General Hospital (01604 235901)  
**Secretary:** Ms C Westgate, Royal Brompton Hospital (0171 352 8121)
5. **British Paediatric Cardiac Association (BPCA)**  
**President:** Dr E Silove, Birmingham Children's Hospital (0121 454 4851)  
**Treasurer:** Professor B Anderson, Royal Brompton Hospital (0171 352 8121)  
**Secretary:** Mr Babula Sethia, Birmingham Children's Hospital (0121 454 4851)
6. **British Society for Cardiovascular Research (BSCR)**  
**President:** Dr P Cummins, University of Birmingham Medical School, (0121 414 6896)  
**Treasurer:** Dr C L Wainwright, University of Strathclyde (0141 552 4400 ext 2405)  
**Secretary:** Dr M Avkiran, The Rayne Institute, St Thomas' Hospital (0171 928 9292)
7. **British Association for Cardiac Rehabilitation (BACR)**  
**President:** Ms H Stokes, National Institute for Nursing, Radcliffe Infirmary, Oxford (01865 224833)  
**Treasurer:** Mr R Tipson, Action Heart, Dudley (01384 230222)  
**Secretary:** Mrs S Turner, Rehabilitation Unit, Alton Health Centre (01420 544794)
8. **Association of British Cardiac Nurses (ABCN)**  
**President:** Ms A. Townsend, c/o BCS, 9 Fitzroy Square, London W1P 5AH  
**Secretary:** Ms J Burgess, c/o BCS, 9 Fitzroy Square, London W1P 5AH
9. **Society of Cardiological Technicians (SCT)**  
**President:** Mr G Tate, General Infirmary, Leeds (0113 292 6736)  
**Secretary:** Ms G McClintock, Craigavon Area Hospital, Belfast (01762 334444)  
**Treasurer:** Dr L Goulding, John Radcliffe Hospital, Oxford (01865 741166)

---

## BRITISH CARDIAC SOCIETY

---

### COMMITTEES OF THE BRITISH CARDIAC SOCIETY 1996

#### Joint Audit & Medical Practice Committee

David de Bono (Chairman), Jennifer Adgey, Raphael Balcon, David Bennett, Mark Dancy, John Dark, Huon Gray, David Hackett, Howard Swanton, Robert West, Richard Wray, Anthony Hopkins, John Kennedy

#### Education Committee

Stephen Ball (Chairman), Nick Boon, Chris Davidson, John Davies, David Lipkin, Tony Mourant, Brian Pentecost, Michael Petch, Derek Rowlands, Man Fai Shiu, Christopher Wren

#### Epidemiology & Prevention Committee

Dennis Boyle (Chairman), John Cleland, Brian Pentecost, Hugh Tunstall-Pedoe, Richard Wray, Tom Treasure, Helen Stokes

#### Ethical & Legal Committee

Keith Fox (Chairman), Raphael Balcon, Stewart Hunter, Jeff Green, John Parker

#### Technicians' Committee

Mick Martin (Chairman), Nick Brooks, Vera Hoskinson, Catriona MacGregor, Shakeel Qureshi, Doug Skehan, Margaret Slater, Graham Tate

#### Training & Manpower Committee

Michael Webb-Peploe (Chairman), Roger Boyle, Ronnie Campbell, Jane Flint, Roger Hall, Stewart Hunter, John Martin, Howard Swanton

#### IT Committee

Tony Rickards (Chairman), Raphael Balcon, Ronnie Campbell, David de Bono

#### The Programme Committee for this meeting was:

Ronnie Campbell (Chairman), Raphael Balcon, Nick Brooks, John Cleland, Andrew McLeod, Paul Oldershaw

#### The Programme Committee wishes to acknowledge the generous help given in abstract selection by the following:

G D Angelini	D C Cumberland	I M Graham	M I M Noble	G R Sutherland
S G Ball	H J Dargie	H Gray	<b>P Oldershaw</b>	R Sutton
D H Bennett	J Dark	<b>A Harley</b>	D Pennell	<b>T Treasure</b>
J Birkhead	M J Davies	G Hart	J R Pepper	H D Tunstall-Pedoe
R Bonser	W Davies	A M Hegearty	M Petch	<b>M Tynan</b>
<b>N Boon</b>	J Deanfield	S Holmberg	P Schofield	R Underwood
J Bourke	D de Bono	B R Keeton	M E Scott	P Vallance
R M Boyle	J Flint	<b>A Lahiri</b>	B Sethia	D Ward
<b>R W F Campbell</b>	<b>K A A Fox</b>	M J Lewis	M Shattock	<b>P L Weissberg</b>
J Caplin	K Fox	W J McKenna	T R D Shaw	D J Wheatley
C Chan	<b>A Fraser</b>	D Miller	U Sigwart	<b>D Wood</b>
A J S Coats	M Gammage	R G Murray	I Simpson	<b>D M Yellon</b>
S M Cobbe	J Gibbs	A W Nathan	J D Skehan	
D Crossman	D Gibson	P Nihoyannopoulos	A Struthers	

*Names shown in bold are the Designated Markers who co-ordinate the decision making process for one of the abstract categories.*

## PROGRAMME AT A GLANCE

<b>Tuesday 7 May</b>	<b>Hall 1 (SECC) Plenary Sessions+BCIS</b>	<b>Hall 2 (SECC) Free Communications</b>	<b>Exhibition Hall Hall 4 (SECC) Moderated Posters</b>	<b>Castle 1/2 (Moat House) Free Communications</b>	<b>Argyll Suite (Moat House) Affiliated Groups</b>
08.30 – 10.00	<b>BCIS:</b> Place of coronary angioplasty in 1996	Muscles and valves Papers 131–136	Electrophysiology I Papers 137–146	Non-pharmacological therapy Papers 147–152	
10.00 – 11.00	Coffee: Exhibition	Coffee: Exhibition	Coffee: Exhibition	Coffee: Exhibition	Coffee: Exhibition
11.00 – 12.30	Plenary: Surgery for end-stage heart disease	Imaging I Papers 153–158	Cell biology I Papers 159–168	Management of acute MI Papers 169–174	<b>BPEG:</b> Sudden cardiac death
12.30 – 14.00	Lunch: Exhibition: Posters	Lunch: Exhibition: Posters	Lunch: Exhibition: Posters	Lunch: Exhibition: Posters	Lunch: Exhibition: Posters
14.00 – 15.30		Judges' Choice I Papers 175–180	Cardiac muscle Papers 181–190	Vascular biology Papers 191–196	<b>BNCG:</b> CAD in women: Can nuclear cardiology help solve the problems?
15.30 – 16.00	Tea: Exhibition: Posters	Tea: Exhibition: Posters	Tea: Exhibition: Posters	Tea: Exhibition: Posters	Tea: Exhibition: Posters
16.00 – 17.00	St Cyres Lecture: Dr Kim Fox Ischaemia: Iceberg or mirage?				
17.15 – 18.45		Cardiologists in Training: Liaison Meeting: 17.15–18.15 Meeting of Regional Specialty Advisers: 18.15–18.45			
<b>Wednesday 8 May</b>	<b>Hall 1 (SECC) Plenary Sessions+BSE</b>	<b>Hall 2 (SECC) Free Communications +YRWP</b>	<b>Exhibition Hall Hall 4 (SECC) Moderated Posters</b>	<b>Castle 1/2 (Moat House) +BPCA Free Communications</b>	<b>Argyll Suite (Moat House) Nurses' Day</b>
08.30 – 10.00	Plenary: Heart failure update	Cell biology II Papers 197–202	Audit, training and population research Papers 203–212	<b>BPCA:</b> The pulmonary circulation in congenital heart disease I	<b>ABCN</b> Annual General Meeting
10.00 – 11.00	Coffee: Exhibition: Posters	Coffee: Exhibition: Posters	Coffee: Exhibition: Posters	Coffee: Exhibition: Posters	Coffee: Exhibition: Posters
11.00 – 12.30	Plenary: Application of today's molecular biology to tomorrow's clinical practice BSCR sponsored	Electrophysiology II Papers 213–218	Imaging II Papers 219–228	<b>BPCA:</b> The pulmonary circulation in congenital heart disease I	The advanced nurse practitioner Measuring outcomes
12.30 – 14.00	Lunch: Exhibition: Posters	Lunch: Exhibition: Posters	Lunch: Exhibition: Posters	Lunch: Exhibition: Posters	Lunch: Exhibition: Posters
14.00 – 15.30	<b>BSE:</b> Current clinical issues	Young Research Workers Prize A–D	Non-pharmacological approaches Papers 229–238	Muscle function Papers 239–244	Nursing priorities for action Patient perceptions
15.30 – 16.00	Tea: Exhibition	Tea: Exhibition	Tea: Exhibition	Tea: Exhibition	
16.00 – 17.00	Thomas Lewis Lecture: Dr Paul Yock Advances in intravascular ultrasound				
17.00 – 18.30	Annual General Meeting (members only)				
<b>Thursday 9 May</b>	<b>Hall 1 (SECC) Plenary Sessions</b>	<b>Hall 2 (SECC) Free Communications</b>	<b>Exhibition Hall Hall 4 (SECC) Moderated Posters</b>	<b>Castle 1/2 (Moat House) Free Communications +BACR</b>	<b>Argyll Suite (Moat House) Technicians' Day</b>
08.30 – 10.00	Plenary: The funding of cardiovascular research in tomorrow's world	Interventions for coronary artery disease Papers 245–250	Vascular biology Papers 251–260	Community concerns Papers 261–266	SCT Business Meeting
10.00 – 11.00	Coffee: Exhibition: Posters	Coffee: Exhibition: Posters	Coffee: Exhibition: Posters	Coffee: Exhibition: Posters	Coffee: Exhibition: Posters
11.00 – 12.30	Plenary: Coronary disease: Population studies	Judges' Choice II Papers 267–272	Cardiac surgery, coagulation Papers 273–282	<b>BACR:</b> Evidence based practice – Cost effectiveness of cardiac rehabilitation Cardiac rehabilitation: hospital and community interface Angina management and behavioural change	SCT Fits, faints and flops!
12.30 – 14.00	Lunch: Exhibition	Lunch: Exhibition	Lunch: Exhibition: Posters	Lunch: Exhibition	Lunch: Exhibition
14.00 – 16.00	Practical cardiology				Tilt table testing Event recorders Alternative non-invasive evaluation of arrhythmias
16.00	Finish	Finish	Finish	Finish	

---

**COMMITTEE MEETINGS**


---

**Tuesday 7 May 1996**

<b>Committee/Group</b>	<b>Time</b>	<b>Location</b>
BCIS Industry/Council	12.30 – 14.00	Hebrides (Moat House)
BPEG Council	12.30 – 14.00	Barra (Moat House)
BNCG Business Meeting	13.00 – 14.00	Jura (Moat House)
Ethical and Legal	12.30 – 14.00	Boardroom (Moat House)
Heart Editorial	12.30 – 14.00	Castle 1/2 (Moat House)
Press Conference	12.30 – 14.00	Castle 3 (Moat House)
BCIS Council	17.30 – 19.30	Hebrides (Moat House)
BPCA Council	18.00 – 19.30	Barra (Moat House)

---

**Wednesday 8 May 1996**

<b>Committee/Group</b>	<b>Time</b>	<b>Location</b>
Training and Manpower	07.00 – 08.00	Barra (Moat House)
Joint Audit and Medical Practice	12.30 – 14.00	Castle 3 (Moat House)
BPCA AGM	12.30 – 13.30	Castle 1/2 (Moat House)
BSE Council	12.30 – 14.00	Hebrides (Moat House)
Education	12.30 – 14.00	Boardroom (Moat House)
RITA III	12.45 – 14.00	Barra/Jura (Moat House)
SCT	14.00 – 17.00	Castle 3 (Moat House)
RITA Nurses	16.45 – 18.00	Barra/Jura (Moat House)

---

**Thursday 9 May 1996**

<b>Committee/Group</b>	<b>Time</b>	<b>Location</b>
Epidemiology and Prevention	12.30 – 14.00	Castle 3 (Moat House)
Technicians	12.30 – 14.00	Hebrides (Moat House)

---

---

**THURSDAY 9 MAY 1996**


---

08.00	<b>Main Concourse (SECC)</b> Registration	11.00 – 12.30	<b>Hall 2 (SECC)</b> Free communications <b>Judges' Choice II</b> Chairmen: Dr Cherry Wainwright and Prof Jurgen Meyer Papers 267-272
08.30 – 10.00	<b>Hall 1 (SECC)</b> Plenary session <b>The funding of cardiovascular research in tomorrow's world</b> Chairmen: Prof A John Camm and Prof David de Bono <i>Priorities and funding for cardiovascular research</i> Prof John Swales, Director of Research and Development, The National Health Service <i>The Wellcome Trust and cardiovascular research</i> Dr David Gordon, Programme Director, The Wellcome Trust <i>MRC strategy for cardiovascular research</i> Dr Mike Davies, Board Secretary, Medical Research Council <i>The developing role of the British Heart Foundation</i> Prof Brian Pentecost, Medical Director, British Heart Foundation Discussion	11.00 – 12.30	<b>Exhibition Hall (Hall 4, SECC)</b> Moderated posters <b>Cardiac surgery, coagulation</b> Chairmen: Prof Gordon Lowe and Prof David Wheatley Papers 273-282
08.30 – 10.00	<b>Hall 2 (SECC)</b> Free communications <b>Interventions for coronary artery disease</b> Chairmen: Dr David Cumberland and Dr Ian Hutton Papers 245-250	11.00 – 12.30	<b>Castle 1/2 (Moat House)</b> British Association for Cardiac Rehabilitation Chairman: Dr Jane Flint <i>Evidence based practice: Cost-effectiveness of cardiac rehabilitation</i> Dr Rod Taylor <i>Cardiac rehabilitation: Hospital and community interface – an innovative approach</i> Dr Christopher Isles <i>Angina management and behavioural change</i> Dr Christopher Bundy
08.30 – 10.00	<b>Exhibition Hall (Hall 4, SECC)</b> Moderated posters <b>Vascular biology</b> Chairman: Prof Andrew Henderson Papers 251-260	11.00 – 12.30	<b>Argyll Suite (Moat House)</b> Technicians' Day For programme see p. 74
08.30 – 10.00	<b>Castle 1/2 (Moat House)</b> Free communications <b>Community concerns</b> Chairmen: Dr Dennis Boyle and Dr Caroline Morrison Papers 261-266	12.30 – 14.00	<b>Exhibition Hall (Hall 4, SECC)</b> Lunch Poster viewing Posters 1-130 – Presenters not in attendance Exhibition viewing
09.00 – 10.00	<b>Argyll Suite (Moat House)</b> Society of Cardiological Technicians Business meeting	14.00 – 16.00	<b>Hall 1 (SECC)</b> <b>Practical Cardiology</b> Chairman: Dr Andrew McLeod <i>How to perform coronary angiography</i> Dr Raphael Balcon <i>The management of infective endocarditis</i> Dr Howard Swanton <i>Treatment of acute MI. What do we still need to know?</i> Dr Rory Collins
10.00 – 11.00	<b>Exhibition Hall (Hall 4, SECC)</b> Coffee Poster viewing Posters 1-130 – Presenters in attendance Moderated posters on view Exhibition viewing	14.00 – 16.00	<b>Argyll Suite (Moat House)</b> Technicians' Day
11.00 – 12.30	<b>Hall 1 (SECC)</b> Plenary session <b>Coronary disease: Population studies</b> Chairmen: Dr Douglas Chamberlain and Prof David Wood <i>The UK Heart Attack Study</i> <i>Acute heart attack: The scale of the problem and possible solutions</i> Dr Robin Norris <i>WOSCOPS and 4S: Summary results and comparison with the prognostic benefits of revascularisation by surgery or PTCA</i> Prof Stuart Cobbe <i>How cost-effective is primary, secondary and 'tertiary' prevention with lipid lowering agents?</i> Prof Lawrence Ramsay <i>C: AOS: How good is the evidence for dietary vitamin supplementation for the treatment or prevention of coronary disease in developed countries</i> Prof Morris Brown	16.00	Close of meeting

---

## THURSDAY 9 MAY 1996: TECHNICIANS' DAY PROGRAMME

---

### Evaluation of arrhythmias

- 09.00 – 10.00 Business meeting
- 10.00 – 11.00 Coffee and Exhibition
- 11.00 – 11.45 Fits, faints, flops!  
Prof John Stephenson, Professor of Neurology, Royal Hospital for Sick Children, Glasgow
- 11.45 – 12.30 Exhibition
- 12.30 – 14.00 Lunch and Exhibition
- 14.00 – 14.30 Tilt table testing  
Dr Adam Fitzpatrick
- 14.30 – 15.00 Event recorders  
Mr Richard Maryan (MSCT)
- 15.00 – 15.30 Coffee
- 15.30 – 16.00 Alternative non-invasive evaluation of arrhythmias  
Dr David Mulcahy



## VOLUME 75: PROGRAMME SUPPLEMENT AUTHOR INDEX

- Aalkjaer C** *see* Kelly MP *et al*  
**Abedi H** *see* Dawes KE *et al*  
**Abu Ousa A** *see* Akhras F *et al*  
**Acar P** *see* Cao Q-L *et al*; Delabays A *et al*; Yao J *et al*  
**Adams JN** *see* Trent RJ *et al*  
**Adgey AAJ** *see* Harbinson MT *et al*  
**Adwani S, Whitehead B, Rees P, Elliott M, de Leval M.** Is routine endomyocardial biopsy essential for rejection surveillance in paediatric heart transplant recipients? 65 Pr  
**Aggarwal RK, Ireland DC, de Bono DP, Gershlick AH.** Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIB/IIIA antibody, 175 JC  
**Aggarwal RK, Ireland DC, de Bono DP, Gershlick AH.** In-vitro preparation, characterisation and antithrombogenicity of platelet-targeted urokinase immobilised to polymer coated stent wire, 247  
**Agre P** *see* Connolly DL *et al*  
**Ahmed J** *see* Tweddel AC *et al*  
**Aitman T** *see* Baliga R *et al*  
**Akhras F, Abu Ousa A, Rustom M, Duncan H, Chamsi-Pasha H, Jabbad H.** Early and late follow-up results of primary coronary angioplasty compared to intravenous streptokinase in acute myocardial infarction, 172  
**Akhras F, Abu Ousa A, Swann G, Rustom M.** Does low inflation pressure and prolonged coronary dilatation strategy affect restenosis rate? Early and late results, 98 Pr  
**Al-Katoubi A** *see* Stanbridge RdeL *et al*  
**Al-Mohammad A, Norton MY, Showell N, Mikecz P, Walton S.** Can the TIMI-flow grade predict the presence of hibernating myocardium? 280 MP  
**Al-Mohammad A** *see also* Fath-Ordoubadi F *et al*; Hillis GS *et al*; Trent RJ *et al*  
**Alamgir F** *see* Zaman A *et al*  
**Alberti KGMM** *see* Harland J *et al*  
**Allen JD** *see* Harbinson MT *et al*  
**Almond DG** *see* Chauhan A *et al*  
**Amende I** *see* Blessing E *et al*  
**Amersey R** *see* Beatt KJ *et al*  
**Anagnostopoulos C** *see* Gunning MG *et al*  
**Anastasakis A** *see* Kyriakidis M *et al*  
**Anderson DG, Kenny RA, Thomson R.** Anticoagulation of patients with atrial fibrillation. A theoretical exercise in the cost for one general practice, 113 Pr  
**Anderson DR** *see* Yates RWM *et al*  
**Anderson HR** *see* Poloniecki JD *et al*  
**Anderson JMcC** *see* Harbinson MT *et al*  
**Anderson MH** *see* Malik IS and Anderson MH  
**Andrews R, Walsh J, Curtis S, Evans A, Cowley AJ.** Abnormalities of skeletal muscle metabolism are present at rest in congestive heart failure: relationship between these abnormalities and symptoms, 37 Pr  
**Andrews R** *see also* Lindsay HSJ *et al*; Walsh JT *et al*  
**Angelini GD** *see* Birdi I *et al*; Birdi IS *et al*; Izzat MB *et al*; Kadir I *et al*  
**Anker S** *see* Chua TP *et al*  
**Anker SD, Lees B, Chua T, Harrington D, Ponikowski P, Kox W, Poole-Wilson PA, Coats AJS.** Body composition and strength in chronic heart failure: reduced muscle efficiency in cardiac cachexia, 33 Pr  
**Annex BH** *see* Channon KM *et al*  
**Anning PB, Grocott-Mason RM, Lewis MJ, Shah AM.** Differential left ventricular relaxant effects of -SH and non-SH containing ACE inhibitors, 200  
**Apple KA** *see* Pagano D *et al*  
**Arca-Sedda F** *see* Montgomery H *et al*  
**Armstrong J** *see* Galea J *et al*  
**Aronowitz M** *see* Yao J *et al*  
**Atkinson RW** *see* Poloniecki JD *et al*  
**Avkiran M, Haworth RS, Yasutake M.** Thrombin - more than a thrombogenic mediator: activation of the cardiac sarcolemmal Na<sup>+</sup>/H<sup>+</sup> exchanger via the cloned thrombin receptor, 197  
**Baliga R, Lammertsma A, Rhodes C, Aitman T, Scott J, Kooner JS.** Positron emission tomography localises insulin resistance to skeletal muscle in premature coronary heart disease, 48 Pr  
**Ball J** *see* Deane ANS *et al*  
**Ball JB, Bloomer TN, Williams GJ.** Endothelial function of the brachial artery is not impaired in patients with syndrome X, 252 MP  
**Banner N** *see* Parry D *et al*  
**Barbeau G** *see* Chauhan A *et al*  
**Barbeteas J** *see* Kyriakidis M *et al*  
**Barlow CW** *see* Heriot AG *et al*  
**Baron DW** *see* Lowe HC *et al*  
**Barry PW** *see* Mullen MJ *et al*  
**Basu S, Senior R, Raval U, Dore C, Lahiri A.** Following myocardial infarction and thrombolysis, stress and nitroglycerine enhanced rest TL-201 imaging has superior prognostic value compared to redistribution imaging, 270 JC  
**Basu S** *see also* Senior R *et al*; Soman P *et al*  
**Batin PD** *see* Lindsay HSJ *et al*  
**Baylis SA** *see* Robinson NMK *et al*  
**Bayston T** *see* Stubbs P *et al*  
**Beatt KJ, Huehns TY, Amersey R, Greenwood TW, Stubbs P.** Is the 'wait and see' strategy for invasive investigation post myocardial infarction flawed? 173  
**Beatt KJ** *see also* Fath-Ordoubadi F and Beatt KJ; Fath-Ordoubadi F *et al*  
**Beatty G** *see* Schilling RJ *et al*  
**Beevers DG** *see* Lip GYH *et al*  
**Belcher PR** *see* Huwez FU *et al*  
**Bell P** *see* Brackenbury ET *et al*  
**Bellamy M, Gorman ST, Brownlee M, Ramsey MW, Lewis MJ, Goodfellow J, Henderson AH.** Endothelial function declines in hypercholesterolaemic women following the menopause, 36 Pr  
**Bellamy M** *see also* Tweddel AC *et al*  
**Bennett DH** *see* Goode GK *et al*  
**Bennett JL** *see* Keenan DJM *et al*  
**Benson LN** *see* Magee AG *et al*  
**Bhagat K, Collier J, Vallance P.** Vascular inflammation and its effects on smooth muscle and endothelial function: a study in healthy volunteers, A  
**Bhargava B, Holme E, Birnie D, Hood S, Swan L, MacIntyre P, Hillis WS.** Measurement of streptokinase antibodies or inhibitors in blood: comparison of a rapid desk top test panel as conventional antibody and resistance assays, 28 Pr  
**Bhatti F** *see* Dyke C *et al*  
**Bhopal R** *see* Harland J *et al*  
**Birdi I, Caputo M, Underwood M, Angelini GD, Bryan AJ.** Normothermic systemic perfusion does not compromise cold myocardial protection during coronary artery surgery, 106 Pr  
**Birdi IS, Regragui IA, Izzat MB, Bryan AJ, Angelini GD.** A randomised study of the effects of cardiopulmonary bypass temperature on neuropsychological deficit after coronary artery surgery, 274 MP  
**Birnie D, Holme E, McKay IC, Hood S, McColl KEL, Hillis WS.** Association between antibodies to mycobacterial heat shock protein 65 and coronary atherosclerosis: possible mechanism of action of a *Helicobacter pylori* in increasing cardiovascular risk, 166 MP  
**Birnie D** *see also* Bhargava B *et al*  
**Bishop G** *see* Montgomery HE *et al*  
**Blake DR** *see* Richens TE *et al*  
**Blankoff I** *see* Slade AKB *et al*  
**Blann AD** *see* Lip GYH *et al*  
**Blatchford O** *see* Pell JP *et al*  
**Blazing MA** *see* Channon KM *et al*  
**Blessing E, Hausmann D, Sturm M, Mügge A, Amende I.** Incomplete expansion of stents despite high-pressure implantation: the role of intravascular ultrasound, 95 Pr  
**Blessing E, Hausmann D, Sturm M, Mügge A, Amende I.** Intravascular ultrasound and stent implantation: intra- and inter-observer variability, 224 MP  
**Bloomer TN** *see* Ball JB *et al*  
**Bognolo G** *see* Pagano D *et al*  
**Boivin CM** *see* Hamdan HK *et al*  
**Bomanji J** *see* Prvulovich E *et al*  
**Bonnar C, Davie A, Caruana L, McMurray JJV, Struthers AD.** The value of QT dispersion in identifying patients with heart failure due to left ventricular systolic dysfunction, 25 Pr

- Bonser RS** *see* Pagano D *et al*  
**Boon NA** *see* Newby DE *et al*  
**Bossingham CM** *see* Khandekar S *et al*  
**Bourke JP** *see* Doig JC *et al*  
**Boutin C** *see* Gladman G *et al*  
**Bowker TJ, Wood DA, Davies MJ, Sheppard MN, Cary NRB, Hobson HL, Burton JDK, Chambers DR, Dawling S, Riemersma RA, Pyke SDM, Thompson SG.** A national survey of sudden unexpected cardiac or unexplained death in adults (SADS), 261  
**Brackenbury ET, Spyt TJ, Bell P, Firmin RL, Leverment JN, Hickey MS, Sosnowski AW.** Combined carotid and coronary revascularisation, 234 MP  
**Brady AJB** *see* Luu N-T *et al*  
**Brady S** *see* Holt ND *et al*  
**Brawn W, Sreeram N, Sethia B, Wright J, de Giovanni J, Silove E.** Univentricular heart with systemic outflow obstruction: the primary Damus procedure as an alternative to pulmonary banding, 238 MP  
**Brawn W** *see also* McLeod K *et al*  
**Brawn WJ** *see* Gupta NK *et al*  
**Brecker SJD, Kelly PA, Chua TP, Gibson DG.** Effects of permanent dual chamber pacing in end-stage dilated cardiomyopathy, 46 Pr  
**Brecker SJD, Koh TW, Timmis AD, Rothman MT, Layton CA, Balcon R.** Coronary stenting for unstable angina is safe and effective, 86 Pr  
**Brennand-Roper D** *see* Patel NR *et al*  
**Bridgeman CJ, King AR, Francis SE, Crossman DC.** Apoptosis of human umbilical vein endothelial cells (HUVEC) - role of interleukin-1 $\beta$  converting enzyme (ICE) and associated proteases, 11 Pr  
**Broadhurst P** *see* Kerawalla A *et al*  
**Brooks NH** *see* Goode GK *et al*; Grant SCD *et al*  
**Brooksby WP** *see* Lindsay HSJ *et al*  
**Brown AS, Moro MA, Darley-Usmar V, Radomski M, Martin JF.** Peroxynitrite causes the expression of platelet P-selectin but inhibits the internalisation of GPIb, effects that might have important consequences in acute ischaemic syndromes, 162 MP  
**Brown AS** *see also* Belder AJ *et al*  
**Brown EM, Salmon AP, Gnanapragasam J, Monro JL, Lamb RK, Tsang VT, Keeton BR.** The results of applying echo data derived from critical aortic stenosis to infants with coarctation of the aorta, 158  
**Brown MJ** *see* Stephens NG *et al*  
**Brown RIG** *see* Chauhan A *et al*  
**Browne H** *see* Clesham GJ *et al*  
**Brownlee M** *see* Bellamy M *et al*  
**Bruun B** *see* Connolly DL *et al*  
**Bryan AJ** *see* Birdi I *et al*; Birdi IS *et al*; Izzat MB *et al*; Kadir I *et al*  
**Bryant SM** *see* Shipsey SJ *et al*  
**Buchalter MB** *see* Prendergast BD *et al*  
**Bucher TA** *see* Redwood SR *et al*  
**Bucknall C** *see* Kamalvand K *et al*; Patel NR *et al*  
**Bulbeck VJ** *see* Murphy CF *et al*  
**Bull C** *see* Gardiner HM *et al*  
**Bull T** *see* Clarkson P *et al*; Thorne SA *et al*  
**Buller CE** *see* Chauhan A *et al*  
**Burgess R** *see* Wilde NT *et al*  
**Burman E** *see* Gunning MG *et al*  
**Burman ED** *see* Pennell DJ *et al*  
**Burrell D** *see* McLeod K *et al*  
**Burton JDK** *see* Bowker TJ *et al*  
**Bush A** *see* Shekerdemian L *et al*  
**Bygrave A** *see* Slade AKB *et al*  
**Byrne J, Morton JJ, Metcalfe MJ, Dargie HJ.** Baseline assessment of plasma brain natriuretic peptide and simple clinical variables predict long-term left ventricular function following acute myocardial infarction, 31 Pr  
**Byrne J, Morton JJ, Metcalfe MJ, Dargie HJ.** Brain natriuretic peptide (BNP) and simple clinical variables predict left ventricular dysfunction following myocardial infarction, 30 Pr  
  
**Cairns H** *see* Langford EJ *et al*  
**Calver AL, Radvan J, Dawkins KD, Gray HH, Morgan JM, Simpson IA.** Early experience with the Prostar<sup>TM</sup> percutaneous vascular closure device in patients following coronary intervention, 96 Pr  
**Calviño R** *see* Salomone OA *et al*  
**Camici PG** *see* Pagano D *et al*; Spyrou N *et al*  
**Camm AJ** *see* Hnatkova K *et al*  
**Campbell RWF** *see* Doig JC *et al*  
**Campbell S** *see* de Belder AJ *et al*  
**Cao Q-L, Masani ND, Delabays A, Magni G, Acar P, Laskari C, Yao J, De Castro S, Pandian NG.** Two new ultrasound modalities - harmonic imaging and triggered mode - improve delineation of myocardial perfusion defects by three-dimensional contrast echocardiography, 155  
**Cao Q-L** *see also* Delabays A *et al*; Yao J *et al*  
**Caplin JL** *see* Walters MI *et al*  
**Caputo M** *see* Birdi I *et al*  
**Cardinal D** *see* Connelly DT *et al*  
**Carr CS, Grover GJ, Yellon DM.** Comparison of ischaemic preconditioning and a highly selective ATP-dependent potassium channel opener in isolated human atrial muscle, 198  
**Caruana L** *see* Bonnar C *et al*  
**Cary NR** *see* Connolly DL *et al*  
**Cary NRB** *see* Bowker TJ *et al*  
**Casadei B** *see* Singh JP *et al*  
**Chambers DR** *see* Bowker TJ *et al*  
**Chambers JB** *see* Wang Z *et al*  
**Chambers JC, Ross DN, Somerville J.** The pulmonary autograft operation: long term results of the pioneer series, 276 MP  
**Chamsi-Pasha H** *see* Akhras F *et al*  
**Channon KM, Blazing MA, Shetty GA, Youngblood SA, George SE.** Adenoviral gene transfer of nitric oxide synthase to vascular cells, 193  
**Channon KM, Fulton GJ, Davies MG, Peters KG, Ezekowitz MD, Hagen PO, Annex BH.** Spatial and temporal changes in tissue factor protein expression in experimental venous bypass grafts, 165 MP  
**Channon KM, Fulton GJ, Shetty GA, Blazing MA, Annex BH, Hagen PO, George SE.** Adenoviral gene transfer to venous bypass grafts and native vessels: a comparative study, 163 MP  
**Charles IG** *see* Robinson NMK *et al*  
**Charlesworth A** *see* Kearney MT *et al*; Walsh JT *et al*; Wilcox RG *et al*  
**Chase R** *see* Dawkins KD *et al*  
**Chase RC** *see* Murphy CF *et al*  
**Chaturvedi R, Lincoln C, Shore D, White P, Redington A.** Modified ultrafiltration improves cardiac systolic and diastolic function immediately after cardiopulmonary bypass in children, 275 MP  
**Chauhan A, More RS, Mullins PA, Taylor G, Petch MC, Schofield PM.** L-arginine reverses the age associated endothelial dysfunction in humans, 255 MP  
**Chauhan A, Penn IM, Ricci DR, Buller CE, Almond DG, Lazzam C, Marquis J, Webb JG, Roy L, Barbeau G, O'Neill BJ, Rizo L, Wong C, Foley JB, Brown RIG, Sridhar K, Fischman DL.** Coronary artery stenting reduces late clinical events in restenosis lesions: final results from the trial of angioplasty and stents in Canada (TASC I), 148  
**Chauhan A, Penn IM, Ricci DR, Buller CE, Almond DG, Lazzam C, Marquis J, Webb JG, Roy L, Barbeau G, O'Neill BJ, Rizo L, Wong C, Foley JB, Brown RIG, Sridhar K, Fischman DL.** Do de novo and restenosis lesions react differently to coronary intervention? Angiographic insights from the trial of angioplasty and stents in Canada (TASC I), 229 MP  
**Chee A, Rosenthal E, Huggon I, Qureshi SA, Baker E, Tynan M.** Balloon dilation of the aortic valve in neonatal critical aortic stenosis, 94 Pr  
**Cheeseman K** *see* Stephens NG *et al*  
**Chen Z** *see* Mounsey JP *et al*  
**Chia H** *see* Patel NR *et al*  
**Chin D, Gaughan S, Higson M, Wray R, McLeod A, Monaghan MJ.** Low-cost transmission of cardiac angiograms between secondary and tertiary cardiac units, 207 MP  
**Chua T** *see* Anker SD *et al*  
**Chua TP, Harrington D, Ponikowski P, Webb-Peploe K, Anker S, Poole-Wilson PA, Coats AJS.** Suppression of chemosensitivity and the effects on exercise tolerance in patients with chronic heart failure, 134  
**Chua TP** *see also* Brecker SJD *et al*; Gunning MG *et al*  
**Clark CE** *see* Redwood SR *et al*  
**Clarkson P, Montgomery H, Donald A, Powe A, Bull T, Dollery C, Jubbs M, World M, Deanfield J.** Exercise training enhances endothelial function in young men, 254 MP  
**Clarkson P** *see also* Montgomery H *et al*; Montgomery HE *et al*; Thorne SA *et al*  
**Clarkson PBM, Prasad N, MacDonald TM.** DD genotype of the angiotensin-converting enzyme (ACE) gene is associated with abnormal diastolic function in essential hypertension, 199  
**Clayton RM** *see* El Habbal MH *et al*  
**Cleland JGF** *see* Puri S *et al*

- Clesham GJ, Browne H, Efstathiou S, Weissberg PL.** Gene expression after *in vitro* and *in vivo* gene transfer into VSMCs, 191
- Clesham GJ, Shanahan CM, Weissberg PL.** Gene expression from the cytomegalovirus immediate early promoter in embryonic, neonatal and adult rat vascular smooth muscle cells, 160 MP
- Clesham GJ** *see also* Connolly DL *et al*
- Coats A** *see* Cowie MR *et al*
- Coats AJS** *see* Anker SD *et al*; Chua TP *et al*
- Cobbe SM** *see* Ng GA *et al*; Wallbridge DR *et al*
- Codd MB** *see* McKenna CJ *et al*
- Cohen A** *see* Stanbridge RdeL *et al*
- Collaborative Heart Failure Study Group** *see* Lindsay HSJ *et al*
- Collier J** *see* Bhagat K *et al*
- Collinson P** *see* Stubbs P *et al*
- Connaughton M, Hearse DJ, Shattock MJ.** Preconditioning and the extracellular space: implications for ischaemia-induced changes in cell volume, 3 Pr
- Connelly DT, Cardinal D, Foley L, Corrigan S, Waters M, Lemery R, Steinhaus DM.** Is routine pre-discharge testing necessary for patients with implantable defibrillators? 71 Pr
- Connolly DL, Shanahan CM, Cary NR, Monard SP, Bruun B, Ho LKF, Osbourn JK, Clesham GJ, Agre P, Weissberg PL.** Aquaporin-1 is expressed in rat and human arteries and may play a role in vascular function in health and disease, 268 JC
- Cooke R** *see* Wang Z *et al*
- Cooklin M, McComb JM.** QRS morphology during AV node reentrant tachycardia, 76 Pr
- Coonar A** *see* Kyriakidis M *et al*
- Cooper JM** *see* Turner LF *et al*
- Coromilas J** *see* Peters NS *et al*
- Corr L** *see* Patel NR *et al*
- Corrigan S** *see* Connelly DT *et al*
- Costa D** *see* Prvulovich E *et al*
- Cowan JC** *see* Lindsay HSJ *et al*
- Cowell R** *see* Fotopoulos GD *et al*
- Cowie MR, Penston H, Wood DA, Coats A, Thompson S, Poole-Wilson PA, Sutton GC.** A population-based survey of the incidence of heart failure, 129 Pr
- Cowley A** *see* Staniforth A *et al*
- Cowley AJ** *see* Andrews R *et al*; Kearney MT *et al*; Lindsay HSJ *et al*; Walsh JT *et al*
- Crake T** *see* Tousoulis D *et al*
- Crilly J** *see* Khurana CS *et al*
- Crook R, Leatham EW, Salomone OA, Hossein-Nia M, Grainger DJ, Kaski JC.** Plasma levels of active transforming growth factor- $\beta$  are reduced in patients with three vessel coronary artery disease, 259 MP
- Crossman DC** *see* Bridgeman CJ *et al*; Francis SE *et al*; Galea J *et al*; Gunn J *et al*; John AE *et al*
- Cubukcu AA** *see* Deaner ANS *et al*
- Cumberland DC** *see* Gunn J *et al*
- Curtis S** *see* Andrews R *et al*
- Curzen NP, Evans TW.** Is the pulmonary circulation hypersensitive to endothelin-1 in endotoxaemia? 16 Pr
- Dana A** *see* Fath-Ordoubadi F *et al*
- Dargie HJ** *see* Byrne J *et al*; McDonagh TA *et al*; Pell JP *et al*
- Dark JH** *see* Holt ND *et al*; Villaquiran J *et al*
- Darley-Usmar V** *see* Brown AS *et al*
- Davidson C** *see* Warren A *et al*
- Davie A** *see* Bonnar C *et al*
- Davies A** *see* Khurana CS *et al*
- Davies CH, O'Gara P, Wynne DG, Poole-Wilson PA, Harding SE.** Could a reduction of basal myocyte cAMP contribute to the progression of heart failure? 186 MP
- Davies DW** *see* Schilling RJ *et al*; Spyrou N *et al*
- Davies G** *see* Gunning MG *et al*; Tousoulis D *et al*
- Davies GJ** *see* Haider AW *et al*
- Davies MG** *see* Channon KM *et al*
- Davies MJ** *see* Bowker TJ *et al*
- Davis GK, Roberts DH.** Audit of physician training in temporary cardiac pacing from District General Hospitals in the North West Region, 209 MP
- Dawes KE, Abedi H, Martin JF, Zachary I.** Hypoxia alters the chemotactic and proliferative response of vascular smooth muscle cells to platelet-derived growth factor-BB, 21 Pr
- Dawkins KD, Chase R, Morgan JM, Gnanapragasam J, Salmon AP, Keeton BR.** Pacing in children: single centre experience of 77 cases, 75 Pr
- Dawkins KD, Gray HH, Morgan JM, Simpson IA.** Coronary stenting: cost implications for purchasers, 89 Pr
- Dawkins KD, Simpson IA, Sigwart U, Serruys PW.** Early results of the WEST European stent trial using the ACS Multilink™ stent, 230 MP
- Dawkins KD** *see also* Calver AL *et al*; Murphy CF *et al*
- Dawling S** *see* Bowker TJ *et al*
- de Belder A, Salas E, Langford E, Marrinan M, Martin JF.** Coronary artery vein graft platelet activation *in vivo* is inhibited by GSNO, 104 Pr
- de Belder AJ, Lees C, Brown AS, Langford EJ, Campbell S, Martin JF.** The hypertension and platelet activation of pre-eclampsia are reduced by S-nitrosoglutathione, 256 MP
- de Belder AJ** *see also* Langford EJ *et al*
- de Belder MA** *see* Khurana CS *et al*
- de Bono D** *see* Salame MY *et al*
- de Bono DP** *see* Aggarwal RK *et al*; Glancy JM *et al*; Salame MY *et al*
- De Castro S** *see* Cao Q-L *et al*
- de Giovanni J** *see* Brawn W *et al*
- de Leval M** *see* Adwani S *et al*
- de Leval MR** *see* Foran JPM *et al*; Gardiner HM *et al*
- Deaner ANS, Cubukcu AA, Ball J, Megary S, Sivananthan M, Williams GJ.** Regression of atheroma seen with intravascular ultrasound: a placebo controlled study of the effect of gemfibrozil on peripheral atherosclerosis, 154
- Deanfield J** *see* Clarkson P *et al*; Montgomery H *et al*
- Deanfield JE** *see* Gardiner HM *et al*; Thorne SA *et al*
- DeGiovanni J** *see* McLeod K *et al*
- Delabays A, Cao Q-L, Yao J, Magni G, Kanojia A, Acar P, Laskari C, Masani ND, Schwartz SL, Pandian NG.** Three-dimensional contrast echocardiography in acute myocardial infarction: *in vivo* quantification of infarct mass, 271 JC
- Delabays A** *see also* Cao Q-L *et al*; Yao J *et al*
- Dempsey G** *see* Harbinson MT *et al*
- Denne L** *see* Stables RH and Denne L
- Derrick G** *see* Irvine T *et al*
- Dhillon RS** *see* Gardiner HM *et al*
- Dittrich H** *see* Hancock J *et al*
- Dixon GF, Norris RM, Vincent R.** Heart attack action!: a campaign to improve community knowledge, 262
- Dodd NJF** *see* Grech ED *et al*
- Doig JC, Downar E, Saito J, Furniss SS, Bourke JP, Campbell RWF.** Ventricular tachycardia of arrhythmogenic right ventricular disease - evidence for localised reentry from cardiac mapping, 218
- Dollery C** *see* Clarkson P *et al*; Montgomery HE *et al*
- Donald A** *see* Clarkson P *et al*
- Donald AE** *see* Thorne SA *et al*
- Doran BRH** *see* Keenan DJM *et al*
- Dore C** *see* Basu S *et al*
- Douglas JT** *see* Keenan DJM *et al*
- Downar E** *see* Doig JC *et al*
- Doyle L** *see* Keenan DJM *et al*
- Draper NJ, Shah AM.** Contrasting effect of NO synthase inhibition on LV function during early and late reoxygenation, 187 MP
- Duff GW** *see* Francis SE *et al*
- Duncan H** *see* Akhras F *et al*
- Dunn B** *see* Fawzy ME *et al*
- Dunn FG** *see* Kennedy JA *et al*; MacIntyre PD *et al*; Pell ACH *et al*; Prasad N *et al*; Wallbridge DR *et al*
- Dupont E** *see* Kaprielian RR *et al*
- Dutka DP, Ramrakha P, Strong R, Oakley CM.** Should CK-MB be used to determine the cause of chest pain? 116 Pr
- Dutka DP** *see also* Puri S *et al*
- Dyke C, Santini F, Khaghani A, Bhatti F, Mitchell A, Yacoub M.** Long term results of heterotopic heart transplantation in patients with secondary pulmonary hypertension, 99 Pr
- Dyke C** *see also* Santini F *et al*
- Ebrahim SB** *see* Perry IJ *et al*
- Edwards S** *see* Santini F *et al*
- Edwards TJ, Langley S, Gardiner D, Livesey SA, Simpson IA.** Long term results and echo assessment of homograft aortic valve replacement, 152
- EEC Concerted Action on Positron (PET) Investigations of Cellular Regeneration and Degeneration.** Predictive value of FDG imaging in 502 patients with chronic ischaemic left ventricular dysfunction enrolled in a prospective European multicentre viability study, 226 MP
- Efstathiou S** *see* Clesham GJ *et al*
- El Gamel A** *see* Grant SCD *et al*
- El Gaylani NK.** Coronary angioplasty is underused in the management of acute myocardial infarction, 91 Pr

- El Habbal MH, Clayton RM, Lawrence J, Taylor JFN.** An experience of right heart stents in children, 68 Pr
- El Habbal MH, Smith LJ.** Non-invasive reduction of body water by using air flow kinetics, 112 Pr
- El-Widaa H** *see* Grocott-Mason RM *et al*
- Ell PJ** *see* Gunning MG *et al*; Prvulovich E *et al*
- Elliott M** *see* Adwani S *et al*
- Elliott MJ** *see* Foran JPM *et al*
- Elliott P** *see* Sepp R *et al*
- Elliott PM, Rosano GMC, Gill J, Kaski JC, Poole-Wilson PA, McKenna WJ.** Continuous coronary sinus pH monitoring during dipyridamole stress in patients with angina and hypertrophic cardiomyopathy, 272 JC
- Elliott PM** *see also* Salomone OA *et al*
- Ellis G** *see* Tweddel AC *et al*
- Engelmann MG** *see* Huehns TY *et al*
- Erbel R** *see* Ramo MP *et al*
- Esin S** *see* Huehns TY *et al*
- Etherington PJE** *see* Fluck DS *et al*
- European Jewel Investigators** *see* Garratt CJ and Glancy JM
- Evans A** *see* Andrews R *et al*; Meleady R *et al*
- Evans AJ** *see* Kearney MT *et al*
- Evans TW** *see* Curzen NP and Evans TW
- Evans W** *see* Tweddel AC *et al*
- Ewan AE** *see* Jepson NS *et al*
- Ezekowitz MD** *see* Channon KM *et al*
- Faichney A** *see* Kennedy JA *et al*
- Faragher EB** *see* Grech ED *et al*
- Farzaneh F** *see* Huggon IC *et al*
- Fath-Ordoubadi F, Al-Mohammad A, Heuhns TY, Dana A, Beatt KJ.** Prehospital versus hospital thrombolysis: an overview of randomised trials, 169
- Fath-Ordoubadi F, Beatt KJ.** Glucose-insulin-potassium (GIK) therapy for acute myocardial infarction: overview of randomised placebo controlled trials, 174
- Fawzy ME, Mimish L, Sivanandam V, Pieters F, Jayaram L, Patel A, Khan B.** Mitral balloon valvotomy in 300 consecutive patients using Inoue balloon technique, influence of mitral valve anatomy on the immediate and long term results, 136
- Fawzy ME, Sivanandam V, Rifai A, Dunn B, von Sinner W, Patel A, Jayaram L, Niazi K.** Balloon angioplasty of native coarctation in adults, long term follow up, 64 Pr
- Fenn LN** *see* Palka P *et al*
- Finn A** *see* John AE *et al*
- Firmin DN** *see* Pennell DJ *et al*
- Firmin RL** *see* Brackenbury ET *et al*
- Fischman DL** *see* Chauhan A *et al*
- Fitzgerald P** *see* Ramo MP *et al*
- Fleming AD** *see* Palka P *et al*
- Flemming S** *see* Montgomery H *et al*
- Fluck DS, Etherington PJE, O'Hare D, Sheridan DJ, Winlove CP.** Solute exchange in the ischaemic myocardium: the voltammetric hydrogen clearance technique and radioactive microspheres, 47 Pr
- Foale R** *see* Spyrou N *et al*
- Foley JB** *see* Chauhan A *et al*
- Foley L** *see* Connelly DT *et al*
- Foran JPM, Sullivan ID, Elliott MJ, de Leval MR.** Left ventricle mass/volume ratio does not predict early surgical outcome in infants older than 21 days undergoing arterial switch surgery for simple transposition of the great arteries, 70 Pr
- Forbat SM** *see* Gunning MG *et al*
- Ford I** *see* McDonagh TA *et al*
- Forster KM** *see* Penny DJ *et al*
- Forty J** *see* Villaquiran J *et al*
- Fotopoulos GD, Jepson NS, Mason MJ, Knight RC, Cowell R, Ilsley CDJ, Paul VE.** Stabilisation of refractory ventricular arrhythmias by intra-aortic balloon counterpulsation, 74 Pr
- Fotopoulos GD** *see also* Jepson NS *et al*
- Foulsham L** *see* Parry D *et al*
- Fox K** *see* Gunning MG *et al*
- Fox KAA** *see* Lindsay HSJ *et al*; Newby DE *et al*; Palka P *et al*
- Francis SE, Duff GW, Crossman DC.** *c-fms* proto-oncogene expression is increased in endothelial and smooth muscle cells following vascular grafting, 161 MP
- Francis SE** *see also* Bridgeman CJ *et al*; Galea J *et al*; Gunn J *et al*; John AE *et al*
- Frantz S** *see* Salame MY *et al*
- Freedom RM** *see* Magee AG *et al*
- Fulton GJ** *see* Channon KM *et al*
- Furniss SS** *see* Doig JC *et al*; Plummer CJ *et al*
- Galea J, Armstrong J, Francis SE, Crossman DC, Holt CM.** Early response gene expression and vascular cell proliferation in human saphenous vein prepared for coronary bypass grafting, 279 MP
- Galea J** *see also* John AE *et al*
- Gallagher P** *see* Meleady R *et al*
- Gammage MD** *see* Luu N-T *et al*; Marshall HJ *et al*
- Garcia S** *see* Goode GK *et al*
- Gardiner D** *see* Edwards TJ *et al*
- Gardiner HM, Dhillon RS, Bull C, de Leval MR, Deanfield JE.** Incidence and determinants of arrhythmia following total cavopulmonary connection: a prospective study of 119 cases, 142 MP
- Garratt CJ, Glancy JM.** Variation in selection criteria for cardioverter-defibrillator implantation in different European countries, 179 JC
- Gatehouse PD** *see* Pennell DJ *et al*
- Gatzoulis MA, Norgård G, Moraes F, Lincoln C, Shore DF, Shinebourne EA, Redington AN.** QRS evolution and ventricular arrhythmias after repair of tetralogy of Fallot: the influence of operative techniques and postoperative physiology, 150
- Gatzoulis MA, Till JA, Redington AN.** QRS/QT/QT dispersion and symptomatic ventricular arrhythmias after repair of tetralogy of Fallot, 143 MP
- Gaughan S** *see* Chin D *et al*
- Gavaghan TP** *see* Lowe HC *et al*
- Gemmell JD** *see* MacIntyre PD *et al*
- George SE** *see* Channon KM *et al*
- Gershlick AH** *see* Aggarwal RK *et al*
- Gibbs C** *see* Lip GYH *et al*
- Gibson DG** *see* Brecker SJD *et al*; Jin XY *et al*; Knight CJ *et al*
- Gill J** *see* Elliott PM *et al*
- Ginks WR** *see* Wong YK and Ginks WR
- Gladman G, Silverman E, Luy L, Boutin C, Smallhorn J.** Foetal echocardiographic screening of pregnancies at increased risk for foetal complete heart block, 66 Pr
- Glancy JM, Weston PJ, Thurston H, de Bono DP.** Baroreflex sensitivity and markers of ventricular repolarisation in asymptomatic diabetics, 81 Pr
- Glancy JM** *see also* Garratt CJ and Glancy JM
- Gnanapragasam J** *see* Brown EM *et al*; Dawkins KD *et al*
- Godman MJ** *see* Lange A *et al*
- Goldman JH** *see* Hossein-Nia M *et al*
- Goode GK, Garcia S, Heagerty AM.** Dietary marine fish oil improves endothelial function in hypercholesterolaemic patients, 17 Pr
- Goode GK, Wharton N, Brooks NH, Bennett DH, Levy RD.** Coronary stenting without anticoagulation or intravascular ultrasound: a retrospective analysis, 231 MP
- Goodfellow J** *see* Bellamy M *et al*; Ramsey MW *et al*; Tweddel AC *et al*
- Gorman ST** *see* Bellamy M *et al*
- Graham I** *see* Meleady R *et al*
- Graham TR** *see* Pagano D *et al*
- Grahame-Clark C** *see* Sporton S *et al*
- Grainger DJ** *see* Crook R *et al*
- Grant PJ** *see* Ossei-Gerning N *et al*
- Grant SCD, El Gamel A, Brooks NH, Levy RD.** Routine coronary angiography after heart transplantation: time to stop, 220 MP
- Grant SCD, Williams A, El Gamel A, Sawyer R, Yonan N, Levy RD.** Use of chest x-ray (CXR) after biopsy of the transplanted heart, 219 MP
- Grasso R** *see* Lindsay HSJ *et al*
- Gray HH** *see* Calver AL *et al*; Dawkins KD *et al*
- Grech ED, Dodd NJF, Jackson MJ, Faragher EB, Ramsdale DR.** Evidence for free radical generation following primary coronary angioplasty recanalisation in acute myocardial infarction, 1 Pr
- Greenwood TW** *see* Beatt KJ *et al*
- Griffith M, Kullar K, Jordan PJ.** The learning curve for radiofrequency ablation is more than 160 procedures, 145 MP
- Griffith MJ** *see* Marshall HJ *et al*
- Griffith TM** *see* Hutcheson IR and Griffith TM
- Grocott-Mason RM, El-Widaa H, Yacoub M, Ilsley CD, Mitchell AG.** PTCA in allograft coronary disease - is it worthwhile? 245
- Grocott-Mason RM** *see also* Anning PB *et al*
- Grohmann M** *see* Gunn J *et al*
- Grover GJ** *see* Carr CS *et al*
- Gunn J, Holt CM, Francis SE, Shepherd L, Malik N, Grohmann M, Crossman DC, Cumberland DC.** Restenosis after balloon angioplasty: intimal hyperplasia or vessel remodelling, 88 Pr

- Gunning M** *see* Knight CJ *et al*
- Gunning MG, Anagnostopoulos C, Davies G, Forbat SM, Ell PJ, Underwood SR.** Gated Tc-99m tetrofosmin SPECT in the assessment of left ventricular contractility: a comparison with cine magnetic resonance imaging, 53 Pr
- Gunning MG, Knight CJ, Anagnostopoulos C, Chua TP, Burman E, Pennell DJ, Pepper J, Ell PJ, Fox K, Underwood SR.** Identification of hibernating myocardium: a comparison of TI-201, Tc-99m tetrofosmin, and dobutamine cine magnetic resonance imaging, 242
- Günzburg WH** *see* Huehns TY *et al*
- Gupta NK, Shankar S, Brawn WJ, Sethia B.** Experience with the Fontan procedure in older patients, 63 Pr
- Hadjinicolau L** *see* Stanbridge RdeL *et al*
- Hagen PO** *see* Channon KM *et al*
- Haider AW, Tousoulis D, Davies GJ.** Arrhythmic preconditioning in patients with variant angina, 73 Pr
- Haider AW** *see also* Tousoulis D *et al*
- Hainsworth R** *see* Lindsay HSJ *et al*
- Hall JA** *see* Khurana CS *et al*
- Hall RJC** *see* Rinaldi CA *et al*
- Hamdan HK, Jordan PJ, Poyner RM, Boivin CM, Littler WA.** The importance of early quantitative exercise thallium-201 tomography after coronary angioplasty for predicting angina recurrence, 223 MP
- Hampton JR** *see* Wilcox RG *et al*
- Hancock J, Dittrich H, Jewitt DE, Monaghan MJ.** Diagnostic ultrasound intensities may destroy contrast microspheres in-vivo: implications for ultrasound perfusion imaging, 60 Pr
- Hancock J, Dittrich H, Jewitt DE, Monaghan MJ.** New technologies for echocardiographic myocardial perfusion imaging, 228 MP
- Hancock J, Thomas MR, Wainwright RJ, Jewitt DE.** Changes in global and regional LV function following successful PTCA of a total coronary occlusion, 243
- Harbinson MT, Trouton T, Imam Z, Allen JD, Dempsey G, Anderson JMcC, Adgey AAJ.** Rounded versus standard biphasic waveforms for catheter atrial defibrillation, 82 Pr
- Harding SE** *see* Davies CH *et al*
- Hardman S** *see* Sporton S *et al*
- Harland J, Unwin N, Bhopal R, White M, Watson W, Stephenson P, Alberti KGM.** Low levels of coronary heart disease and risk factors in a UK Chinese population, 130 Pr
- Harrington D** *see* Anker SD *et al*; Chua TP *et al*
- Harris Z** *see* Marshall HJ *et al*
- Hart G** *see* Shipsey SJ *et al*; Singh JP *et al*
- Hausmann D** *see* Blessing E *et al*
- Hawkins M** *see* Kearney MT *et al*; Walsh JT *et al*
- Haworth RS** *see* Avkiran M *et al*
- Hayes A** *see* Wang Z *et al*
- Heagerty AM** *see* Goode GK *et al*; Sinha S and Heagerty AM
- Hearse DJ** *see* Connaughton M *et al*
- Hemingway H** *see* Montgomery HE *et al*
- Henderson AH** *see* Bellamy M *et al*; Tweddel AC *et al*
- Hendry B** *see* Langford EJ *et al*
- Henein M** *see* Knight CJ *et al*
- Henry R** *see* Thorne SA *et al*
- Heriot AG, Barlow CW, Large SR.** Cost implications of reduced left ventricular function in coronary artery bypass surgery, 123 Pr
- Heslop PS** *see* Plummer CJ *et al*
- Heuhns TY** *see* Fath-Ordoubadi F *et al*
- Hickey MS** *see* Brackenbury ET *et al*
- Higham PD** *see* Khurana CS *et al*
- Higson M** *see* Chin D *et al*
- Hillis GS, Al-Mohammad A, Woods M, Jennings KP.** Alterations in the management of cardiac failure: evidence of improvement, 210 MP
- Hillis GS, Mlynski RA, Stewart KN, Jennings KP.** The expression of  $\beta_1$  integrins by cultured human coronary artery vascular smooth muscle cells, 10 Pr
- Hillis WS** *see* Bhargava B *et al*; Birnie D *et al*; MacIntyre PD *et al*
- Hnatkova K, Staunton A, Camm AJ, Malik M.** Comparison of numerical indices of the wavelet and standard time-domain analysis of signal averaged electrocardiogram in survivors of acute myocardial infarction with and without follow-up events, 140 MP
- Ho LKF** *see* Connolly DL *et al*
- Hobson HL** *see* Bowker TJ *et al*
- Höfling B** *see* Huehns TY *et al*
- Hogg KJ** *see* MacIntyre PD *et al*; Pell ACH *et al*; Prasad N *et al*
- Holdright D** *see* Prvulovich E *et al*
- Holme E** *see* Bhargava B *et al*; Birnie D *et al*
- Holt CM** *see* Galea J *et al*; Gunn J *et al*; John AE *et al*
- Holt D** *see* Salomone OA *et al*
- Holt DW** *see* Hossein-Nia M *et al*
- Holt ND, Brady S, Dark JH, McComb JM.** Recipient atrial remnant: does it exhibit normal electrophysiology? 77 Pr
- Holt P** *see* Kamalvand K *et al*
- Hong MK** *see* Redwood SR *et al*
- Hood S** *see* Bhargava B *et al*; Birnie D *et al*
- Hooper J** *see* Jenkins DP *et al*
- Horton R** *see* Pagano D *et al*
- Hossein-Nia M, Goldman JH, Keeling PJ, Holt DW, McKenna WJ.** Creatine kinase isoforms as circulating markers of deterioration in idiopathic dilated cardiomyopathy, 183 MP
- Hossein-Nia M** *see also* Crook R *et al*
- Huehns TY, Esin S, Mrochen S, Pahl C, Engelmann MG, Schmidt M, Höfling B, Günzburg WH, Nikol S.** Local gene transfer of the antisense to senescent cell-derived inhibitor 1 creates neointima, 194
- Huehns TY, Schrittenloher P-K, Mrochen S, Traxler H, Höfling B, Günzburg WH, Nikol S.** Local delivery of the gene for an amphipathic peptide inhibits neointimal hyperplasia, 192
- Huehns TY** *see also* Beatt KJ *et al*
- Huggon I** *see* Chee A *et al*
- Huggon IC, Towner P, Moscoso G, Moniz C, Farzaneh F, Tynan M.** Cloning of human GATA-6: a new regulatory gene with a potential role in the control of myocardial differentiation and growth, 190 MP
- Hughes JMB** *see* Puri S *et al*
- Humphries S** *see* Montgomery H *et al*; Montgomery HE *et al*
- Hutcheson IR, Griffith TM.** Mechanotransduction through the endothelial cytoskeleton mediates flow- but not agonist-induced nitric oxide release, 168 MP
- Hutton I** *see* Woldman S *et al*
- Huwey FU, Belcher PR, McPhaden AR, Naik SK, Wheatley DJ.** The prevalence and natural course of *Helicobacter pylori* among heart transplant recipients, 111 Pr
- Ilsley CD** *see* Grocott-Mason RM *et al*
- Ilsley CDJ** *see* Fotopoulos GD *et al*; Jepson NS *et al*; Mason MJ *et al*
- Imam Z** *see* Harbinson MT *et al*
- Ireland DC** *see* Aggarwal RK *et al*
- Ireland H** *see* Stubbs P *et al*
- Irvine T, Derrick G, Kenny A.** Three-dimensional reconstruction of in vivo colour Doppler flow events - initial experience, 156
- Izzat MB, Mehta D, Jeremy J, Bryan AJ, Newby AC, Angelini GD.** Non-restrictive external stenting reduces medial and neointimal thickening in a pig model of arteriovenous bypass grafting, B
- Izzat MB** *see also* Birdi IS *et al*; Kadir I *et al*
- Jabbar H** *see* Akhras F *et al*
- Jackman WM** *see* Schilling RJ *et al*
- Jackson G** *see* Patel NR *et al*
- Jackson MJ** *see* Grech ED *et al*
- Jain D** *see* Sayer J *et al*
- Jarritt P** *see* Prvulovich E *et al*
- Jayaram L** *see* Fawzy ME *et al*
- Jenkins DP, Pugsley WB, Kemp M, Hooper J, Yellon DM.** Ischaemic preconditioning reduces troponin-T release in patients undergoing cardiac surgery, 240
- Jennings KP** *see* Hillis GS *et al*
- Jepson N** *see* Mason MJ *et al*
- Jepson NS, Fotopoulos GD, Mason MJ, Ewan AE, Paul VE, Ilsley CDJ.** Reduced QT dispersion with repeated ischaemia at angioplasty - evidence of an anti-arrhythmic effect of preconditioning in humans, 144 MP
- Jepson NS** *see also* Fotopoulos GD *et al*
- Jeremy J** *see* Izzat MB *et al*
- Jewitt DE** *see* Hancock J *et al*; Robinson NMK *et al*
- Jin XY, Zhang ZM, Gibson DG, Yacoub MH, Pepper JR.** Remodeling of left ventricular function following aortic valve replacement using stentless valve, 102 Pr
- John AE, Galea J, Francis SE, Holt CM, Crossman DC, Finn A.** Neutrophils are a source of interleukin-8 in human cardiopulmonary bypass surgery, 100 Pr
- John JE** *see* Mounsey JP *et al*
- Johnston J** *see* Singh JP *et al*
- Jones EA** *see* Tweddel AC *et al*
- Jones LR** *see* Mounsey JP *et al*
- Jordan PJ** *see* Griffith M *et al*; Hamdan HK *et al*
- Jubb M** *see* Clarkson P *et al*; Montgomery H *et al*

- Kaddoura S.** Endothelin-1 plays a functional role in noradrenaline-induced ventricular hypertrophy *in vivo* and *in vitro*, C
- Kaddoura S** *see also* Turner LF *et al*
- Kadir I, Izzat MB, Wilde P, Bryan AJ, Angelini GD.** Dynamics of small size St. Jude medical aortic prostheses: *in vivo* studies using dobutamine echocardiography, 105 Pr
- Kahr O** *see* Kelly MP *et al*
- Kamalvand K, Kotsakis A, Tan K, Holt P, Bucknall C, Sulke N.** Do patients prefer mode switching? 215
- Kamalvand K, Stafford P, Tan K, Vincent R, Sulke N.** Does the signal averaged P wave predict duration of sinus rhythm after cardioversion? 139 MP
- Kamalvand K, Tan K, Smeeton N, Stafford P, Vincent R, Sulke N.** Predictors of sinus rhythm duration post intra-atrial cardioversion in patients with chronic atrial fibrillation, 79 Pr
- Kamalvand K** *see also* Sulke N *et al*
- Kanojia A** *see* Delabays A *et al*
- Kaprielian RR, Dupont E, Poole-Wilson PA, Yacoub MH, Khaghani A, Severs NJ.** Angiotensin II receptor type 1 (AT1R) mRNA is upregulated in atria of patients with end-stage heart failure, 27 Pr
- Kaski JC** *see* Crook R *et al*; Elliott PM *et al*; Salomone OA *et al*
- Kaul S** *see* Senior R *et al*
- Kearney MT, Charlesworth A, Hawkins M, Macdonald IA, Cowley AJ.** Postprandial worsening of angina: meal composition and timing are important determinants of onset of ischaemia and chest pain, 41 Pr
- Kearney MT, Macdonald IA, Stubbs TA, Evans AJ, Cowley AJ.** Insulin mediated vasodilatation causes postprandial hypotension in the elderly, 42 Pr
- Kearney P** *see* Ramo MP *et al*
- Keeling PJ** *see* Hossein-Nia M *et al*; Yi G *et al*
- Keenan DJM, Bennett JL, Doyle L, Shaw J, Doran BRH, Douglas JT.** Aprotinin prevents fibrin formation in cardiac surgery, 101 Pr
- Keenan DJM** *see also* Wilde NT *et al*
- Keeton BR** *see* Brown EM *et al*; Dawkins KD *et al*
- Kelly F** *see* Stephens NG *et al*
- Kelly MP, Kahr O, Aalkjaer C, Samani NJ.** Changes in expression of components of the renin-angiotensin system in post myocardial infarction heart failure and after ACE inhibitor treatment, 40 Pr
- Kelly PA** *see* Brecker SJD *et al*
- Kemp M** *see* Jenkins DP *et al*
- Kendall F** *see* Stubbs P *et al*
- Kennedy JA, McArthur JD, Turnbull CM, Reid JH, McMillan NC, Dunn FG, Rae AP, Faichney A, MacLeod K, Parker PG, Robertson LJ.** Radiographic evaluation of Björk-Shiley convexo-concave valves, 178 JC
- Kenny A** *see* Irvine T *et al*
- Kenny RA** *see* Anderson DG *et al*
- Kent KM** *see* Redwood SR *et al*
- Kerawalla A, Broadhurst P, Nathan AW.** Chronic endocardial pacemaker lead extraction using the 'traction-countertraction' technique, 72 Pr
- Kesson E** *see* Pell ACH *et al*
- Khaghani A** *see* Dyke C *et al*; Kaprielian RR *et al*
- Khan B** *see* Fawzy ME *et al*
- Khandekar S, Bossingham CM, Murphy JJ.** 'Open access' echocardiography for suspected heart failure: would a 12 lead electrocardiogram be just as good? 119 Pr
- Khandekar S, Murphy JJ.** Variations in the management of acute myocardial infarction in one health region, 124 Pr
- Khattar R** *see* Senior R *et al*; Soman P *et al*
- Khattar RS, Senior R, Raval U, Lahiri A.** Comparison of arbutamine stress sestamibi SPECT imaging and echocardiography for the detection of coronary artery disease, 50 Pr
- Khurana CS, Mandawat MK, Higham PD, Crilley J, Davies A, Hall JA, de Belder MA.** Mitral valvuloplasty in patients with a left atrial thrombus despite conventional anticoagulation: use of aggressive anticoagulation, 236 MP
- Kiernan L** *see* Montgomery H *et al*; Montgomery HE *et al*
- Kimber P** *see* Salame MY *et al*
- King AR** *see* Bridgeman CJ *et al*
- Kinnear W** *see* Staniforth A *et al*
- Kinsey C** *see* Soman P *et al*
- Knight CJ, Gunning M, Henein M, Vecht R, Sutton R, Gibson DG, Somerville J, Sigwart U.** Gradient reduction following non-surgical septal reduction in hypertrophic obstructive cardiomyopathy is maintained over three month follow-up, 235 MP
- Knight CJ** *see also* Gunning MG *et al*
- Knight RC** *see* Fotopoulos GD *et al*
- Koh TW** *see* Brecker SJD *et al*
- Kondoh Y** *see* Ramsey MW *et al*
- Kooner JS** *see* Baliga R *et al*
- Kotsakis A** *see* Kamalvand K *et al*
- Kox W** *see* Anker SD *et al*
- Kranzhöfer A, Baker AH, Newby AC.** Expression of tissue inhibitors of metalloproteinases (TIMPS) in human saphenous vein, 159 MP
- Kullar K** *see* Griffith M *et al*
- Kyriakidis M, Anastasakis A, Prasad K, Barbetseas J, Coonar A, Theofistou A, Tokta R, Richter D, McKenna WJ, Toutouzas P.** Hypertrophic cardiomyopathy: new evidence suggests utility of ECG as a diagnostic tool, 131
- Laban C** *see* Needham EWA *et al*
- Lahiri A** *see* Basu S *et al*; Khattar RS *et al*; Senior R *et al*; Soman P *et al*
- Lamb D** *see* Ramo MP *et al*
- Lamb RK** *see* Brown EM *et al*
- Lammertsma A** *see* Baliga R *et al*
- Lane D** *see* Stubbs P *et al*
- Lange A, Godman MJ, Palka P, Shaw TRD, Sutherland GR.** Three-dimensional definition of atrial septal defect by Doppler myocardial imaging, 157
- Lange A** *see also* Palka P *et al*
- Langford E** *see* de Belder A *et al*
- Langford EJ, de Belder AJ, Cairns H, Hendry B, Wainwright RJ.** Should patients receiving renal transplants undergo pre-operative cardiac investigation? 122 Pr
- Langford EJ, Salas E, Marrinan MT, Martin JF, de Belder AJ.** Platelet activation and deposition in saphenous vein grafts is inhibited *in vitro* by S-nitrosoglutathione, 15 Pr
- Langford EJ** *see also* de Belder AJ *et al*
- Langley S** *see* Edwards TJ *et al*
- Lansky AJ** *see* Redwood SR *et al*
- Large SR** *see* Heriot AG *et al*
- Laskari C** *see* Cao Q-L *et al*; Delabays A *et al*; Yao J *et al*
- Lawrence J** *see* El Habbal MH *et al*
- Lawson CS** *see* Murphy CF *et al*
- Layton CA** *see* Brecker SJD *et al*
- Lazarus JH** *see* Tweddel AC *et al*
- Lazzam C** *see* Chauhan A *et al*
- Leatham EW** *see* Crook R *et al*
- Lee EM, Porter JN, Shapiro LM, Wells FC.** Mitral valve surgery in the elderly, 110 Pr
- Lee EM, Shapiro LM, Wells FC.** The importance of subvalvular preservation and early operation in mitral valve surgery, 278 MP
- Lees B** *see* Anker SD *et al*
- Lees C** *see* de Belder AJ *et al*
- Lefroy DC** *see* Tousoulis D *et al*
- Lemery R** *see* Connelly DT *et al*
- Leon MB** *see* Redwood SR *et al*
- Leslie WS** *see* Morrison CE *et al*
- Leverment JN** *see* Brackenbury ET *et al*
- Levy RD** *see* Goode GK *et al*; Grant SCD *et al*
- Lewis MJ** *see* Anning PB *et al*; Bellamy M *et al*; Pepper CB *et al*
- Lim R** *see* Walters MI *et al*
- Lincoln C** *see* Chaturvedi R *et al*; Gatzoulis MA *et al*; Shekerdeman L *et al*
- Lindsay HSJ, Batin PD, Nolan JP, Andrews R, Brooksby WP, Mullen M, Neilson JMM, Cowley AJ, Fox KAA, for the Collaborative Heart Failure Study Group.** Late potentials in chronic heart failure: correlation with prognostic markers from a multi-centre study of autonomic dysfunction in heart failure, 32 Pr
- Lindsay HSJ, Mohamed AL, Grasso R, Hainsworth R, Cowan JC.** Impaired baroreceptor sensitivity early after myocardial infarction is associated with ventricular dilatation, 133
- Linka AZ** *see* Rinaldi CA *et al*
- Lip GYH, Blann AD, Lip PL, Gibbs C, Beevers DG.** Left ventricular hypertrophy is associated with abnormal thrombogenesis and endothelial dysfunction, 24 Pr
- Lip PL** *see* Lip GYH *et al*
- Littler WA** *see* Hamdan HK *et al*
- Livesey SA** *see* Edwards TJ *et al*
- Lloyd G** *see* Patel NR *et al*
- Lonn AHR** *see* Prvulovich E *et al*
- Lorimer AR** *see* Wallbridge DR *et al*
- Lowe GDO** *see* McDonagh TA *et al*; Woodward M *et al*
- Lowe HC, Roy PR, Walker BW, Baron DW, Gavaghan TP, Morgan JJ.** Palmaz Schatz stent deployment without intravascular ultrasound guidance using antiplatelet therapy with aspirin alone, 246



- Lucas GS *see* Wilde NT *et al*  
 Ludlam CA *see* Newby DE *et al*  
 Ludman PF *see* Stephens NG *et al*  
 Luu N-T, Brady AJB, Gammage MD. Role of heparin in the regulation of cardiac myocyte growth, 8 Pr  
 Luy L *see* Gladman G *et al*
- McArthur JD *see* Kennedy JA *et al*  
 McArthur P *see* Tweddel AC *et al*  
 McCann HA *see* McKenna CJ *et al*  
 McCluskey MK *see* Morrison C *et al*  
 McColl KEL *see* Birnie D *et al*; McDonagh TA *et al*  
 McComb JM *see* Cooklin M and McComb JM; Holt ND *et al*  
 McCrindle BW *see* Magee AG *et al*  
 McDicken WN *see* Palka P *et al*; Ramo MP *et al*  
 McDonagh TA, Morrison CE, McMurray JJ, Ford I, Tunstall-Pedoe H, Dargie HJ. Determinants of global left ventricular systolic dysfunction in north Glasgow, 266  
 McDonagh TA, Morrison CE, Woodward M, McMurray JJV, Tunstall-Pedoe H, McColl KEL, Lowe GDO, Dargie HJ. *Helicobacter pylori* infection and coronary heart disease in north Glasgow, 212 MPr  
 Macdonald IA *see* Kearney MT *et al*  
 MacDonald TM *see* Clarkson PBM *et al*  
 McEwan J *see* Montgomery H *et al*; Montgomery HE *et al*  
 MacFarlane NG. Myocardium from a chronic coronary artery ligation model has altered responses to reactive oxygen species, 2 Pr  
 Macfarlane PW *see* Wallbridge DR *et al*  
 MacIntyre P *see* Bhargava B *et al*  
 MacIntyre PD, Gemmill JD, Hogg KJ, Dunn FG, Rae AP, Hillis WS. Pre-discharge exercise testing in the prediction of cardiac events over 5 yrs following thrombolysis for acute myocardial infarction, 29 Pr  
 McKay IC *see* Birnie D *et al*  
 McKenna CJ, Codd MB, McCann HA, Sugrue DD. The aetiology of idiopathic dilated cardiomyopathy (DCM): familial prevalence and HLA-types, 202  
 McKenna CJ, Codd MB, McCann HA, Sugrue DD. The aetiology of idiopathic dilated cardiomyopathy (DCM): the first alcohol case-control study, 182 MPr  
 McKenna W *see* Montgomery HE *et al*; Slade AKB *et al*  
 McKenna WJ *see* Elliott PM *et al*; Hossein-Nia M *et al*; Kyriakidis M *et al*; Sepp R *et al*; Yi G *et al*  
 McLaughlin SC *see* Wallbridge DR *et al*  
 McLeod A *see* Chin D *et al*  
 McLeod K *see* Kennedy JA *et al*  
 McLeod K, DeGiovanni J, Silove E, Burrell D, Stumper O, Brawn W. Technetium-sestamibi (MIBI) to estimate left ventricular fibrosis in patients considered for surgical conversion to arterial switch, 69 Pr  
 McMaster D *see* Meleady R *et al*  
 McMillan NC *see* Kennedy JA *et al*  
 McMurray JJ *see* McDonagh TA *et al*  
 McMurray JJV *see* Bonnar C *et al*; McDonagh TA *et al*  
 McPhaden AR *see* Huwez FU *et al*  
 McQuiston A *see* Woldman S *et al*  
 Magee AG, McCrindle BW, Benson LN, Williams WG, Freedom RM. Systemic venous collaterals after the bidirectional cavopulmonary anastomosis - prevalence and risk factors, 149  
 Magee AG, Wax D, Nykanen D, Benson LN. Balloon dilatation of critical aortic stenosis in neonates using an antegrade catheter approach, 67 Pr  
 Magni G *see* Cao Q-L *et al*; Delabays A *et al*; Yao J *et al*  
 Mahadeva H *see* Salame MY *et al*  
 Maisey MN *see* Yates RWM *et al*  
 Malik IS, Anderson MH. Cost-efficacy of cholesterol lowering: West of Scotland Coronary Prevention Study versus the Scandinavian Simvastatin Survival Study, 250  
 Malik M *see* Hnatkova K *et al*; Yi G *et al*  
 Malik N *see* Gunn J *et al*  
 Mandawat MK *see* Khurana CS *et al*  
 Mansfield MW *see* Ossei-Gerning N *et al*  
 Marinho MF *see* Singh JP *et al*  
 Marquis J *see* Chauhan A *et al*  
 Marrinan M *see* de Belder A *et al*  
 Marrinan MT *see* Langford EJ *et al*  
 Marshall HJ, Harris Z, Griffith MJ, Gammage MD. Atrioventricular node ablation and implantation of dual chamber mode-switching pacemakers for paroxysmal atrial fibrillation - effects on quality of life, exercise capacity and left ventricular systolic function, 213
- Martin JF *see* Brown AS *et al*; Dawes KE *et al*; de Belder A *et al*; de Belder AJ *et al*; Langford EJ *et al*; Robinson NMK *et al*  
 Martin W *see* Ng GA *et al*; Salame MY *et al*; Woldman S *et al*  
 Masani ND *see* Cao Q-L *et al*; Delabays A *et al*; Rinaldi CA *et al*; Yao J *et al*  
 Mason MJ, Jepson N, Wright G, Townsend ER, Ilsley CDJ. Complementary role of stellate ganglion blockade and thoracoscopic sympathectomy in the management of intractable angina, 147  
 Mason MJ *see also* Fotopoulos GD *et al*; Jepson NS *et al*  
 Mason NP *see* Mullen MJ *et al*  
 Masumori S *see* Newby DE *et al*  
 Mattu RK *see* Needham EWA *et al*; Sepp R *et al*  
 Means AR *see* Mounsey JP *et al*  
 Megary S *see* Deane ANS *et al*  
 Mehta D *see* Izzat MB *et al*  
 Meleady R, Gallagher P, Shields D, McMaster D, Evans A, Rozen R, Graham I, Whitehead AS. A gene mutation which contributes to coronary heart disease risk, 127 Pr  
 Melkert R *see* Violaris AG *et al*  
 Mendall MA *see* Whincup PH *et al*  
 Metcalfe MJ *see* Byrne J *et al*  
 Mikecz P *see* Al-Mohammad A *et al*  
 Miles J *see* Unsworth-White MJ *et al*  
 Miller P, Sreeram N, Silove E. Intravenous isoprenaline infusion to unmask gradients across the aortic arch during cardiac catheterization, 97 Pr  
 Miller P, Sreeram N, Townsend P, Morton DB. Thermal balloon angioplasty of experimental arterial stenoses in lambs: a pilot study, 23 Pr  
 Mills P *see* Zaman A *et al*  
 Mills PG *see* Richens TE *et al*  
 Mimish L *see* Fawzy ME *et al*  
 Mintz GS *see* Redwood SR *et al*  
 Mitchell A *see* Dyke C *et al*  
 Mitchell AG *see* Grocott-Mason RM *et al*  
 Mitchinson M *see* Stephens NG *et al*  
 Mitchinson MJ *see* Stephens NG *et al*  
 Mlynski RA *see* Hillis GS *et al*  
 Mohamed AL *see* Lindsay HSJ *et al*  
 Monaghan MJ *see* Chin D *et al*; Hancock J *et al*  
 Monard SP *see* Connolly DL *et al*  
 Moniz C *see* Huggon IC *et al*  
 Monroe JL *see* Brown EM *et al*  
 Montgomery H, Kiernan L, Whitworth C, Flemming S, Mullins J, McEwan J. Angiotensin-converting enzyme inhibition at non-hypotensive doses prevents development of malignant hypertension in a rat model, 9 Pr  
 Montgomery H, Nwose D, Arca-Sedda F, Clarkson P, Jubb M, World M, Deanfield J, Winder A, McEwan J, Humphries S. The fibrinogen gene G-143-A polymorphism influences the acute-phase response of serum fibrinogen to severe exercise, 196  
 Montgomery H *see also* Clarkson P *et al*  
 Montgomery HE, Clarkson P, Dollery C, Prasad K, Hemingway H, Kiernan L, Bishop G, Statters D, Talmud P, Humphries S, McKenna W, McEwan J. The renin-angiotensin system and left ventricular hypertrophy: rat and human studies, D  
 Moorman JR *see* Mounsey JP *et al*  
 Moraes F *see* Gatzoulis MA *et al*  
 More RS *see* Chauhan A *et al*; Salame MY *et al*  
 Morgan JJ *see* Lowe HC *et al*  
 Morgan JM *see* Calver AL *et al*; Dawkins KD *et al*; Murphy CF *et al*  
 Moro MA *see* Brown AS *et al*  
 Morris RW *see* Perry IJ *et al*  
 Morrison C, McCluskey MK, Tunstall-Pedoe H. Cholesterol - whom do we test and whom should we test, 114 Pr  
 Morrison C *see also* Tunstall-Pedoe H *et al*  
 Morrison CE, Woodward M, Leslie WS, Tunstall-Pedoe H. The pathway through myocardial infarction - effects of age, sex and socio-economic group, 264  
 Morrison CE *see also* McDonagh TA *et al*; Pell ACH *et al*; Pell JP *et al*  
 Morton DB *see* Miller P *et al*  
 Morton JJ *see* Byrne J *et al*  
 Moscoso G *see* Huggon IC *et al*  
 Moseley D *see* Stubbs P *et al*  
 Mounsey JP, John JE, Chen Z, Moorman JR, Jones LR. Expression of phospholemman 1-43 induces chloride currents in *Xenopus* oocytes, 6 Pr  
 Mounsey JP, John JE, Means AR, Moorman JR. Modulation of oocyte-expressed skeletal muscle sodium channels by NIMA kinase, 7 Pr

- Mrochen S** *see* Huehns TY *et al*  
**Mügge A** *see* Blessing E *et al*  
**Mullen M** *see* Lindsay HSJ *et al*  
**Mullen MJ, Mason NP, Barry PW.** Changes in cardiac parasympathetic activity on induction to and acclimatization to hypobaric hypoxia, 26 Pr  
**Mullins J** *see* Montgomery H *et al*  
**Mullins PA** *see* Chauhan A *et al*  
**Murday AJ** *see* Unsworth-White MJ *et al*  
**Murphy CF, Bulbeck VJ, Chase RC, Lawson CS, Dawkins KD, Morgan JM.** Is mode switching DDDR pacing superior to VVIR pacing following atrioventricular node ablation for refractory atrial fibrillation? 214  
**Murphy JJ** *see* Khandekar S *et al*; Khandekar S and Murphy JJ  
**Musialek P** *see* Singh JP *et al*
- Naik SK** *see* Huwez FU *et al*  
**Nathan AW** *see* Kerawalla A *et al*  
**Natt RS** *see* Needham EWA *et al*  
**Needham EWA, Sweetnam P, Laban C, Natt RS, Yarnell J, Mattu RK.** The lipoprotein lipase gene locus associates with serum HDL and apo-AI levels, 164 MP  
**Needham EWA** *see also* Sepp R *et al*  
**Neillson JMM** *see* Lindsay HSJ *et al*  
**NETWORK Investigators** *see* Poole-Wilson PA  
**Newby A** *see* Zaltsman A and Newby A  
**Newby AC** *see* Izzat MB *et al*; Kranzhöfer A *et al*  
**Newby DE, Boon NA, Webb DJ, Ludlam CA, Fox KAA, Wright RA.** Effect of intra-arterial substance P on the release of tissue plasminogen activator in the human forearm, 13 Pr  
**Newby DE, Masumori S, Boon NA, Webb DJ.** Angiotensin II does not contribute to basal forearm vascular tone in healthy man, 12 Pr  
**Ng GA, Martin W, Rae AP, Rankin AC, Cobbe SM.** Late ventricular activation identified with radionuclide ventriculography in arrhythmogenic right ventricular dysplasia, 52 Pr  
**Niazi K** *see* Fawzy ME *et al*  
**Nikol S** *see* Huehns TY *et al*  
**Noble M** *see* Stubbs P *et al*  
**Noble MIM** *see* Stubbs P *et al*  
**Nolan JP** *see* Lindsay HSJ *et al*  
**Norell MS** *see* Walters MI *et al*  
**Norgård G** *see* Gatzoulis MA *et al*  
**Norris RM** *see* Dixon GF *et al*  
**Norton MY** *see* Al-Mohammad A *et al*; Trent RJ *et al*  
**Nwose D** *see* Montgomery H *et al*  
**Nykanen D** *see* Magee AG *et al*
- Oakley CM** *see* Dutka DP *et al*; Puri S *et al*  
**O'Callaghan C** *see* Salame MY *et al*  
**O'Connor B** *see* Stubbs P *et al*  
**O'Donoghue A** *see* Sepp R *et al*  
**O'Farrell D** *see* Slade AKB *et al*  
**O'Gara P** *see* Davies CH *et al*  
**O'Hare D** *see* Fluck DS *et al*  
**O'Neill BJ** *see* Chauhan A *et al*  
**Osbourn JK** *see* Connolly DL *et al*  
**Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson JJ, Grant PJ.** Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to myocardial infarction in patients undergoing coronary angiography, 257 MP  
**Ovaert C, Rosenthal E, Qureshi SA, Baker EJ, Tynan M.** Outcome after transcatheter valvotomy for pulmonary valvar atresia and intact septum in neonates, 237 MP
- Pagano D, Camici PG, Horton R, Townsend JN, Apple KA, Bonser RS.** Revascularisation in ischaemic cardiomyopathy: effects on exercise capacity and ejection fraction, 244  
**Pagano D, Rooney SJ, Bognolo G, Graham TR, Bonser RS.** Aortic root replacement with a zero porosity gelatin-impregnated composite graft, 108 Pr  
**Pahl C** *see* Huehns TY *et al*  
**Palka P, Lange A, Fleming AD, Starkey IR, Fenn LN, Shaw TRD, Fox KAA, McDicken WN, Sutherland GR.** Transmural velocity gradients - a new ultrasonic index for hypertrophic cardiomyopathy hearts, 61 Pr  
**Palka P** *see also* Lange A *et al*  
**Pandian NG** *see* Cao Q-L *et al*; Delabays A *et al*; Yao J *et al*  
**Parker DJ** *see* Unsworth-White MJ *et al*  
**Parker PG** *see* Kennedy JA *et al*  
**Parry D, Foulsham L, Banner N, Wharton J, Yacoub M.** Functional and clinical significance of sympathetic reinnervation following cardiac transplantation, 107 Pr  
**Parry G** *see* Villaquiran J *et al*  
**Parsons A** *see* Stephens NG *et al*  
**Patel A** *see* Fawzy ME *et al*  
**Patel NR, Tan K, Chia H, Lloyd G, Corr L, Sulke N, Brennand-Roper D, Jackson G, Bucknall C.** Intra-coronary stent deployment: is antiplatelet therapy sufficient? 93 Pr  
**Paul E** *see* Sayer J *et al*  
**Paul VE** *see* Fotopoulos GD *et al*; Jepson NS *et al*  
**Pell ACH, Kesson E, Srikanthan VS, Prasad N, Hogg KJ, Morrison CE, Dunn FG.** How should open access echocardiography be organised? Lessons from a directed access service, 117 Pr  
**Pell ACH, Srikanthan VS, Prasad N, Kesson E, Morrison CE, Hogg KJ, Dunn FG.** Achieving effective use of general practitioner requested echocardiography: should access be open or targeted? 132  
**Pell ACH** *see also* Pell JP *et al*; Prasad N *et al*  
**Pell JP, Pell ACH, Morrison CE, Blatchford O, Dargie HJ.** Factors affecting uptake of cardiac rehabilitation in Glasgow, 208 MP  
**Penn IM** *see* Chauhan A *et al*  
**Pennell DJ, Gatehouse PD, Burman ED, Underwood SR, Firmin DN.** Myocardial perfusion imaging performed using echoplanar single shot magnetic resonance imaging with a mobile 0.5 Tesla scanner, 225 MP  
**Pennell DJ** *see also* Gunning MG *et al*  
**Penny DJ, Sano T, Forster KM, Smolich JJ.** Increased modulation by nitric oxide of dobutamine-induced pulmonary vasodilation during postnatal development in sheep, 22 Pr  
**Penny DJ, Sano T, Forster KM, Smolich JJ.** Increases in systemic oxygen consumption offset improvements in systemic oxygen delivery during dobutamine infusion in newborn lambs, 39 Pr  
**Penston H** *see* Cowie MR *et al*  
**Pepper CB, Lewis MJ, Shah AM.** Assessment of steady state myofilament calcium response in intact isolated cardiac myocytes: modulation by the cardiac endothelium, 267 JC  
**Pepper J** *see* Gunning MG *et al*  
**Pepper JR** *see* Jin XY *et al*  
**Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG.** Serum total homocysteine and coronary heart disease in middle-aged British men, 180 JC  
**Perry IJ** *see also* Whincup PH *et al*  
**Petch MC** *see* Chauhan A *et al*; Stephens NG *et al*  
**Peters KG** *see* Channon KM *et al*  
**Peters NS, Coromilas J, Severs NJ, Wit AL.** Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of canine infarcts that cause ventricular tachycardia, 78 Pr  
**Peters NS** *see also* Schilling RJ *et al*  
**Philippou H** *see* Stubbs P *et al*  
**Pichard AD** *see* Redwood SR *et al*  
**Pieters F** *see* Fawzy ME *et al*  
**Plummer CJ, Furniss SS, Heslop PS, Walker DJ.** Objective assessment of activity in heart disease, 125 Pr  
**Poloniecki JD, Atkinson RW, Ponce de Leon A, Anderson HR.** Emergency admissions in London for acute myocardial infarction are associated with short-term increases in atmospheric pollution: are there any implications? 118 Pr  
**Ponce de Leon A** *see* Poloniecki JD *et al*  
**Ponikowski P** *see* Anker SD *et al*; Chua TP *et al*  
**Poole-Wilson PA.** The NETWORK Study. The effect of dose of an ACE-inhibitor on outcome in patients with heart failure, 185 MP  
**Poole-Wilson PA** *see also* Anker SD *et al*; Chua TP *et al*; Cowie MR *et al*; Davies CH *et al*; Elliott PM *et al*; Kaprielian RR *et al*; Turner LF *et al*  
**Popma JJ** *see* Redwood SR *et al*  
**Porter JN** *see* Lee EM *et al*  
**Powe A** *see* Clarkson P *et al*  
**Powe AJ** *see* Thorne SA *et al*  
**Poyner RM** *see* Hamdan HK *et al*  
**Prasad K** *see* Kyriakidis M *et al*; Montgomery HE *et al*; Sepp R *et al*  
**Prasad N, Wright A, Pell ACH, Rae AP, Hogg KJ, Dunn FG.** Direct admission to the coronary care unit by the ambulance service in patients with suspected myocardial infarction, 263  
**Prasad N** *see also* Clarkson PBM *et al*; Pell ACH *et al*  
**Prendergast BD, Shandall A, Buchalter MB.** What do we do when thrombolysis fails? A United Kingdom survey, 265  
**Pringle SD** *see* Wallbridge DR *et al*



- Prvulovich E, Bomanji J, Holdright D, Costa D, Ell PJ.** The role of  $^{18}\text{F}$ -FDG SPET in detection of hibernating myocardium: comparison with rest-redistribution  $^{201}\text{Tl}$  SPET, 241
- Prvulovich E, Lonn AHR, Bomanji J, Jarritt P, Ell PJ.** Attenuation correction in thallium myocardial perfusion imaging, 57 Pr
- Pugsley WB** *see* Jenkins DP *et al*
- Puri S, Baker BL, Dutka DP, Oakley CM, Hughes JMB, Cleland JGF.** Inhalation of nitric oxide improves the cardiac output response to exercise in chronic heart failure, 135
- Purkayastha DD** *see* Redwood SR *et al*
- Pyke SDM** *see* Bowker TJ *et al*; Wood DA *et al*
- Qureshi SA** *see* Chee A *et al*; Ovaert C *et al*
- Radomski M** *see* Brown AS *et al*
- Radvan J** *see* Calver AL *et al*
- Rae AP** *see* Kennedy JA *et al*; MacIntyre PD *et al*; Ng GA *et al*; Prasad N *et al*
- Ramo MP, Spencer T, Sutherland GR, Salter DM, Kearney P, Lamb D, Shaw TRD, McDicken WN, Erbel R, Fitzgerald P.** Can radiofrequency data analysis of intravascular ultrasound accurately characterize coronary atherosclerosis? 153
- Ramrakha P** *see* Dutka DP *et al*
- Ramsdale DR** *see* Grech ED *et al*
- Ramsey MW, Goodfellow J, Kondoh Y, Sugawara M, Yaginuma T.** Effects of posture on systemic arterial wave intensity in man, 35 Pr
- Ramsey MW** *see also* Bellamy M *et al*
- Ranjadayalan K** *see* Sayer J *et al*
- Rankin AC** *see* Ng GA *et al*
- Raval U** *see* Basu S *et al*; Khattar RS *et al*; Senior R *et al*; Soman P *et al*
- Rawles J, Sinclair C, Waugh N.** Call-to-needle times in Grampian: the pivotal role of the general practitioner in achieving early thrombolysis, 205 MP
- Ray S** *see* Sayer J *et al*; Senior R *et al*
- Reardon K** *see* Yi G *et al*
- Redington A** *see* Chaturvedi R *et al*; Shekerdemian L *et al*
- Redington AN** *see* Gatzoulis MA *et al*
- Redwood SR, Popma JJ, Kent KM, Pichard AD, Satler LF, Mintz GS, Hong MK, Clark CE, Bucher TA, Lansky AJ, Purkayastha DD, Leon MB.** Prognostic significance of CK-MB elevation following ablative new-device angioplasty in native coronary arteries, 248
- Rees P** *see* Adwani S *et al*
- Refsum H** *see* Perry IJ *et al*
- Regragui IA** *see* Birdi IS *et al*
- Reid JH** *see* Kennedy JA *et al*
- Rhodes C** *see* Baliga R *et al*
- Ricci DR** *see* Chauhan A *et al*
- Richens T** *see* Zaman A *et al*
- Richens TE, Stevens CR, Blake DR, Mills PG.** The effect of monocyte co-culture on smooth muscle cell proliferation, 19 Pr
- Richter D** *see* Kyriakidis M *et al*
- Riemersma RA** *see* Bowker TJ *et al*
- Rifai A** *see* Fawzy ME *et al*
- Rinaldi CA, Linka AZ, Masani ND, Hall RJC.** Cumulative and prolonged left ventricular dysfunction due to myocardial stunning following repetitive exercise-induced ischaemia, 181 MP
- Rinaldi CA, Linka AZ, Masani ND, Hall RJC.** Ischaemic preconditioning attenuates myocardial stunning following repetitive exercise, 269 JC
- Rinaldi CA, Linka AZ, Masani ND, Hall RJC.** Postischaemic overshoot precedes exercise-induced myocardial stunning, 239
- Rizo L** *see* Chauhan A *et al*
- Roberts DH** *see* Davis GK and Roberts DH
- Robertson LJ** *see* Kennedy JA *et al*
- Robinson NMK, Baylis SA, Westmore KR, Martin JF, Charles IG.** In-situ hybridisation localises myocardial inducible nitric oxide synthase mRNA to non-myocyte cells during septic shock, 4 Pr
- Robinson NMK, Wainwright RJ, Thomas MR, Jewitt DE.** Is reduced anticoagulation effective following optimal stent deployment? 90 Pr
- Rooney SJ** *see* Pagano D *et al*
- Rosano GMC** *see* Elliott PM *et al*
- Rosen S** *see* Tousoulis D *et al*
- Rosenthal E** *see* Chee A *et al*; Ovaert C *et al*
- Ross DN** *see* Chambers JC *et al*
- Rothman M** *see* Zaman A *et al*
- Rothman MT** *see* Brecker SJD *et al*
- Roy L** *see* Chauhan A *et al*
- Roy PR** *see* Lowe HC *et al*
- Rozen R** *see* Meleady R *et al*
- Rustom M** *see* Akhras F *et al*
- Sadoul N** *see* Slade AKB *et al*
- Saito J** *see* Doig JC *et al*
- Salame MY, Kimber P, O'Callaghan C, Frantz S, de Bono D, Williams B.** Cyclical mechanical strain induces plasminogen activator inhibitor-1 expression in human vascular smooth muscle cells, 258 MP
- Salame MY, More RS, Martin W, Mahadeva H, de Bono DP.** Time sequence of changes in vessel wall urokinase-type plasminogen activator following experimental angioplasty, 195
- Salas E** *see* de Belder A *et al*; Langford EJ *et al*
- Salmon AP** *see* Brown EM *et al*; Dawkins KD *et al*
- Salomone OA, Elliott PM, Zhang Y, Calviño R, Holt D, Kaski JC.** Plasma endothelin levels correlate with the severity of coronary atherosclerosis in patients with chronic stable angina pectoris, 260 MP
- Salomone OA** *see also* Crook R *et al*
- Salter DM** *see* Ramo MP *et al*
- Samani NJ** *see* Kelly MP *et al*
- Sano T** *see* Penny DJ *et al*
- Santini F, Stavri G, Edwards S, Dyke C, Yacoub M.** Early results of a prospective randomized trial of homograft versus pulmonary autograft replacement of the aortic valve, 151
- Santini F** *see also* Dyke C *et al*
- Satler LF** *see* Redwood SR *et al*
- Saumarez RC** *see* Slade AKB *et al*
- Sawyer J** *see* Grant SCD *et al*
- Sayer J, Jain D, Ranjadayalan K, Paul E, Ray S, Timmis AD.** Prognosis in patients with chest pain referred for outpatient cardiological assessment, 128 Pr
- Schapira AHV** *see* Turner LF *et al*
- Schilling RJ, Jackman WM, Peters NS, Beatty G, Davies DW.** Initial experience with mapping human endocardial activation using a novel non-contact catheter mapping system, 217
- Schmidt M** *see* Huehns TY *et al*
- Schofield PM** *see* Chauhan A *et al*; Stephens NG *et al*
- Schrittenloher P-K** *see* Huehns TY *et al*
- Schwartz SL** *see* Delabays A *et al*
- Scott J** *see* Baliga R *et al*
- Searl C** *see* Tweddel AC *et al*
- Seed M** *see* Stubbs P *et al*
- Senior R, Kaul S, Raval U, Lahiri A.** Painless myocardial ischaemia is an important factor in the genesis of effort intolerance in severe congestive heart failure due to coronary artery disease, 184 MP
- Senior R, Soman P, Ray S, Basu S, Khattar R, Lahiri A.** Dobutamine stress echocardiography reliably predicts future cardiac events in patients undergoing diagnostic coronary angiography, 58 Pr
- Senior R** *see also* Basu S *et al*; Khattar RS *et al*; Soman P *et al*
- Sepp R, Mattu RK, Needham EWA, Elliott P, Prasad K, O'Donoghue A, McKenna WJ.** Myotonic kinase gene (CTG)n repeat associates with hypertrophic cardiomyopathy, 45 Pr
- Serruys PW** *see* Dawkins KD *et al*; Violaris AG *et al*
- Sethia B** *see* Brawn W *et al*; Gupta NK *et al*
- Severs NJ** *see* Kaprielian RR *et al*; Peters NS *et al*
- Shah AM** *see* Anning PB *et al*; Draper NJ and Shah AM; Pepper CB *et al*
- Shanahan CM** *see* Clesham GJ *et al*; Connolly DL *et al*
- Shandall A** *see* Prendergast BD *et al*
- Shankar S** *see* Gupta NK *et al*
- Shaper AG** *see* Perry IJ *et al*
- Shapiro LM** *see* Lee EM *et al*; Stephens NG *et al*
- Shattock MJ** *see* Connaughton M *et al*
- Shaw J** *see* Keenan DJM *et al*
- Shaw TRD** *see* Lange A *et al*; Palka P *et al*; Ramo MP *et al*
- Shekerdemian L, Shore D, Lincoln C, Bush A, Redington A.** The differential effects of negative pressure ventilation (NPV) on cardiac output in children, 177 JC
- Shepherd L** *see* Gunn J *et al*
- Sheppard MN** *see* Bowker TJ *et al*
- Sheridan DJ** *see* Fluck DS *et al*
- Shetty GA** *see* Channon KM *et al*
- Shields D** *see* Meleady R *et al*
- Shinebourne EA** *see* Gatzoulis MA *et al*
- Shipsey SJ, Bryant SM, Hart G.** A cellular basis for T wave inversion in cardiac hypertrophy? 188 MP

- Shipsey SJ, Bryant SM, Hart G.** Differential effects of hypertrophy on regional density of the transient outward current, 5 Pr
- Shipsey SJ, Bryant SM, Hart G.** Regional effects of cardiac hypertrophy: a basis for arrhythmogenesis? 189 MP
- Shore D** *see* Chaturvedi R *et al*; Shekerdemian L *et al*
- Shore DF** *see* Gatzoulis MA *et al*
- Showell N** *see* Al-Mohammad A *et al*
- Sigwart U** *see* Dawkins KD *et al*; Knight CJ *et al*
- Silove E** *see* Brawn W *et al*; McLeod K *et al*; Miller P *et al*
- Silverman E** *see* Gladman G *et al*
- Simpson IA** *see* Calver AL *et al*; Dawkins KD *et al*; Edwards TJ *et al*
- Sinclair C** *see* Rawles J *et al*
- Singh JP, Johnston J, Sleight P, Casadei B, Hart G.** Morning increase in QT interval variability: implications for mechanisms underlying the circadian pattern of cardiac risk, 80 Pr
- Singh JP, Marinho MF, Sleight P, Johnston J, Hart G.** Abnormal rate adaptation of the QT interval in patients with hypertensive left ventricular hypertrophy, 83 Pr
- Singh JP, Marinho MF, Sleight P, Musialek P, Hart G.** The influence of beta-blockade on rate dependent changes of the QT interval in acute myocardial infarction, 84 Pr
- Sinha S, Heagerty AM.** Adventitial changes following coronary artery balloon injury, 14 Pr
- Sivanandam V** *see* Fawzy ME *et al*
- Sivananthan M** *see* Deane ANS *et al*
- Skene AM** *see* Wilcox RG *et al*
- Slade AKB, Blankoff I, Sadoul N, Bygrave A, O'Farrell D, McKenna W, Saumarez RC.** Intramyocardial conduction abnormalities in idiopathic dilated cardiomyopathy may refine risk assessment, 216
- Sleight P** *see* Singh JP *et al*
- Smallhorn J** *see* Gladman G *et al*
- Smeeton N** *see* Kamalvand K *et al*; Sulke N *et al*
- Smith EEJ** *see* Unsworth-White MJ *et al*
- Smith LJ** *see* El Habbal MH and Smith LJ
- Smolich JJ** *see* Penny DJ *et al*
- Sogliani F** *see* Spyrou N *et al*
- Soman P, Basu S, Raval U, Kinsey C, Khattar R, Senior R, Lahiri A.** Reverse redistribution of thallium after myocardial infarction indicates low risk, 49 Pr
- Soman P** *see also* Senior R *et al*
- Somerville J** *see* Chambers JC *et al*; Knight CJ *et al*
- Sosnowski AW** *see* Brackenbury ET *et al*
- Spencer T** *see* Ramo MP *et al*
- Sporton S, Hardman S, Sutton P, Walker J, Grahame-Clark C, Taggart P.** Can the QT interval be used to detect increased dispersion of repolarisation induced by ischaemia? 85 Pr
- Spyrou N, Foale R, Davies DW, Sogliani F, Stanbridge RdeL, Camici PG.** Progressive recovery of tissue perfusion following coronary artery bypass grafting: evidence of 'microvascular stunning' in man, 233 MP
- Spyt TJ** *see* Brackenbury ET *et al*
- Sreeram N** *see* Brawn W *et al*; Miller P *et al*
- Sridhar K** *see* Chauhan A *et al*
- Srikanthan VS** *see* Pell ACH *et al*
- Stables RH.** A new concept database for interventional cardiology: improving data collection with an advanced graphical user interface, 87 Pr
- Stables RH, Denne L.** Testing the appropriateness of coronary revascularisation: application of the University of Maryland Revascularisation Appropriateness Scoring System (RAS) to UK angioplasty practice, 221 MP
- Stafford P** *see* Kamalvand K *et al*; Sulke N *et al*
- Stanbridge RdeL, Cohen A, Hadjinicolaou L, Al-Katoubi A.** Early experience with minimal invasive coronary artery bypass grafting, 232 MP
- Stanbridge RdeL** *see also* Spyrou N *et al*
- Staniforth A, Kinnear W, Cowley A.** Predictors and prevalence of nocturnal desaturation in patients with maximally treated stable cardiac failure, 43 Pr
- Starkey IR** *see* Palka P *et al*
- Statters D** *see* Montgomery HE *et al*
- Staunton A** *see* Hnatkova K *et al*
- Stavri G** *see* Santini F *et al*
- Steinhaus DM** *see* Connelly DT *et al*
- Stephens NG, Ludman PF, Petch MC, Schofield PM, Shapiro LM.** Changing from aggressive anticoagulation to treatment with aspirin alone for coronary stents: the experience of one centre in the UK, 92 Pr
- Stephens NG, Parsons A, Cheeseman K, Kelly F, Schofield PM, Mitchinson MJ, Brown MJ.** Anticoagulant effects of vitamin E treatment in patients with coronary disease, 282 MP
- Stephens NG, Parsons A, Schofield PM, Mitchinson M, Brown MJ.** A randomised controlled trial of vitamin E in patients with coronary disease: the Cambridge Heart Antioxidant Study (CHAOS), 176 JC
- Stephenson P** *see* Harland J *et al*
- Stevens CR** *see* Richens TE *et al*
- Stevenson JC** *see* Wingrove CS and Stevenson JC
- Stewart KN** *see* Hillis GS *et al*
- Stickland MH** *see* Ossei-Gerning N *et al*
- Strachan DP** *see* Whincup PH *et al*
- Strong R** *see* Dutka DP *et al*
- Struthers AD** *see* Bonnar C *et al*
- Stubbs P, Collinson P, Kendall F, Noble M, Seed M.** The prognostic significance of lipoprotein(a) concentrations following myocardial infarction, 249
- Stubbs P, Ireland H, Noble M, Bayston T, Lane D.** Prothrombotic importance of the Factor V Leiden genotype mutation in acute coronary syndromes, 18 Pr
- Stubbs P, Philippou H, Collinson P, Moseley D, Noble M, Lane D.** Admission coagulation activation in patients with unstable angina in relation to cardiac troponin T concentrations, 281 MP
- Stubbs P, Seed M, Collinson P, O'Connor B, Moseley D, Noble MIM.** The role of lipoprotein(a) in the pathogenesis of unstable angina, 34 Pr
- Stubbs P** *see also* Beatt KJ *et al*
- Stubbs TA** *see* Kearney MT *et al*
- Stumper O** *see* McLeod K *et al*
- Sturm M** *see* Blessing E *et al*
- Sugawara M** *see* Ramsey MW *et al*
- Sugrue DD** *see* McKenna CJ *et al*
- Sulke N, Kamalvand K, Tan K, Smeeton N, Stafford P, Vincent R.** A prospective evaluation of recurrent atrial endocardial defibrillation in patients with refractory chronic atrial flutter and fibrillation, 137 MP
- Sulke N** *see also* Kamalvand K *et al*; Patel NR *et al*
- Sullivan ID** *see* Foran JPM *et al*
- Sutherland GR** *see* Lange A *et al*; Palka P *et al*; Ramo MP *et al*
- Sutton GC** *see* Cowie MR *et al*
- Sutton P** *see* Sporton S *et al*
- Sutton R** *see* Knight CJ *et al*
- Swan L** *see* Bhargava B *et al*
- Swann G** *see* Akhras F *et al*
- Sweetnam P** *see* Needham EWA *et al*
- Taggart P** *see* Sporton S *et al*
- Talmud P** *see* Montgomery HE *et al*
- Tan K** *see* Kamalvand K *et al*; Patel NR *et al*; Sulke N *et al*
- Tavendale R** *see* Tunstall-Pedoe H *et al*
- Taylor G** *see* Chauhan A *et al*
- Taylor JFN** *see* El Habbal MH *et al*
- Theofistou A** *see* Kyriakidis M *et al*
- Thomas MR** *see* Hancock J *et al*; Robinson NMK *et al*
- Thompson S** *see* Cowie MR *et al*
- Thompson SG** *see* Bowker TJ *et al*; Wood DA *et al*
- Thomson H** *see* Thorne SA *et al*
- Thomson R** *see* Anderson DG *et al*
- Thorne SA, Clarkson P, Henry R, Donald AE, Thomson H, Powe AJ, Bull T, Deanfield JE.** Mechanisms of impaired vascular reactivity in insulin dependent diabetes mellitus and hypercholesterolaemia, 251 MP
- Thurston H** *see* Glancy JM *et al*
- Till JA** *see* Gatzoulis MA *et al*
- Timeyin J** *see* Warren A *et al*
- TIMI 9 Investigators.** Hirudin (<sup>TM</sup>Revasc) vs heparin after thrombolysis in acute myocardial infarction: preliminary results from the TIMI 9B study, 171
- Timmis AD** *see* Brecker SJD *et al*; Sayer J *et al*
- Tokta R** *see* Kyriakidis M *et al*
- Tousoulis D, Davies G, Lefroy DC, Rosen S, Haider AW, Crake T.** Localised endothelial dysfunction in patients with chest pain and normal coronary arteriograms, 253 MP
- Tousoulis D** *see also* Haider AW *et al*
- Toutouzas P** *see* Kyriakidis M *et al*
- Townend JN** *see* Pagano D *et al*
- Towner P** *see* Huggon IC *et al*
- Townsend ER** *see* Mason MJ *et al*
- Townsend P** *see* Miller P *et al*
- Traxler H** *see* Huehns TY *et al*
- Treasure T** *see* Unsworth-White MJ *et al*
- Trent RJ, Adams JN, Al-Mohammad A, Norton MY, Walton S.** Gated rest 99 Tm MIBI-SPECT in the assessment of myocardial viability: comparison with 13 NH3/18 FDG PET, 56 Pr

- Trouton T** *see* Harbinson MT *et al*  
**Tsang VT** *see* Brown EM *et al*  
**Tunstall-Pedoe H, Morrison C, Woodward M.** 28-day case fatality of coronary events, and the proportion of out of hospital deaths, in relation to age, sex and previous coronary heart disease (CHD): the Glastow MONICA Project, 203 MPr  
**Tunstall-Pedoe H, Woodward M, Tavendale R.** Serum total cholesterol, HDL-cholesterol and non-fasting triglycerides, and eight-year coronary events in the follow-up of men and women in the Scottish Heart Health Study (SHHS), 120 Pr  
**Tunstall-Pedoe H** *see also* McDonagh TA *et al*; Morrison C *et al*; Morrison CE *et al*; Woodward M *et al*  
**Turnbull CM** *see* Kennedy JA *et al*  
**Turner LF, Kaddoura S, Cooper JM, Schapira AHV, Poole-Wilson PA.** Previously-reported mitochondrial DNA mutations are not a common cause of idiopathic dilated cardiomyopathy, 201  
**Tweddel AC, Jones EA, Evans W, Goodfellow J, Ellis G, McArthur P, Bellamy M, Henderson AH.** Vascular or myocardial abnormality in microvascular angina: thallium and technetium perfusion imaging compared, 54 Pr  
**Tweddel AC, Searl C, Ahmed J, Jones EA, Evans W, Lazarus JH.** Thallium scans in patients with thyrotoxicosis, 55 Pr  
**Tynan M** *see* Chee A *et al*; Huggon IC *et al*; Ovaert C *et al*  
**Tynan MJ** *see* Yates RWM *et al*
- Ueland PM** *see* Perry IJ *et al*  
**Underwood M** *see* Birdi I *et al*  
**Underwood SR** *see* Gunning MG *et al*; Pennell DJ *et al*  
**United Kingdom Heart Attack Study Group** *see* Wong PSC  
**Unsworth-White MJ, Miles J, Whitley E, Treasure T, Murday AJ.** Changes in left ventricular dimensions after aortic valve replacement, 277 MPr  
**Unsworth-White MJ, Valencia O, Murday AJ, Parker DJ, Treasure T, Smith EEJ.** Cerebral events after cardiac surgery, 273 MPr  
**Unwin N** *see* Harland J *et al*
- Valencia O** *see* Unsworth-White MJ *et al*  
**Vallance P** *see* Bhagat K *et al*  
**Vannan MA** *see* Yao J *et al*  
**Vecht R** *see* Knight CJ *et al*  
**Villaquiran J, Parry G, Dark JH, Forty J.** Post-infarct septal rupture - improvement in surgical outcome in the nineties, 103 Pr  
**Vincent R** *see* Dixon GF *et al*; Kamalvand K *et al*; Sulke N *et al*  
**Violaris AG, Melkert R, Serruys PW.** Favourable arterial remodelling (defined as a negative absolute loss) after coronary angioplasty. A quantitative angiographic analysis, 222 MPr  
**von Sinner W** *see* Fawzy ME *et al*
- Wainwright RJ** *see* Hancock J *et al*; Langford EJ *et al*; Robinson NMK *et al*  
**Walker BW** *see* Lowe HC *et al*  
**Walker DJ** *see* Plummer CJ *et al*  
**Walker J** *see* Sporton S *et al*  
**Walker M** *see* Whincup PH *et al*  
**Wallbridge DR, McLaughlin SC, Cobbe SM, Macfarlane PW, Lorimer AR, Dunn FG, Pringle SD.** Impaired heart rate variability predicts increased mortality in hypertensive left ventricular hypertrophy, 141 MPr  
**Walsh J** *see* Andrews R *et al*  
**Walsh JT, Charlesworth A, Andrews R, Hawkins M, Cowley AJ.** Daily activity levels predict prognosis in patients with chronic heart failure, 38 Pr  
**Walters MI, Wright M, Lim R, Norell MS, Caplin JL.** Current guidelines for DC cardioversion of atrial fibrillation: low energy or low efficacy? 146 MPr  
**Walton S** *see* Al-Mohammad A *et al*; Trent RJ *et al*  
**Wang Z, Cooke R, Hayes A, Chambers JB.** Left ventricular mass correlates better with valve resistance than effective orifice area in aortic stenosis, 59 Pr  
**Warren A, Wong PSC, Timeyin J, Davidson C.** Implementation of guidelines for prescribing angiotensin converting enzyme inhibitors for the management of heart failure in hospital, 126 Pr  
**Waters M** *see* Connelly DT *et al*  
**Watson W** *see* Harland J *et al*  
**Waugh N** *see* Rawles J *et al*
- Wax D** *see* Magee AG *et al*  
**Webb DJ** *see* Newby DE *et al*  
**Webb JG** *see* Chauhan A *et al*  
**Webb-Peploe K** *see* Chua TP *et al*  
**Weissberg PL** *see* Clesham GJ *et al*; Connolly DL *et al*  
**Wells FC** *see* Lee EM *et al*  
**Westmore KR** *see* Robinson NMK *et al*  
**Weston PJ** *see* Glancy JM *et al*  
**Wharton J** *see* Parry D *et al*  
**Wharton N** *see* Goode GK *et al*  
**Wheatley DJ** *see* Huwez FU *et al*  
**Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M.** *Helicobacter pylori* infection and coronary heart disease in middle-aged men: prospective relations in a nested case-control study, 211 MPr  
**White M** *see* Harland J *et al*  
**White P** *see* Chaturvedi R *et al*  
**Whitehead AS** *see* Meleady R *et al*  
**Whitehead B** *see* Adwani S *et al*  
**Whitley E** *see* Unsworth-White MJ *et al*  
**Whitworth C** *see* Montgomery H *et al*  
**Wilcox RG, Hampton JR, Charlesworth A, Skene AM.** Differences in short-term outcome for acute MI between Germany and the UK: the role of clinical trial data in the resource utilisation debate, 204 MPr  
**Wilde NT, Burgess R, Keenan DJM, Lucas GS.** The effect of cardiopulmonary bypass (CPB) on the circulating megakaryocytes, 109 Pr  
**Wilde P** *see* Kadir I *et al*  
**Williams A** *see* Grant SCD *et al*  
**Williams B** *see* Salame MY *et al*  
**Williams GJ** *see* Ball JB *et al*; Deaner ANS *et al*  
**Williams R** *see* Zaman A *et al*  
**Williams WG** *see* Magee AG *et al*  
**Wilson IJ** *see* Ossei-Gerning N *et al*  
**Winder A** *see* Montgomery H *et al*  
**Wingrove CS, Stevenson JC.** Effect of 17 $\beta$ -estradiol on endothelin-1 release by human endothelial cells, 20 Pr  
**Winlove CP** *see* Fluck DS *et al*  
**Wit AL** *see* Peters NS *et al*  
**Woldman S, McQuiston A, Martin W, Hutton I.** Arbutamine blood pool ventriculography: an alternative to exercise thallium scintigraphy? 51 Pr  
**Wong C** *see* Chauhan A *et al*  
**Wong PSC.** Acute myocardial infarction presenting with primary ST depression: the need for early intervention, 170  
**Wong PSC** *see also* Warren A *et al*  
**Wong YK, Ginks WR.** Post mortem findings in assessing success of out of hospital resuscitation, 206 MPr  
**Wood DA, Pyke SDM, Thompson SG.** Cholesterol lowering drug therapy in the prevention of coronary heart disease in the population - evidence from WOSCOPS and 4S applied to the British Family Heart Study, 115 Pr  
**Wood DA** *see also* Bowker TJ *et al*; Cowie MR *et al*  
**Woods M** *see* Hillis GS *et al*  
**Woodward M, Tunstall-Pedoe H, Lowe GDO.** Fibrinogen as a risk factor for coronary heart disease (CHD) in the eight-year follow-up of men and women in the Scottish Heart Health Study, 121 Pr  
**Woodward M** *see also* McDonagh TA *et al*; Morrison CE *et al*; Tunstall-Pedoe H *et al*  
**World M** *see* Clarkson P *et al*; Montgomery H *et al*  
**Wray R** *see* Chin D *et al*  
**Wright A** *see* Prasad N *et al*  
**Wright G** *see* Mason MJ *et al*  
**Wright J** *see* Brawn W *et al*  
**Wright M** *see* Walters MI *et al*  
**Wright RA** *see* Newby DE *et al*  
**Wynne DG** *see* Davies CH *et al*
- Yacoub M** *see* Dyke C *et al*; Grocott-Mason RM *et al*; Parry D *et al*; Santini F *et al*  
**Yacoub MH** *see* Jin XY *et al*; Kaprielian RR *et al*  
**Yaginuma T** *see* Ramsey MW *et al*  
**Yao J, Cao Q-L, Delabays A, Magni G, Acar P, Laskari C, Masani ND, Aronowitz M, Vannan MA, Pandian NG.** Quantification of regional myocardial dysfunction using three-dimensional echocardiography allows accurate estimation of myocardial infarct mass *in vivo*, 62 Pr  
**Yao J** *see also* Cao Q-L *et al*; Delabays A *et al*  
**Yarnell J** *see* Needham EWA *et al*

**Yasutake M** *see* Avkiran M *et al*

**Yates RWM, Anderson DR, Tynan MJ, Maisey MN, Baker EJ.** Positron emission tomography demonstrates normal myocardial perfusion after arterial switch operation in the neonatal period, 227 MPr

**Yellon DM** *see* Carr CS *et al*; Jenkins DP *et al*

**Yi G, Keeling PJ, Reardon K, McKenna WJ, Malik M.** Heart rate variability and signal averaged electrocardiography as predictors of clinical deterioration in patients with idiopathic dilated cardiomyopathy, 44 Pr

**Yonan N** *see* Grant SCD *et al*

**Youngblood SA** *see* Channon KM *et al*

**Zachary I** *see* Dawes KE *et al*

**Zaltsman A, Newby A.** Gelatinase activity is increased by atherosclerosis in cholesterol-fed rabbits, 167 MPr

**Zaman A, Alamgir F, Richens T, Williams R, Rothman M, Mills P.** Prediction of atrial fibrillation after coronary artery bypass surgery, 138 MPr

**Zhang Y** *see* Salomone OA *et al*

**Zhang ZM** *see* Jin XY *et al*

*Pr=Poster: MPr=Moderated Poster: JC=Judges Choice: A, B, C, D=Young Research Workers Prize*

## VOLUME 75: PROGRAMME SUPPLEMENT SUBJECT INDEX

**Ablation**

Gradient reduction following non-surgical septal reduction in hypertrophic obstructive cardiomyopathy is maintained over three month follow-up, 235 MPr

Is mode switching DDDR pacing superior to VVIR pacing following atrioventricular node ablation for refractory atrial fibrillation? 214

**Acetylcholine**, Localised endothelial dysfunction in patients with chest pain and normal coronary arteriograms, 253 MPr

**Action potential**

A cellular basis for T wave inversion in cardiac hypertrophy? 188 MPr

Regional effects of cardiac hypertrophy: a basis for arrhythmogenesis? 189 MPr

**Activation mapping**, Initial experience with mapping human endocardial activation using a novel non-contact catheter mapping system, 217

**Activity**, Objective assessment of activity in heart disease, 125 Pr

**Adenosine**, Myocardial perfusion imaging performed using echo-planar single shot magnetic resonance imaging with a mobile 0.5 Tesla scanner, 225 MPr

**Adenoviral gene transfer**

Adenoviral gene transfer of nitric oxide synthase to vascular cells, 193

Adenoviral gene transfer to venous bypass grafts and native vessels: a comparative study, 163 MPr

Gene expression after in vitro and in vivo gene transfer into VSMCs, 191

Gene expression from the cytomegalovirus immediate early promoter in embryonic, neonatal and adult rat vascular smooth muscle cells, 160 MPr

**Adventitia**, Adventitial changes following coronary artery balloon injury, 14 Pr

**Age**, L-arginine reverses the age associated endothelial dysfunction in humans, 255 MPr

**Air flow kinetics**, Non-invasive reduction of body water by using air flow kinetics, 112 Pr

**Air pollution**, Emergency admissions in London for acute myocardial infarction are associated with short-term increases in atmospheric pollution: are there any implications? 118 Pr

**Alcohol**, The aetiology of idiopathic dilated cardiomyopathy (DCM): the first alcohol case-control study, 182 MPr

**Allograft coronary artery disease**, PTCA in allograft coronary disease – is it worthwhile? 245

**Ambulance service**, Direct admission to the coronary care unit by the ambulance service in patients with suspected myocardial infarction, 263

**Amphipathic peptide**, Local delivery of the gene for an amphipathic peptide inhibits neointimal hyperplasia, 192

**Angina**

Admission coagulation activation in patients with unstable angina in relation to cardiac troponin T concentrations, 281 MPr

Arrhythmic preconditioning in patients with variant angina, 73 Pr

Complementary role of stellate ganglion blockade and thoracoscopic sympathectomy in the management of intractable angina, 147

Continuous coronary sinus pH monitoring during dipyridamole stress in patients with angina and hypertrophic cardiomyopathy, 272 JC

Coronary stenting for unstable angina is safe and effective, 86 Pr

Plasma endothelin levels correlate with the severity of coronary atherosclerosis in patients with chronic stable angina pectoris, 260 MPr

Plasma levels of active transforming growth factor- $\beta$  are reduced in patients with three vessel coronary artery disease, 259 MPr

Postprandial worsening of angina: meal composition and timing are important determinants of onset of ischaemia and chest pain, 41 Pr

Prognosis in patients with chest pain referred for outpatient cardiological assessment, 128 Pr

The role of lipoprotein(a) in the pathogenesis of unstable angina, 34 Pr

Vascular or myocardial abnormality in microvascular angina: thallium and technetium perfusion imaging compared, 54 Pr

**Angiography**, Routine coronary angiography after heart transplantation: time to stop, 220 MPr

**Angiotensin-converting enzyme**

Angiotensin-converting enzyme inhibition at non-hypotensive doses prevents development of malignant hypertension in a rat model, 9 Pr

The renin-angiotensin system and left ventricular hypertrophy: rat and human studies, D

**Angiotensin-converting enzyme gene**, DD genotype of the angiotensin-converting enzyme (ACE) gene is associated with abnormal diastolic function in essential hypertension, 199

**Angiotensin-converting enzyme inhibitor**

Alterations in the management of cardiac failure: evidence of improvement, 210 MPr

Changes in expression of components of the renin-angiotensin system in post myocardial infarction heart failure and after ACE inhibitor treatment, 40 Pr

Differential left ventricular relaxant effects of -SH and non-SH containing ACE inhibitors, 200

Implementation of guidelines for prescribing angiotensin converting enzyme inhibitors for the management of heart failure in hospital, 126 Pr

The Network study. The effect of dose of an ACE-inhibitor on outcome in patients with heart failure, 185 MPr

**Angiotensin II**, Angiotensin II does not contribute to basal forearm vascular tone in healthy man, 12 Pr

**Angiotensin receptor**, Angiotensin II receptor type 1 (AT1R) mRNA is upregulated in atria of patients with end-stage heart failure, 27 Pr

**Annuloaortic ectasia**, Aortic root replacement with a zero porosity gelatin-impregnated composite graft, 108 Pr

**Anticoagulation**

Anticoagulation of patients with atrial fibrillation. A theoretical exercise in the cost for one general practice, 113 Pr

Changing from aggressive anticoagulation to treatment with aspirin alone for coronary stents: the experience of one centre in the UK, 92 Pr

Hirudin (<sup>TM</sup>Revasc) vs heparin after thrombolysis in acute myocardial infarction: preliminary results from the TIMI 9B study, 171

Is reduced anticoagulation effective following optimal stent deployment? 90 Pr

Mitral valvuloplasty in patients with a left atrial thrombus despite conventional anticoagulation: use of aggressive anticoagulation, 236 MPr

**Antitachycardia pacing**, Is routine pre-discharge testing necessary for patients with implantable defibrillators? 71 Pr

**Aortic root replacement**, Aortic root replacement with a zero porosity gelatin-impregnated composite graft, 108 Pr

**Aortic stenosis**

Balloon dilatation of critical aortic stenosis in neonates using an antegrade catheter approach, 67 Pr

Balloon dilation of the aortic valve in neonatal critical aortic stenosis, 94 Pr

Left ventricular mass correlates better with valve resistance than effective orifice area in aortic stenosis, 59 Pr

**Aortic valve**, The pulmonary autograft operation: long term results of the pioneer series, 276 MPr

**Aortic valve replacement**

Changes in left ventricular dimensions after aortic valve replacement, 277 MPr

Early results of a prospective randomized trial of homograft versus pulmonary autograft replacement of the aortic valve, 151

Long term results and echo assessment of homograft aortic valve replacement, 152

Remodeling of left ventricular function following aortic valve replacement using stentless valve, 102 Pr

**Apoptosis**, Apoptosis of human umbilical vein endothelial cells (HUVEC) – role of interleukin-1 $\beta$  converting enzyme (ICE) and associated proteases, 11 Pr

**Aprotinin**, Aprotinin prevents fibrin formation in cardiac surgery, 101 Pr

**Aquaporin-1**, Aquaporin-1 is expressed in rat and human arteries and may play a role in vascular function in health and disease, 268 JC

**Arbutamine**

Arbutamine blood pool ventriculography: an alternative to exercise thallium scintigraphy? 51 Pr

Comparison of arbutamine stress sestamibi SPECT imaging and echocardiography for the detection of coronary artery disease, 50 Pr

**Arrhythmia**, Incidence and determinants of arrhythmia following total cavopulmonary connection: a prospective study of 119 cases, 142 MPr

**Arrhythmogenic right ventricular dysplasia**, Late ventricular activation identified with radionuclide ventriculography in arrhythmogenic right ventricular dysplasia, 52 Pr

**Arterial closure**, Early experience with the Prostar<sup>TM</sup> percutaneous vascular closure device in patients following coronary intervention, **96 Pr**

**Arterial haemodynamics**, Effects of posture on systemic arterial wave intensity in man, **35 Pr**

**Arterial stenosis**, Thermal balloon angioplasty of experimental arterial stenoses in lambs: a pilot study, **23 Pr**

#### **Arterial switch**

Left ventricle mass/volume ratio does not predict early surgical outcome in infants older than 21 days undergoing arterial switch surgery for simple transposition of the great arteries, **70 Pr**

Positron emission tomography demonstrates normal myocardial perfusion after arterial switch operation in the neonatal period, **227 MPPr**

Technetium-sestamibi (MIBI) to estimate left ventricular fibrosis in patients considered for surgical conversion to arterial switch, **69 Pr**

#### **Aspirin**

Changing from aggressive anticoagulation to treatment with aspirin alone for coronary stents: the experience of one centre in the UK, **92 Pr**

Coronary stenting without anticoagulation or intravascular ultrasound: a retrospective analysis, **231 MPPr**

Palmaz Schatz stent deployment without intravascular ultrasound guidance using antiplatelet therapy with aspirin alone, **246**

**Atheroma regression**, Regression of atheroma seen with intravascular ultrasound: a placebo controlled study of the effect of gemfibrozil on peripheral atherosclerosis, **154**

#### **Atherosclerosis**

Association between antibodies to mycobacterial heat shock protein 65 and coronary atherosclerosis: possible mechanism of action of a *Helicobacter pylori* in increasing cardiovascular risk, **166 MPPr**

Can radiofrequency data analysis of intravascular ultrasound accurately characterize coronary atherosclerosis? **153**

Expression of tissue inhibitors of metalloproteinases (TIMPs) in human saphenous vein, **159 MPPr**

Gelatinase activity is increased by atherosclerosis in cholesterol-fed rabbits, **167 MPPr**

Hypoxia alters the chemotactic and proliferative response of vascular smooth muscle cells to platelet-derived growth factor-BB, **21 Pr**

Plasma endothelin levels correlate with the severity of coronary atherosclerosis in patients with chronic stable angina pectoris, **260 MPPr**

Routine coronary angiography after heart transplantation: time to stop, **220 MPPr**

**ATP-dependent potassium channel**, Comparison of ischaemic preconditioning and a highly selective ATP-dependent potassium channel opener in isolated human atrial muscle, **198**

#### **Atrial defibrillation**

A prospective evaluation of recurrent atrial endocardial defibrillation in patients with refractory chronic atrial flutter and fibrillation, **137 MPPr**

Rounded versus standard biphasic waveforms for catheter atrial defibrillation, **82 Pr**

#### **Atrial fibrillation**

Anticoagulation of patients with atrial fibrillation. A theoretical exercise in the cost for one general practice, **113 Pr**

Atrioventricular node ablation and implantation of dual chamber mode-switching pacemakers for paroxysmal atrial fibrillation – effects on quality of life, exercise capacity and left ventricular systolic function, **212**

Current guidelines for DC cardioversion of atrial fibrillation: low energy or low efficacy? **146 MPPr**

Prediction of atrial fibrillation after coronary artery bypass surgery, **138 MPPr**

Predictors of sinus rhythm duration post intra-atrial cardioversion in patients with chronic atrial fibrillation, **79 Pr**

**Atrial septal defect**, Three-dimensional definition of atrial septal defect by Doppler myocardial imaging, **157**

**Attenuation**, Attenuation correction in thallium myocardial perfusion imaging, **57 Pr**

#### **Audit**

A new concept database for interventional cardiology: improving data collection with an advanced graphical user interface, **87 Pr**

Alterations in the management of cardiac failure: evidence of improvement, **210 MPPr**

Audit of physician training in temporary cardiac pacing from District General Hospitals in the North West Region, **209 MPPr**

Differences in short-term outcome for acute MI between Germany and the UK: the role of clinical trial data in the resource utilisation debate, **204 MPPr**

Should patients receiving renal transplants undergo pre-operative cardiac investigation? **122 Pr**

Testing the appropriateness of coronary revascularisation: application of the University of Maryland Revascularisation Appropriateness Scoring System (RAS) to UK angioplasty practice, **221 MPPr**

The learning curve for radiofrequency ablation is more than 160 procedures, **145 MPPr**

Variations in the management of acute myocardial infarction in one health region, **124 Pr**

**AV node reentry**, QRS morphology during AV node reentrant tachycardia, **76 Pr**

#### **Balloon dilatation**

Balloon dilation of the aortic valve in neonatal critical aortic stenosis, **94 Pr**

Thermal balloon angioplasty of experimental arterial stenoses in lambs: a pilot study, **23 Pr**

**Banding**, Univentricular heart with systemic outflow obstruction: the primary Damus procedure as an alternative to pulmonary banding, **238 MPPr**

**Baroreceptor sensitivity**, Impaired baroreceptor sensitivity early after myocardial infarction is associated with ventricular dilatation, **133**

**Baroreflex sensitivity**, Baroreflex sensitivity and markers of ventricular repolarisation in asymptomatic diabetics, **81 Pr**

**Beta blockers**, The influence of beta-blockade on rate dependent changes of the QT interval in acute myocardial infarction, **84 Pr**

**Bidirectional cavopulmonary anastomosis**, Systemic venous collaterals after the bidirectional cavopulmonary anastomosis – prevalence and risk factors, **149**

**Biphasic waveforms**, Rounded versus standard biphasic waveforms for catheter atrial defibrillation, **82 Pr**

**Björk-Shiley Convexo-Concave valves**, Radiographic evaluation of Björk-Shiley Convexo-Concave valves, **178 JC**

**BMS 180448**, Comparison of ischaemic preconditioning and a highly selective ATP-dependent potassium channel opener in isolated human atrial muscle, **198**

**Body composition**, Body composition and strength in chronic heart failure: reduced muscle efficiency in cardiac cachexia, **33 Pr**

**Brachial artery**, Endothelial function of the brachial artery is not impaired in patients with syndrome X, **252 MPPr**

**Bradykinin**, Differential left ventricular relaxant effects of -SH and non-SH containing ACE inhibitors, **200**

**BSCC valves**, Radiographic evaluation of Björk-Shiley Convexo-Concave valves, **178 JC**

**c-fms expression**, *c-fms* proto-oncogene expression is increased in endothelial and smooth muscle cells following vascular grafting, **161 MPPr**

**Calcium**, Assessment of steady state myofilament calcium response in intact isolated cardiac myocytes: modulation by the cardiac endothelium, **267 JC**

**cAMP**, Could a reduction of basal myocyte cAMP contribute to the progression of heart failure? **186 MPPr**

**Cardiac angiography**, Low-cost transmission of cardiac angiograms between secondary and tertiary cardiac units, **207 MPPr**

**Cardiac cachexia**, Body composition and strength in chronic heart failure: reduced muscle efficiency in cardiac cachexia, **33 Pr**

**Cardiac mapping**, Ventricular tachycardia of arrhythmogenic right ventricular disease – evidence for localised reentry from cardiac mapping, **218**

#### **Cardiac output**

Inhalation of nitric oxide improves the cardiac output response to exercise in chronic heart failure, **135**

The differential effects of negative pressure ventilation (NPV) on cardiac output in children, **177 JC**

#### **Cardiac surgery**

Aprotinin prevents fibrin formation in cardiac surgery, **101 Pr**

Cerebral events after cardiac surgery, **273 MPPr**

Post-infarct septal rupture – improvement in surgical outcome in the nineties, **103 Pr**

#### **Cardiopulmonary bypass**

A randomised study of the effects of cardiopulmonary bypass temperature on neuropsychological deficit after coronary artery surgery, **274 MPPr**

Modified ultrafiltration improves cardiac systolic and diastolic function immediately after cardiopulmonary bypass in children, **275 MPPr**

- Neutrophils are a source of interleukin-8 in human cardiopulmonary bypass surgery, **100 Pr**
- Normothermic systemic perfusion does not compromise cold myocardial protection during coronary artery surgery, **106 Pr**
- The effect of cardiopulmonary bypass (CPB) on the circulating megakaryocytes, **109 Pr**
- Cardioversion**
- Current guidelines for DC cardioversion of atrial fibrillation: low energy or low efficacy? **146 MPr**
- Does the signal averaged P wave predict duration of sinus rhythm after cardioversion, **139 MPr**
- Predictors of sinus rhythm duration post intra-atrial cardioversion in patients with chronic atrial fibrillation, **79 Pr**
- Cardioverter-defibrillator**, Variation in selection criteria for cardioverter-defibrillator implantation in different European countries, **179 JC**
- Carotid revascularisation**, Combined carotid and coronary revascularisation, **234 MPr**
- Catheter**, Initial experience with mapping human endocardial activation using a novel non-contact catheter mapping system, **217**
- Catheter defibrillation**, Rounded versus standard biphasic waveforms for catheter atrial defibrillation, **82 Pr**
- Catheterisation**, Intravenous isoprenaline infusion to unmask gradients across the aortic arch during cardiac catheterization, **97 Pr**
- Cell proliferation**, Early response gene expression and vascular cell proliferation in human saphenous vein prepared for coronary bypass grafting, **279 MPr**
- Cell volume**, Preconditioning and the extracellular space: implications for ischaemia-induced changes in cell volume, **3 Pr**
- Cerebrovascular accidents**, Cerebral events after cardiac surgery, **273 MPr**
- Chemosensitivity**, Suppression of chemosensitivity and the effects on exercise tolerance in patients with chronic heart failure, **134**
- Chest pain**
- Localised endothelial dysfunction in patients with chest pain and normal coronary arteriograms, **253 MPr**
- Prognosis in patients with chest pain referred for outpatient cardiological assessment, **128 Pr**
- Should CK-MB be used to determine the cause of chest pain? **116 Pr**
- Chest x-ray**, Use of chest x-ray (CXR) after biopsy of the transplanted heart, **219 MPr**
- Children**
- Modified ultrafiltration improves cardiac systolic and diastolic function immediately after cardiopulmonary bypass in children, **275 MPr**
- The differential effects of negative pressure ventilation (NPV) on cardiac output in children, **177 JC**
- Chinese**, Low levels of coronary heart disease and risk factors in a UK Chinese population, **130 Pr**
- Chloride channel**, Expression of phospholemman 1-43 induces chloride currents in *Xenopus* oocytes, **6 Pr**
- Cholesterol**
- Cholesterol – whom do we test and whom should we test? **114 Pr**
- Cholesterol lowering drug therapy in the prevention of coronary heart disease in the population – evidence from WOSCOPS and 4S applied to the British Family Heart Study, **115 Pr**
- Cost-efficacy of cholesterol lowering: West of Scotland Coronary Prevention Study versus the Scandinavian Simvastatin Survival Study, **250**
- Gelatinase activity is increased by atherosclerosis in cholesterol-fed rabbits, **167 MPr**
- Serum total cholesterol, HDL-cholesterol and non-fasting triglycerides, and eight-year coronary events in the follow-up of men and women in the Scottish Heart Health Study (SHHS), **120 Pr**
- Circadian pattern**, Morning increase in QT interval variability: implications for mechanisms underlying the circadian pattern of cardiac risk, **80 Pr**
- Clinical trials**
- A randomised controlled trial of vitamin E in patients with coronary disease: the Cambridge Heart Antioxidant Study (CHAOS), **176 JC**
- Differences in short-term outcome for acute MI between Germany and the UK: the role of clinical trial data in the resource utilisation debate, **204 MPr**
- Coagulation**
- Admission coagulation activation in patients with unstable angina in relation to cardiac troponin T concentrations, **281 MPr**
- Aprotinin prevents fibrin formation in cardiac surgery, **101 Pr**
- Coarctation of the aorta**
- Balloon angioplasty of native coarctation in adults, long term follow up, **64 Pr**
- Intravenous isoprenaline infusion to unmask gradients across the aortic arch during cardiac catheterization, **97 Pr**
- The results of applying echo data derived from critical aortic stenosis to infants with coarctation of the aorta, **158**
- Community**, Post mortem findings in assessing success of out of hospital resuscitation, **206 MPr**
- Community education**, Heart attack action!: a campaign to improve community knowledge, **262**
- Computer**
- A new concept database for interventional cardiology: improving data collection with an advanced graphical user interface, **87 Pr**
- Low-cost transmission of cardiac angiograms between secondary and tertiary cardiac units, **207 MPr**
- Congenital complete heart block**, Foetal echocardiographic screening of pregnancies at increased risk for foetal complete heart block, **66 Pr**
- Congenital heart disease**, Experience with the Fontan procedure in older patients, **63 Pr**
- Congestive heart failure**, Abnormalities of skeletal muscle metabolism are present at rest in congestive heart failure: relationship between these abnormalities and symptoms, **37 Pr**
- Contractile proteins**, Myocardium from a chronic coronary artery ligation model has altered responses to reactive oxygen species, **2 Pr**
- Contrast**, New technologies for echocardiographic myocardial perfusion imaging, **228 MPr**
- Contrast echocardiography**, Three-dimensional contrast echocardiography in acute myocardial infarction: *in vivo* quantification of infarct mass, **271 JC**
- Contrast microspheres**, Diagnostic ultrasound intensities may destroy contrast microspheres in-vivo: implications for ultrasound perfusion imaging, **50 Pr**
- Coronary artery bypass grafting**
- Combined carotid and coronary revascularisation, **234 MPr**
- Cost implications of reduced left ventricular function in coronary artery bypass surgery, **123 Pr**
- Early experience with minimal invasive coronary artery bypass grafting, **232 MPr**
- Early response gene expression and vascular cell proliferation in human saphenous vein prepared for coronary bypass grafting, **279 MPr**
- Ischaemic preconditioning reduces troponin-T release in patients undergoing cardiac surgery, **240**
- Non-restrictive external stenting reduces medial and neointimal thickening in a pig model of arteriovenous bypass grafting, **B**
- Prediction of atrial fibrillation after coronary artery bypass surgery, **138 MPr**
- Progressive recovery of tissue perfusion following coronary artery bypass grafting: evidence of 'microvascular stunning' in man, **233 MPr**
- Coronary artery disease**
- 28-day case fatality of coronary events, and the proportion of out of hospital deaths, in relation to age, sex and previous coronary heart disease (CHD): the Glasgow MONICA project, **203 MPr**
- A randomised controlled trial of vitamin E in patients with coronary disease: the Cambridge Heart Antioxidant Study (CHAOS), **176 JC**
- Cholesterol lowering drug therapy in the prevention of coronary heart disease in the population – evidence from WOSCOPS and 4S applied to the British Family Heart Study, **115 Pr**
- Comparison of arbutamine stress sestamibi SPECT imaging and echocardiography for the detection of coronary artery disease, **50 Pr**
- Dobutamine stress echocardiography reliably predicts future cardiac events in patients undergoing diagnostic coronary angiography, **58 Pr**
- Fibrinogen as a risk factor for coronary heart disease (CHD) in the eight-year follow-up of men and women in the Scottish Heart Health Study, **121 Pr**
- Glucose-insulin-potassium (GIK) therapy for acute myocardial infarction: overview of randomised placebo controlled trials, **174**
- Helicobacter pylori* infection and coronary heart disease in middle-aged men: prospective relations in a nested case-control study, **211 MPr**
- Helicobacter pylori* infection and coronary heart disease in north Glasgow, **212 MPr**
- Low levels of coronary heart disease and risk factors in a UK Chinese population, **130 Pr**
- Painless myocardial ischaemia is an important factor in the genesis of effort intolerance in severe congestive heart failure due to coronary artery disease, **184 MPr**



- Plasma levels of active transforming growth factor- $\beta$  are reduced in patients with three vessel coronary artery disease, **259 MPr**
- Positron emission tomography localises insulin resistance to skeletal muscle in premature coronary heart disease, **48 Pr**
- Predictive value of FDG imaging in 502 patients with chronic ischaemic left ventricular dysfunction enrolled in a prospective European multicentre viability study, **226 MPr**
- Prehospital versus hospital thrombolysis: an overview of randomised trials, **169**
- Serum total cholesterol, HDL-cholesterol and non-fasting triglycerides, and eight-year coronary events in the follow-up of men and women in the Scottish Heart Health Study (SHHS), **120 Pr**
- Serum total homocysteine and coronary heart disease in middle-aged British men, **180 JC**
- The lipoprotein lipase gene locus associates with serum HDL and Apo-AI levels, **164 MPr**
- Coronary atheroma**, Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to myocardial infarction in patients undergoing coronary angiography, **257 MPr**
- Coronary care**, Direct admission to the coronary care unit by the ambulance service in patients with suspected myocardial infarction, **263**
- Coronary flow reserve**, Progressive recovery of tissue perfusion following coronary artery bypass grafting: evidence of 'microvascular stunning' in man, **233 MPr**
- Coronary revascularisation**, Combined carotid and coronary revascularisation, **234 MPr**
- Cost**
- Anticoagulation of patients with atrial fibrillation. A theoretical exercise in the cost for one general practice, **113 Pr**
  - Coronary stenting: cost implications for purchasers, **89 Pr**
  - Cost implications of reduced left ventricular function in coronary artery bypass surgery, **123 Pr**
- Cost-efficacy**, Cost-efficacy of cholesterol lowering: West of Scotland Coronary Prevention Study versus the Scandinavian Simvastatin Survival Study, **250**
- Creatine kinase**
- Creatine kinase isoforms as circulating markers of deterioration in idiopathic dilated cardiomyopathy, **183 MPr**
  - Prognostic significance of CK-MB elevation following ablative new-device angioplasty in native coronary arteries, **248**
  - Should CK-MB be used to determine the cause of chest pain? **116 Pr**
- Customary activity**, Daily activity levels predict prognosis in patients with chronic heart failure, **38 Pr**
- Cytokines**, Neutrophils are a source of interleukin-8 in human cardiopulmonary bypass surgery, **100 Pr**
- Cytomegalovirus**, Gene expression from the cytomegalovirus immediate early promoter in embryonic, neonatal and adult rat vascular smooth muscle cells, **160 MPr**
- Damus procedure**, Univentricular heart with systemic outflow obstruction: the primary Damus procedure as an alternative to pulmonary banding, **238 MPr**
- Defibrillator**
- A prospective evaluation of recurrent atrial endocardial defibrillation in patients with refractory chronic atrial flutter and fibrillation, **137 MPr**
  - Predictors of sinus rhythm duration post intra-atrial cardioversion in patients with chronic atrial fibrillation, **79 Pr**
  - Variation in selection criteria for cardioverter-defibrillator implantation in different European countries, **179 JC**
- Deprivation**, Factors affecting uptake of cardiac rehabilitation in Glasgow, **208 MPr**
- Diabetes**
- Baroreflex sensitivity and markers of ventricular repolarisation in asymptomatic diabetics, **81 Pr**
  - Mechanisms of impaired vascular reactivity in insulin dependent diabetes mellitus and hypercholesterolaemia, **251 MPr**
- Diastolic function**, DD genotype of the angiotensin-converting enzyme (ACE) gene is associated with abnormal diastolic function in essential hypertension, **199**
- Dilated cardiomyopathy**
- Creatine kinase isoforms as circulating markers of deterioration in idiopathic dilated cardiomyopathy, **183 MPr**
  - Effects of permanent dual chamber pacing in end-stage dilated cardiomyopathy, **46 Pr**
  - Heart rate variability and signal averaged electrocardiography as predictors of clinical deterioration in patients with idiopathic dilated cardiomyopathy, **44 Pr**
  - Intramyocardial conduction abnormalities in idiopathic dilated cardiomyopathy may refine risk assessment, **216**
- Previously-reported mitochondrial DNA mutations are not a common cause of idiopathic dilated cardiomyopathy, **201**
- The aetiology of idiopathic dilated cardiomyopathy (DCM): familial prevalence and HLA-types, **202**
- The aetiology of idiopathic dilated cardiomyopathy (DCM): the first alcohol case-control study, **182 MPr**
- DNA mitochondrial mutations**, Previously-reported mitochondrial DNA mutations are not a common cause of idiopathic dilated cardiomyopathy, **201**
- Dobutamine**
- Dobutamine stress echocardiography reliably predicts future cardiac events in patients undergoing diagnostic coronary angiography, **58 Pr**
  - Dynamics of small size St Jude medical aortic prostheses: *in vivo* studies using dobutamine echocardiography, **105**
  - Identification of hibernating myocardium: a comparison of TI-201, Tc-99m tetrofosmin, and dobutamine cine magnetic resonance imaging, **242**
  - Increased modulation by nitric oxide of dobutamine-induced pulmonary vasodilation during postnatal development in sheep, **22 Pr**
  - Increases in systemic oxygen consumption offset improvements in systemic oxygen delivery during dobutamine infusion in newborn lambs, **39 Pr**
- Doppler**
- Three-dimensional definition of atrial septal defect by Doppler myocardial imaging, **157**
  - Three-dimensional reconstruction of *in vivo* colour Doppler flow events – initial experience, **156**
- Echocardiography (ultrasound)**
- Achieving effective use of general practitioner requested echocardiography: should access be open or targeted? **132**
  - Changes in left ventricular dimensions after aortic valve replacement, **277 MPr**
  - Comparison of arbutamine stress sestamibi SPECT imaging and echocardiography for the detection of coronary artery disease, **50 Pr**
  - Determinants of global left ventricular systolic dysfunction in north Glasgow, **266**
  - Diagnostic ultrasound intensities may destroy contrast microspheres *in-vivo*: implications for ultrasound perfusion imaging, **50 Pr**
  - Dobutamine stress echocardiography reliably predicts future cardiac events in patients undergoing diagnostic coronary angiography, **58 Pr**
  - Dynamics of small size St Jude medical aortic prostheses: *in vivo* studies using dobutamine echocardiography, **105**
  - Effects of permanent dual chamber pacing in end-stage dilated cardiomyopathy, **46 Pr**
  - Foetal echocardiographic screening of pregnancies at increased risk for foetal complete heart block, **66 Pr**
  - Gradient reduction following non-surgical septal reduction in hypertrophic obstructive cardiomyopathy is maintained over three month follow-up, **235 MPr**
  - How should open access echocardiography be organised? Lessons from a directed access service, **117 Pr**
  - Incomplete expansion of stents despite high-pressure implantation: the role of intravascular ultrasound, **95 Pr**
  - Long term results and echo assessment of homograft aortic valve replacement, **152**
  - 'Open access' echocardiography for suspected heart failure: would 12 lead electrocardiogram be just as good? **119 Pr**
  - QRS evolution and ventricular arrhythmias after repair of tetralogy of Fallot: the influence of operative techniques and postoperative physiology, **150**
  - Quantification of regional myocardial dysfunction using three-dimensional echocardiography allows accurate estimation of myocardial infarct mass *in vivo*, **62 Pr**
  - Should patients receiving renal transplants undergo pre-operative cardiac investigation? **122 Pr**
  - The results of applying echo data derived from critical aortic stenosis to infants with coarctation of the aorta, **158**
  - The value of QT dispersion in identifying patients with heart failure due to left ventricular systolic dysfunction, **25 Pr**
  - Three-dimensional contrast echocardiography in acute myocardial infarction: *in vivo* quantification of infarct mass, **271 JC**
  - Three-dimensional definition of atrial septal defect by Doppler myocardial imaging, **157**
  - Three-dimensional reconstruction of *in vivo* colour Doppler flow events – initial experience, **156**



- Transmural velocity gradients – a new ultrasonic index for hypertrophic cardiomyopathy hearts, **61 Pr**
- Two new ultrasound modalities – harmonic imaging and triggered mode – improve delineation of myocardial perfusion defects by three-dimensional contrast echocardiography, **155**
- Effective orifice area**, Left ventricular mass correlates better with valve resistance than effective orifice area in aortic stenosis, **59 Pr**
- Ejection fraction**, Cost implications of reduced left ventricular function in coronary artery bypass surgery, **123 Pr**
- Elderly patients**, Mitral valve surgery in the elderly, **110 Pr**
- Electrocardiography**
- Hypertrophic cardiomyopathy: new evidence suggests utility of ECG as a diagnostic tool, **131**
- 'Open access' echocardiography for suspected heart failure: would 12 lead electrocardiogram be just as good? **119 Pr**
- Electrophysiology**
- Expression of phospholemman 1-43 induces chloride currents in *Xenopus* oocytes, **6 Pr**
- Modulation of oocyte-expressed skeletal muscle sodium channels by NIMA kinase, **7 Pr**
- QRS morphology during AV node reentrant tachycardia, **76 Pr**
- Recipient atrial remnant: does it exhibit normal electrophysiology? **77 Pr**
- Endocardial defibrillation**, A prospective evaluation of recurrent atrial endocardial defibrillation in patients with refractory chronic atrial flutter and fibrillation, **137 MPr**
- Endomyocardial biopsy**, Is routine endomyocardial biopsy essential for rejection surveillance in paediatric heart transplant recipients? **65 Pr**
- Endothelial cytoskeleton**, Mechanotransduction through the endothelial cytoskeleton mediates flow- but not agonist-induced nitric oxide release, **168 MPr**
- Endothelin**
- Effect of 17 $\beta$ -estradiol on endothelin-1 release by human endothelial cells, **20 Pr**
- Endothelin-1 plays a functional role in noradrenaline-induced ventricular hypertrophy *in vivo* and *in vitro*, **C**
- Is the pulmonary circulation hypersensitive to endothelin-1 in endotoxaemia? **16 Pr**
- Plasma endothelin levels correlate with the severity of coronary atherosclerosis in patients with chronic stable angina pectoris, **260 MPr**
- Endothelium**
- Apoptosis of human umbilical vein endothelial cells (HUVEC) – role of interleukin-1 $\beta$  converting enzyme (ICE) and associated proteases, **11 Pr**
- Aquaporin-1 is expressed in rat and human arteries and may play a role in vascular function in health and disease, **268 JC**
- c-fms* proto-oncogene expression is increased in endothelial and smooth muscle cells following vascular grafting, **161 MPr**
- Dietary marine fish oil improves endothelial function in hypercholesterolaemic patients, **17 Pr**
- Effect of 17 $\beta$ -estradiol on endothelin-1 release by human endothelial cells, **20 Pr**
- Endothelial function of the brachial artery is not impaired in patients with syndrome X, **252 MPr**
- Endothelial function declines in hypercholesterolaemic women following the menopause, **36 Pr**
- Exercise training enhances endothelial function in young men, **254 MPr**
- L-arginine reverses the age associated endothelial dysfunction in humans, **255 MPr**
- Left ventricular hypertrophy is associated with abnormal thrombogenesis and endothelial dysfunction, **24 Pr**
- Localised endothelial dysfunction in patients with chest pain and normal coronary arteriograms, **253 MPr**
- Mechanisms of impaired vascular reactivity in insulin dependent diabetes mellitus and hypercholesterolaemia, **251 MPr**
- Vascular inflammation and its effects on smooth muscle and endothelial function: a study in healthy volunteers, **A**
- Endotoxin**, Vascular inflammation and its effects on smooth muscle and endothelial function: a study in healthy volunteers, **A**
- Epicardium**
- A cellular basis for T wave inversion in cardiac hypertrophy? **188 MPr**
- Differential effects of hypertrophy on regional density of the transient outward current, **5 Pr**
- Regional effects of cardiac hypertrophy: a basis for arrhythmogenesis? **189 MPr**
- Epidemiology**
- A population-based survey of the incidence of heart failure, **129 Pr**
- Determinants of global left ventricular systolic dysfunction in north Glasgow, **266**
- Estradiol**, Effect of 17 $\beta$ -estradiol on endothelin-1 release by human endothelial cells, **20 Pr**
- Europe**, Variation in selection criteria for cardioverter-defibrillator implantation in different European countries, **179 JC**
- Exercise**
- Abnormalities of skeletal muscle metabolism are present at rest in congestive heart failure: relationship between these abnormalities and symptoms, **37 Pr**
- Cumulative and prolonged left ventricular dysfunction due to myocardial stunning following repetitive exercise-induced ischaemia, **181 MPr**
- Daily activity levels predict prognosis in patients with chronic heart failure, **38 Pr**
- Exercise training enhances endothelial function in young men, **254 MPr**
- Ischaemic preconditioning attenuates myocardial stunning following repetitive exercise, **269 JC**
- Objective assessment of activity in heart disease, **125 Pr**
- Postischaemic overshoot precedes exercise-induced myocardial stunning, **239**
- Postprandial worsening of angina: meal composition and timing are important determinants of onset of ischaemia and chest pain, **41 Pr**
- Pre-discharge exercise testing in the prediction of cardiac events over 5 yrs following thrombolysis for acute myocardial infarction, **29 Pr**
- Revascularisation in ischaemic cardiomyopathy: effects on exercise capacity and ejection fraction, **244**
- Suppression of chemosensitivity and the effects on exercise tolerance in patients with chronic heart failure, **134**
- The fibrinogen gene G-143-A polymorphism influences the acute-phase response of serum fibrinogen to severe exercise, **196**
- Extracellular matrix**, The expression of  $\beta$ 1 integrins by cultured human coronary artery vascular smooth muscle cells, **10 Pr**
- Failed thrombolysis**, What do we do when thrombolysis fails? A United Kingdom survey, **265**
- FDG SPET**, The role of  $^{18}\text{F}$ -FDG SPET in detection of hibernating myocardium: comparison with rest-redistribution  $^{201}\text{Tl}$  Thallium SPET, **241**
- Fetus**, Foetal echocardiographic screening of pregnancies at increased risk for foetal complete heart block, **66 Pr**
- Fibrin formation**, Aprotinin prevents fibrin formation in cardiac surgery, **101 Pr**
- Fibrinogen**
- Anticoagulant effects of vitamin E treatment in patients with coronary disease, **282 MPr**
- Fibrinogen as a risk factor for coronary heart disease (CHD) in the eight-year follow-up of men and women in the Scottish Heart Health Study, **121 Pr**
- The fibrinogen gene G-143-A polymorphism influences the acute-phase response of serum fibrinogen to severe exercise, **196**
- First and recurrent event differences**, The pathway through myocardial infarction – effects of age, sex and socio-economic group, **264**
- Fish oil**, Dietary marine fish oil improves endothelial function in hypercholesterolaemic patients, **17 Pr**
- Folate**, A gene mutation which contributes to coronary heart disease risk, **127 Pr**
- Fontan procedure**
- Experience with the Fontan procedure in older patients, **63 Pr**
- Incidence and determinants of arrhythmia following total cavopulmonary connection: a prospective study of 119 cases, **142 MPr**
- Food**, Postprandial worsening of angina: meal composition and timing are important determinants of onset of ischaemia and chest pain, **41 Pr**
- Fourier analysis**, Late ventricular activation identified with radionuclide ventriculography in arrhythmogenic right ventricular dysplasia, **52 Pr**
- Fractures**, Radiographic evaluation of Björk-Shiley Convexo-Concave valves, **178 JC**
- Free radicals**
- Evidence for free radical generation following primary coronary angioplasty recanalisation in acute myocardial infarction, **1 Pr**
- Myocardium from a chronic coronary artery ligation model has altered responses to reactive oxygen species, **2 Pr**
- Peroxyntirite causes the expression of platelet P-selectin but inhibits the internalisation of GPIb, effects that might have important consequences in acute ischaemic syndromes, **162 MPr**
- FS069**, New technologies for echocardiographic myocardial perfusion imaging, **228 MPr**

**Gap junction.** Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of canine infarcts that cause ventricular tachycardia, 78 Pr

**GATA-6 gene.** Cloning of human GATA-6: a new regulatory gene with a potential role in the control of myocardial differentiation and growth, 190 MPPr

**Gated MIBI.** Gated rest 99 Tm MIBI-SPECT in the assessment of myocardial viability: comparison with 13 NH3/18 FDG PET, 56 Pr

**Gated SPECT.** Gated Tc-99m tetrofosmin SPECT in the assessment of left ventricular contractility: a comparison with cine magnetic resonance imaging, 53 Pr

**Gelatinase.** Gelatinase activity is increased by atherosclerosis in cholesterol-fed rabbits, 167 MPPr

**Gemfibrozil.** Regression of atheroma seen with intravascular ultrasound: a placebo controlled study of the effect of gemfibrozil on peripheral atherosclerosis, 154

**Gender.** 28-day case fatality of coronary events, and the proportion of out of hospital deaths, in relation to age, sex and previous coronary heart disease (CHD): the Glasgow MONICA project, 203 MPPr

#### Gene expression

*c-fms* proto-oncogene expression is increased in endothelial and smooth muscle cells following vascular grafting, 161 MPPr

Cloning of human GATA-6: a new regulatory gene with a potential role in the control of myocardial differentiation and growth, 190 MPPr

Early response gene expression and vascular cell proliferation in human saphenous vein prepared for coronary bypass grafting, 279 MPPr

Gene expression from the cytomegalovirus immediate early promoter in embryonic, neonatal and adult rat vascular smooth muscle cells, 160 MPPr

Neutrophils are a source of interleukin-8 in human cardio-pulmonary bypass surgery, 100 Pr

#### Gene mutation

A gene mutation which contributes to coronary heart disease risk, 127 Pr

Prothrombotic importance of the Factor V Leiden genotype mutation in acute coronary syndromes, 18 Pr

#### Gene therapy

Local delivery of the gene for an amphipathic peptide inhibits neointimal hyperplasia, 192

Local gene transfer of the antisense to senescent cell-derived inhibitor 1 creates neointima, 194

#### Gene transfer

Adenoviral gene transfer of nitric oxide synthase to vascular cells, 193

Adenoviral gene transfer to venous bypass grafts and native vessels: a comparative study, 163 MPPr

Gene expression after in vitro and in vivo gene transfer into VSMCs, 191

**General practitioners.** Call-to-needle times in Grampian: the pivotal role of the general practitioner in achieving early thrombolysis, 205 MPPr

#### Genetics

Myotonin kinase gene (GTG)<sub>n</sub> repeat associates with hypertrophic cardiomyopathy, 45 Pr

The aetiology of idiopathic dilated cardiomyopathy (DCM): familial prevalence and HLA-types, 202

**'Gentle PTCA'.** Does low inflation pressure and prolonged coronary dilatation strategy affect restenosis rate? Early and late results, 98 Pr

**Glibenclamide.** Comparison of ischaemic preconditioning and a highly selective ATP-dependent potassium channel opener in isolated human atrial muscle, 198

**Glucose-insulin-potassium therapy.** Glucose-insulin-potassium (GIK) therapy for acute myocardial infarction: overview of randomised placebo controlled trials, 174

**Glycoprotein Ib expression.** Peroxynitrite causes the expression of platelet P-selectin but inhibits the internalisation of GPIb, effects that might have important consequences in acute ischaemic syndromes, 162 MPPr

**Growth factors.** *c-fms* proto-oncogene expression is increased in endothelial and smooth muscle cells following vascular grafting, 161 MPPr

**Harmonic imaging.** Two new ultrasound modalities – harmonic imaging and triggered mode – improve delineation of myocardial perfusion defects by three-dimensional contrast echocardiography, 155

**Heart attack.** Heart attack action!: a campaign to improve community knowledge, 262

#### Heart failure

A population-based survey of the incidence of heart failure, 129 Pr  
Alterations in the management of cardiac failure: evidence of improvement, 210 MPPr

Angiotensin II receptor type 1 (AT1R) mRNA is upregulated in atria of patients with end-stage heart failure, 27 Pr

Baseline assessment of plasma brain natriuretic peptide and simple clinical variables predict long-term left ventricular function following acute myocardial infarction, 31 Pr

Brain natriuretic peptide (BNP) and simple clinical variables predict left ventricular dysfunction following myocardial infarction, 30 Pr

Changes in expression of components of the renin-angiotensin system in post myocardial infarction heart failure and after ACE inhibitor treatment, 40 Pr

Could a reduction of basal myocyte cAMP contribute to the progression of heart failure? 186 MPPr

Daily activity levels predict prognosis in patients with chronic heart failure, 38 Pr

Effects of permanent dual chamber pacing in end-stage dilated cardiomyopathy, 46 Pr

Implementation of guidelines for prescribing angiotensin converting enzyme inhibitors for the management of heart failure in hospital, 126 Pr

Inhalation of nitric oxide improves the cardiac output response to exercise in chronic heart failure, 135

Late potentials in chronic heart failure: correlation with prognostic markers from a multi-centre study of autonomic dysfunction in heart failure, 32 Pr

Long term results of heterotopic heart transplantation in patients with secondary pulmonary hypertension, 99 Pr

'Open access' echocardiography for suspected heart failure: would 12 lead electrocardiogram be just as good? 119 Pr

Painless myocardial ischaemia is an important factor in the genesis of effort intolerance in severe congestive heart failure due to coronary artery disease, 184 MPPr

Predictors and prevalence of nocturnal desaturation in patients with maximally treated stable cardiac failure, 43 Pr

Revascularisation in ischaemic cardiomyopathy: effects on exercise capacity and ejection fraction, 244

Suppression of chemosensitivity and the effects on exercise tolerance in patients with chronic heart failure, 134

The Network study. The effect of dose of an ACE-inhibitor on outcome in patients with heart failure, 185 MPPr

#### Heart rate variability

Changes in cardiac parasympathetic activity on induction to and acclimatization to hypobaric hypoxia, 26 Pr

Heart rate variability and signal averaged electrocardiography as predictors of clinical deterioration in patients with idiopathic dilated cardiomyopathy, 44 Pr

Impaired heart rate variability predicts increased mortality in hypertensive left ventricular hypertrophy, 141 MPPr

#### Heart transplantation

Functional and clinical significance of sympathetic reinnervation following cardiac transplantation, 107 Pr

Is routine endomyocardial biopsy essential for rejection surveillance in paediatric heart transplant recipients? 65 Pr

Long term results of heterotopic heart transplantation in patients with secondary pulmonary hypertension, 99 Pr

PTCA in allograft coronary disease – is it worthwhile? 245

Recipient atrial remnant: does it exhibit normal electrophysiology? 77 Pr

Routine coronary angiography after heart transplantation: time to stop, 220 MPPr

The prevalence and natural course of *Helicobacter pylori* among heart transplant recipients, 111

Use of chest x-ray (CXR) after biopsy of the transplanted heart, 219 MPPr

**Heat shock protein.** Association between antibodies to mycobacterial heat shock protein 65 and coronary atherosclerosis: possible mechanism of action of a *Helicobacter pylori* in increasing cardiovascular risk, 166 MPPr

#### *Helicobacter pylori*

Association between antibodies to mycobacterial heat shock protein 65 and coronary atherosclerosis: possible mechanism of action of a *Helicobacter pylori* in increasing cardiovascular risk, 166 MPPr

*Helicobacter pylori* infection and coronary heart disease in middle-aged men: prospective relations in a nested case-control study, 211 MPPr

*Helicobacter pylori* infection and coronary heart disease in north Glasgow, 212 MPPr

The prevalence and natural course of *Helicobacter pylori* among heart transplant recipients, 111

**Heparin**

Hirudin (<sup>TM</sup>Revasc) vs heparin after thrombolysis in acute myocardial infarction: preliminary results from the TIMI 9B study, 171  
 Role of heparin in the regulation of cardiac myocyte growth, 8 Pr

**Hibernating myocardium**

Can the TIMI-flow grade predict the presence of hibernating myocardium? 280 MPPr

Identification of hibernating myocardium: a comparison of TI-201, Tc-99m tetrofosmin, and dobutamine cine magnetic resonance imaging, 242

The role of <sup>18</sup>F-FDG SPET in detection of hibernating myocardium: comparison with rest-redistribution <sup>201</sup>Thallium SPET, 241

**High density lipoprotein/cholesterol risk**, The lipoprotein lipase gene locus associates with serum HDL and Apo-AI levels, 164 MPPr

**Hirudin**, Hirudin (<sup>TM</sup>Revasc) vs heparin after thrombolysis in acute myocardial infarction: preliminary results from the TIMI 9B study, 171

**HLA-types**, The aetiology of idiopathic dilated cardiomyopathy (DCM): familial prevalence and HLA-types, 202

**Homocysteine**

A gene mutation which contributes to coronary heart disease risk, 127 Pr

Serum total homocysteine and coronary heart disease in middle-aged British men, 180 JC

**Homograft**

Early results of a prospective randomized trial of homograft versus pulmonary autograft replacement of the aortic valve, 151

Long term results and echo assessment of homograft aortic valve replacement, 152

**Hypercholesterolaemia**

Dietary marine fish oil improves endothelial function in hypercholesterolaemic patients, 17 Pr

Endothelial function declines in hypercholesterolaemic women following the menopause, 36 Pr

Mechanisms of impaired vascular reactivity in insulin dependent diabetes mellitus and hypercholesterolaemia, 251 MPPr

**Hypertension**

Cerebral events after cardiac surgery, 273 MPPr

Cyclical mechanical strain induces plasminogen activator inhibitor-1 expression in human vascular smooth muscle cells, 258 MPPr

DD genotype of the angiotensin-converting enzyme (ACE) gene is associated with abnormal diastolic function in essential hypertension, 199

Impaired heart rate variability predicts increased mortality in hypertensive left ventricular hypertrophy, 141 MPPr

The hypertension and platelet activation of pre-eclampsia are reduced by S-nitrosoglutathione, 256 MPPr

**Hypertrophic cardiomyopathy**

Continuous coronary sinus pH monitoring during dipyridamole stress in patients with angina and hypertrophic cardiomyopathy, 272 JC

Gradient reduction following non-surgical septal reduction in hypertrophic obstructive cardiomyopathy is maintained over three month follow-up, 235 MPPr

Hypertrophic cardiomyopathy: new evidence suggests utility of ECG as a diagnostic tool, 131

Myotonin kinase gene (GTG)<sub>n</sub> repeat associates with hypertrophic cardiomyopathy, 45 Pr

Transmural velocity gradients – a new ultrasonic index for hypertrophic cardiomyopathy hearts, 61 Pr

**Hypoplastic left heart**, The results of applying echo data derived from critical aortic stenosis to infants with coarctation of the aorta, 158

**Hypotension**, Insulin mediated vasodilatation causes postprandial hypotension in the elderly, 42 Pr

**Hypoxia**

Changes in cardiac parasympathetic activity on induction to and acclimatization to hypobaric hypoxia, 26 Pr

Contrasting effect of NO synthase inhibition on LV function during early and late reoxygenation, 187 MPPr

Hypoxia alters the chemotactic and proliferative response of vascular smooth muscle cells to platelet-derived growth factor-BB, 21 Pr

**Immunosuppression**, The prevalence and natural course of *Helicobacter pylori* among heart transplant recipients, 111

**Implantable defibrillators**, Is routine pre-discharge testing necessary for patients with implantable defibrillators? 71 Pr

**Inflammation**, Vascular inflammation and its effects on smooth muscle and endothelial function: a study in healthy volunteers, A

**Inotropes**, Increases in systemic oxygen consumption offset improvements in systemic oxygen delivery during dobutamine infusion in newborn lambs, 39 Pr

**Inoue balloon**, Mitral balloon valvotomy in 300 consecutive patients using Inoue balloon technique, influence of mitral valve anatomy on the immediate and long term results, 136

**Insulin**

Insulin mediated vasodilatation causes postprandial hypotension in the elderly, 42 Pr

Positron emission tomography localises insulin resistance to skeletal muscle in premature coronary heart disease, 48 Pr

**Integrins**, The expression of  $\beta 1$  integrins by cultured human coronary artery vascular smooth muscle cells, 10 Pr

**Interleukin-1 $\beta$  converting enzyme**, Apoptosis of human umbilical vein endothelial cells (HUVEC) – role of interleukin-1 $\beta$  converting enzyme (ICE) and associated proteases, 11 Pr

**Interleukin-8**, Neutrophils are a source of interleukin-8 in human cardiopulmonary bypass surgery, 100 Pr

**Intimal hyperplasia**, Non-restrictive external stenting reduces medial and neointimal thickening in a pig model of arteriovenous bypass grafting, B

**Intimal proliferation**, Restenosis after balloon angioplasty: intimal hyperplasia or vessel remodelling? 88 Pr

**Intra-aortic balloon counterpulsation**, Stabilisation of refractory ventricular arrhythmias by intra-aortic balloon counterpulsation, 74 Pr

**Intramyocardial conduction**, Intramyocardial conduction abnormalities in idiopathic dilated cardiomyopathy may refine risk assessment, 216

**Intravascular ultrasound**

Can radiofrequency data analysis of intravascular ultrasound accurately characterize coronary atherosclerosis? 153

Incomplete expansion of stents despite high-pressure implantation: the role of intravascular ultrasound, 95 Pr

Intravascular ultrasound and stent implantation: intra- and inter-observer variability, 224 MPPr

Regression of atheroma seen with intravascular ultrasound: a placebo controlled study of the effect of gemfibrozil on peripheral atherosclerosis, 154

<sup>123</sup>**Iodine MIBG scintigraphy**, Functional and clinical significance of sympathetic reinnervation following cardiac transplantation, 107 Pr

**Ischaemia**

Can the QT interval be used to detect increased dispersion of repolarisation induced by ischaemia? 85 Pr

Can the TIMI-flow grade predict the presence of hibernating myocardium? 280 MPPr

Continuous coronary sinus pH monitoring during dipyridamole stress in patients with angina and hypertrophic cardiomyopathy, 272 JC

Preconditioning and the extracellular space: implications for ischaemia-induced changes in cell volume, 3 Pr

**Ischaemic cardiomyopathy**, Revascularisation in ischaemic cardiomyopathy: effects on exercise capacity and ejection fraction, 244

**Ischaemic heart disease**, Emergency admissions in London for acute myocardial infarction are associated with short-term increases in atmospheric pollution: are there any implications? 118 Pr

**Ischaemic myocardium**, Solute exchange in the ischaemic myocardium: the voltammetric hydrogen clearance technique and radioactive microspheres, 47 Pr

**Ischaemic preconditioning**

Comparison of ischaemic preconditioning and a highly selective ATP-dependent potassium channel opener in isolated human atrial muscle, 198

Ischaemic preconditioning attenuates myocardial stunning following repetitive exercise, 269 JC

Ischaemic preconditioning reduces troponin-T release in patients undergoing cardiac surgery, 240

**Isoprenaline**, Intravenous isoprenaline infusion to unmask gradients across the aortic arch during cardiac catheterization, 97 Pr

**Kidney**, Angiotensin-converting enzyme inhibition at non-hypotensive doses prevents development of malignant hypertension in a rat model, 9 Pr

**Kinase**

Expression of phospholemman 1-43 induces chloride currents in *Xenopus* oocytes, 6 Pr

Modulation of oocyte-expressed skeletal muscle sodium channels by NIMA kinase, 7 Pr

- L-arginine**, L-arginine reverses the age associated endothelial dysfunction in humans, 255 MP
- Lambs**, Thermal balloon angioplasty of experimental arterial stenoses in lambs: a pilot study, 23 Pr
- Late potentials**, Late potentials in chronic heart failure: correlation with prognostic markers from a multi-centre study of autonomic dysfunction in heart failure, 32 Pr
- Lead**, Chronic endocardial pacemaker lead extraction using the 'traction-countertraction' technique, 72 Pr
- Learning curve**, The learning curve for radiofrequency ablation is more than 160 procedures, 145 MP
- Left atrial thrombus**, Mitral valvuloplasty in patients with a left atrial thrombus despite conventional anticoagulation: use of aggressive anticoagulation, 236 MP
- Left ventricular diastolic filling**, DD genotype of the angiotensin-converting enzyme (ACE) gene is associated with abnormal diastolic function in essential hypertension, 199
- Left ventricular dysfunction**, Determinants of global left ventricular systolic dysfunction in north Glasgow, 266
- Left ventricular function**  
Changes in global and regional LV function following successful PTCA of a total coronary occlusion, 243  
Contrasting effect of NO synthase inhibition on LV function during early and late reoxygenation, 187 MP  
Cumulative and prolonged left ventricular dysfunction due to myocardial stunning following repetitive exercise-induced ischaemia, 181 MP  
Gated Tc-99m tetrofosmin SPECT in the assessment of left ventricular contractility: a comparison with cine magnetic resonance imaging, 53 Pr  
Postischaemic overshoot precedes exercise-induced myocardial stunning, 239  
Quantification of regional myocardial dysfunction using three-dimensional echocardiography allows accurate estimation of myocardial infarct mass *in vivo*, 62 Pr  
Remodeling of left ventricular function following aortic valve replacement using stentless valve, 102 Pr  
The value of QT dispersion in identifying patients with heart failure due to left ventricular systolic dysfunction, 25 Pr
- Left ventricular hypertrophy**  
A cellular basis for T wave inversion in cardiac hypertrophy? 188 MP  
Left ventricular hypertrophy is associated with abnormal thrombogenesis and endothelial dysfunction, 24 Pr  
Regional effects of cardiac hypertrophy: a basis for arrhythmogenesis? 189 MP
- Left ventricular mass/volume ratio**, Left ventricle mass/volume ratio does not predict early surgical outcome in infants older than 21 days undergoing arterial switch surgery for simple transposition of the great arteries, 70 Pr
- Lipids**  
Regression of atheroma seen with intravascular ultrasound: a placebo controlled study of the effect of gemfibrozil on peripheral atherosclerosis, 154  
Serum total cholesterol, HDL-cholesterol and non-fasting triglycerides, and eight-year coronary events in the follow-up of men and women in the Scottish Heart Health Study (SHHS), 120 Pr
- Lipoprotein lipase gene**, The lipoprotein lipase gene locus associates with serum HDL and Apo-AI levels, 164 MP
- Lipoproteins**  
The prognostic significance of lipoprotein(a) concentrations following myocardial infarction, 249  
The role of lipoprotein(a) in the pathogenesis of unstable angina, 34 Pr
- Long term follow up**, Balloon angioplasty of native coarctation in adults, long term follow up, 64 Pr
- Losartan**, Angiotensin II does not contribute to basal forearm vascular tone in healthy man, 12 Pr
- Low-cost transmission**, Low-cost transmission of cardiac angiograms between secondary and tertiary cardiac units, 207 MP
- Magnetic resonance imaging**  
Identification of hibernating myocardium: a comparison of TI-201, Tc-99m tetrofosmin, and dobutamine cine magnetic resonance imaging, 242  
Myocardial perfusion imaging performed using echo-planar single shot magnetic resonance imaging with a mobile 0.5 Tesla scanner, 225 MP
- Malignant hypertension**, Angiotensin-converting enzyme inhibition at non-hypotensive doses prevents development of malignant hypertension in a rat model, 9 Pr
- Mapping**  
Initial experience with mapping human endocardial activation using a novel non-contact catheter mapping system, 217  
Ventricular tachycardia of arrhythmogenic right ventricular disease – evidence for localised reentry from cardiac mapping, 218
- Measurement**, Objective assessment of activity in heart disease, 125 Pr
- Megakaryocytes**, The effect of cardiopulmonary bypass (CPB) on the circulating megakaryocytes, 109 Pr
- Menopause**, Endothelial function declines in hypercholesterolaemic women following the menopause, 36 Pr
- Metalloproteinases**, Expression of tissue inhibitors of metalloproteinases (TIMPS) in human saphenous vein, 159 MP
- MIBI imaging**, Technetium-sestamibi (MIBI) to estimate left ventricular fibrosis in patients considered for surgical conversion to arterial switch, 69 Pr
- Microcirculation**, Solute exchange in the ischaemic myocardium: the voltammetric hydrogen clearance technique and radioactive microspheres, 47 Pr
- Microspheres**, Diagnostic ultrasound intensities may destroy contrast microspheres *in-vivo*: implications for ultrasound perfusion imaging, 50 Pr
- Microvascular angina**, Vascular or myocardial abnormality in microvascular angina: thallium and technetium perfusion imaging compared, 54 Pr
- Microvascular stunning**, Progressive recovery of tissue perfusion following coronary artery bypass grafting: evidence of 'microvascular stunning' in man, 233 MP
- Minimal invasive coronary artery surgery**, Early experience with minimal invasive coronary artery bypass grafting, 232 MP
- Mitochondria**, Previously-reported mitochondrial DNA mutations are not a common cause of idiopathic dilated cardiomyopathy, 201
- Mitral balloon valvotomy**, Mitral balloon valvotomy in 300 consecutive patients using Inoue balloon technique, influence of mitral valve anatomy on the immediate and long term results, 136
- Mitral stenosis**, Mitral balloon valvotomy in 300 consecutive patients using Inoue balloon technique, influence of mitral valve anatomy on the immediate and long term results, 136
- Mitral valve surgery**  
Mitral valve surgery in the elderly, 110 Pr  
The importance of subvalvular preservation and early operation in mitral valve surgery, 278 MP
- Mitral valvuloplasty**, Mitral valvuloplasty in patients with a left atrial thrombus despite conventional anticoagulation: use of aggressive anticoagulation, 236 MP
- Mode switching**  
Do patients prefer mode switching? 215  
Is mode switching DDDR pacing superior to VVIR pacing following atrioventricular node ablation for refractory atrial fibrillation? 214
- Monocyte**, The effect of monocyte co-culture on smooth muscle cell proliferation, 19 Pr
- Mortality**  
Daily activity levels predict prognosis in patients with chronic heart failure, 38 Pr  
Prognostic significance of CK-MB elevation following ablative new-device angioplasty in native coronary arteries, 248
- Multilink stent**, Early results of the West European stent trial using the ACS Multilink™ stent, 230 MP
- Muscle atrophy**, Body composition and strength in chronic heart failure: reduced muscle efficiency in cardiac cachexia, 33 Pr
- Mustard's procedure**, Technetium-sestamibi (MIBI) to estimate left ventricular fibrosis in patients considered for surgical conversion to arterial switch, 69 Pr
- Myocardial biopsy**, Use of chest x-ray (CXR) after biopsy of the transplanted heart, 219 MP
- Myocardial contraction**, Assessment of steady state myofilament calcium response in intact isolated cardiac myocytes: modulation by the cardiac endothelium, 267 JC
- Myocardial damage**, Creatine kinase isoforms as circulating markers of deterioration in idiopathic dilated cardiomyopathy, 183 MP
- Myocardial infarction**  
Acute myocardial infarction presenting with primary ST depression: the need for early intervention, 170  
Anticoagulant effects of vitamin E treatment in patients with coronary disease, 282 MP  
Baseline assessment of plasma brain natriuretic peptide and simple clinical variables predict long-term left ventricular function following acute myocardial infarction, 31 Pr  
Brain natriuretic peptide (BNP) and simple clinical variables predict left ventricular dysfunction following myocardial infarction, 30 Pr

- Call-to-needle times in Grampian: the pivotal role of the general practitioner in achieving early thrombolysis, **205 MPr**
- Comparison of numerical indices of the wavelet and standard time-domain analysis of signal averaged electrocardiogram in survivors of acute myocardial infarction with and without follow-up events, **140 MPr**
- Coronary angioplasty is underused in the management of acute myocardial infarction, **91 Pr**
- Differences in short-term outcome for acute MI between Germany and the UK: the role of clinical trial data in the resource utilisation debate, **204 MPr**
- Direct admission to the coronary care unit by the ambulance service in patients with suspected myocardial infarction, **263**
- Early and late follow-up results of primary coronary angioplasty compared to intravenous streptokinase in acute myocardial infarction, **172**
- Emergency admissions in London for acute myocardial infarction are associated with short-term increases in atmospheric pollution: are there any implications? **118 Pr**
- Evidence for free radical generation following primary coronary angioplasty recanalisation in acute myocardial infarction, **1 Pr**
- Factors affecting uptake of cardiac rehabilitation in Glasgow, **208 MPr**
- Following myocardial infarction and thrombolysis, stress and nitroglycerine enhanced rest TL-201 imaging has superior prognostic value compared to redistribution imaging, **270 JC**
- Glucose-insulin-potassium (GIK) therapy for acute myocardial infarction: overview of randomised placebo controlled trials, **174**
- Hirudin (<sup>TM</sup>Revasc) vs heparin after thrombolysis in acute myocardial infarction: preliminary results from the TIMI 9B study, **171**
- Impaired baroreceptor sensitivity early after myocardial infarction is associated with ventricular dilatation, **133**
- Is the 'wait and see' strategy for invasive investigation post myocardial infarction flawed? **173**
- Measurement of streptokinase antibodies or inhibitors in blood: comparison of a rapid desk top test panel as conventional antibody and resistance assays, **28 Pr**
- Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to myocardial infarction in patients undergoing coronary angiography, **257 MPr**
- Post-infarct septal rupture – improvement in surgical outcome in the nineties, **103 Pr**
- Pre-discharge exercise testing in the prediction of cardiac events over 5 yrs following thrombolysis for acute myocardial infarction, **29 Pr**
- Prehospital versus hospital thrombolysis: an overview of randomised trials, **169**
- Quantification of regional myocardial dysfunction using three-dimensional echocardiography allows accurate estimation of myocardial infarct mass *in vivo*, **62 Pr**
- Reverse redistribution of thallium after myocardial infarction indicates low risk, **49 Pr**
- Should CK-MB be used to determine the cause of chest pain? **116 Pr**
- The influence of beta-blockade on rate dependent changes of the QT interval in acute myocardial infarction, **84 Pr**
- The pathway through myocardial infarction – effects of age, sex and socio-economic group, **264**
- The prognostic significance of lipoprotein(a) concentrations following myocardial infarction, **249**
- Three-dimensional contrast echocardiography in acute myocardial infarction: *in vivo* quantification of infarct mass, **271 JC**
- Variations in the management of acute myocardial infarction in one health region, **124 Pr**
- What do we do when thrombolysis fails? A United Kingdom survey, **265**
- Myocardial ischaemia**, Painless myocardial ischaemia is an important factor in the genesis of effort intolerance in severe congestive heart failure due to coronary artery disease, **184 MPr**
- Myocardial necrosis**, Ischaemic preconditioning reduces troponin-T release in patients undergoing cardiac surgery, **240**
- Myocardial perfusion imaging**, Comparison of arbutamine stress sestamibi SPECT imaging and echocardiography for the detection of coronary artery disease, **50 Pr**
- Myocardial protection**, Normothermic systemic perfusion does not compromise cold myocardial protection during coronary artery surgery, **106 Pr**
- Myocardial relaxation**, Differential left ventricular relaxant effects of -SH and non-SH containing ACE inhibitors, **200**
- Myocardial stunning**  
Cumulative and prolonged left ventricular dysfunction due to myocardial stunning following repetitive exercise-induced ischaemia, **181 MPr**
- Ischaemic preconditioning attenuates myocardial stunning following repetitive exercise, **269 JC**
- Postischaemic overshoot precedes exercise-induced myocardial stunning, **239**
- Myocardial viability**  
Gated rest 99 Tm MIBI-SPECT in the assessment of myocardial viability: comparison with 13 NH3/18 FDG PET, **56 Pr**
- Predictive value of FDG imaging in 502 patients with chronic ischaemic left ventricular dysfunction enrolled in a prospective European multicentre viability study, **226 MPr**
- Revascularisation in ischaemic cardiomyopathy: effects on exercise capacity and ejection fraction, **244**
- Myocardium**  
Cloning of human GATA-6: a new regulatory gene with a potential role in the control of myocardial differentiation and growth, **190 MPr**
- Myocardium from a chronic coronary artery ligation model has altered responses to reactive oxygen species, **2 Pr**
- New technologies for echocardiographic myocardial perfusion imaging, **228 MPr**
- Myocytes**  
Assessment of steady state myofilament calcium response in intact isolated cardiac myocytes: modulation by the cardiac endothelium, **267 JC**
- Could a reduction of basal myocyte cAMP contribute to the progression of heart failure? **186 MPr**
- In-situ hybridisation localises myocardial inducible nitric oxide synthase mRNA to non-myocyte cells during septic shock, **4 Pr**
- Role of heparin in the regulation of cardiac myocyte growth, **8 Pr**
- Thrombin – more than a thrombogenic mediator: activation of the cardiac sarcolemmal Na<sup>+</sup>/H<sup>+</sup> exchanger via the cloned thrombin receptor, **197**
- Myotonin kinase**, Myotonin kinase gene (GTG)<sub>n</sub> repeat associates with hypertrophic cardiomyopathy, **45 Pr**
- Na<sup>+</sup>/H<sup>+</sup> exchanger**, Thrombin – more than a thrombogenic mediator: activation of the cardiac sarcolemmal Na<sup>+</sup>/H<sup>+</sup> exchanger via the cloned thrombin receptor, **197**
- National survey**, A national survey of sudden unexpected cardiac or unexplained death in adults (SADS), **261**
- Natriuretic peptides**  
Baseline assessment of plasma brain natriuretic peptide and simple clinical variables predict long-term left ventricular function following acute myocardial infarction, **31 Pr**
- Brain natriuretic peptide (BNP) and simple clinical variables predict left ventricular dysfunction following myocardial infarction, **30 Pr**
- Neointimal hyperplasia**  
Local delivery of the gene for an amphipathic peptide inhibits neointimal hyperplasia, **192**
- Local gene transfer of the antisense to senescent cell-derived inhibitor 1 creates neointima, **194**
- Time sequence of changes in vessel wall urokinase-type plasminogen activator following experimental angioplasty, **195**
- Neonate**  
Balloon dilation of the aortic valve in neonatal critical aortic stenosis, **94 Pr**
- Outcome after transcatheter valvotomy for pulmonary valvar atresia and intact septum in neonates, **237 MPr**
- Neuropsychological functions**, A randomised study of the effects of cardiopulmonary bypass temperature on neuropsychological deficit after coronary artery surgery, **274 MPr**
- Newborn**, Increases in systemic oxygen consumption offset improvements in systemic oxygen delivery during dobutamine infusion in newborn lambs, **39 Pr**
- Nitric oxide**  
Adenoviral gene transfer of nitric oxide synthase to vascular cells, **193**
- Coronary artery vein graft platelet activation *in vivo* is inhibited by GSNO, **104 Pr**
- Exercise training enhances endothelial function in young men, **254 MPr**
- In-situ hybridisation localises myocardial inducible nitric oxide synthase mRNA to non-myocyte cells during septic shock, **4 Pr**
- Increased modulation by nitric oxide of dobutamine-induced pulmonary vasodilation during postnatal development in sheep, **22 Pr**
- Inhalation of nitric oxide improves the cardiac output response to exercise in chronic heart failure, **135**
- Mechanisms of impaired vascular reactivity in insulin dependent diabetes mellitus and hypercholesterolaemia, **251 MPr**

- Mechanotransduction through the endothelial cytoskeleton mediates flow- but not agonist-induced nitric oxide release, **168 MP**
- Platelet activation and deposition in saphenous vein grafts is inhibited *in vitro* by S-nitrosoglutathione, **15 Pr**
- The hypertension and platelet activation of pre-eclampsia are reduced by S-nitrosoglutathione, **256 MP**
- Nitric oxide synthase**, Contrasting effect of NO synthase inhibition on LV function during early and late reoxygenation, **187 MP**
- Noradrenaline**, Endothelin-1 plays a functional role in noradrenaline-induced ventricular hypertrophy *in vivo* and *in vitro*, **C**
- Normothermic systemic perfusion**, Normothermic systemic perfusion does not compromise cold myocardial protection during coronary artery surgery, **106 Pr**
- Oedema**, Non-invasive reduction of body water by using air flow kinetics, **112 Pr**
- Older patients**, Experience with the Fontan procedure in older patients, **63 Pr**
- Open access**
- Achieving effective use of general practitioner requested echocardiography: should access be open or targeted? **132**
- How should open access echocardiography be organised? Lessons from a directed access service, **117 Pr**
- 'Open access' echocardiography for suspected heart failure: would 12 lead electrocardiogram be just as good? **119 Pr**
- Oximetry**, Predictors and prevalence of nocturnal desaturation in patients with maximally treated stable cardiac failure, **43 Pr**
- Oxygen consumption**, Increases in systemic oxygen consumption offset improvements in systemic oxygen delivery during dobutamine infusion in newborn lambs, **39 Pr**
- P-selectin**, Peroxynitrite causes the expression of platelet P-selectin but inhibits the internalisation of GPIb, effects that might have important consequences in acute ischaemic syndromes, **162 MP**
- P wave**, Does the signal averaged P wave predict duration of sinus rhythm after cardioversion, **139 MP**
- Pacemaker (pacing)**
- Atrioventricular node ablation and implantation of dual chamber mode-switching pacemakers for paroxysmal atrial fibrillation – effects on quality of life, exercise capacity and left ventricular systolic function, **212**
- Audit of physician training in temporary cardiac pacing from District General Hospitals in the North West Region, **209 MP**
- Chronic endocardial pacemaker lead extraction using the 'traction-countertraction' technique, **72 Pr**
- Do patients prefer mode switching? **215**
- Effects of permanent dual chamber pacing in end-stage dilated cardiomyopathy, **46 Pr**
- Is mode switching DDDR pacing superior to VVIR pacing following atrioventricular node ablation for refractory atrial fibrillation? **214**
- Is routine pre-discharge testing necessary for patients with implantable defibrillators? **71 Pr**
- Pacing in children: single centre experience of 77 cases, **75 Pr**
- Paediatric**
- Balloon dilatation of critical aortic stenosis in neonates using an antegrade catheter approach, **67 Pr**
- Is routine endomyocardial biopsy essential for rejection surveillance in paediatric heart transplant recipients? **65 Pr**
- Left ventricle mass/volume ratio does not predict early surgical outcome in infants older than 21 days undergoing arterial switch surgery for simple transposition of the great arteries, **70 Pr**
- Modified ultrafiltration improves cardiac systolic and diastolic function immediately after cardiopulmonary bypass in children, **275 MP**
- Non-invasive reduction of body water by using air flow kinetics, **112 Pr**
- Pacing in children: single centre experience of 77 cases, **75 Pr**
- The differential effects of negative pressure ventilation (NPV) on cardiac output in children, **177 JC**
- Parasympathetic nervous system**, Changes in cardiac parasympathetic activity on induction to and acclimatization to hypobaric hypoxia, **26 Pr**
- Paroxysmal atrial fibrillation**, Atrioventricular node ablation and implantation of dual chamber mode-switching pacemakers for paroxysmal atrial fibrillation – effects on quality of life, exercise capacity and left ventricular systolic function, **212**
- Percutaneous transluminal coronary angioplasty**
- A new concept database for interventional cardiology: improving data collection with an advanced graphical user interface, **87 Pr**
- Balloon angioplasty of native coarctation in adults, long term follow up, **64 Pr**
- Balloon dilatation of critical aortic stenosis in neonates using an antegrade catheter approach, **67 Pr**
- Changes in global and regional LV function following successful PTCA of a total coronary occlusion, **243**
- Coronary angioplasty is underused in the management of acute myocardial infarction, **91 Pr**
- Coronary artery stenting reduces late clinical events in restenosis lesions: final results from the Trial of Angioplasty and Stents in Canada (TASC I), **148**
- Coronary stenting: cost implications for purchasers, **89 Pr**
- Coronary stenting for unstable angina is safe and effective, **86 Pr**
- Do de novo and restenosis lesions react differently to coronary intervention? Angiographic insights from the Trial of Angioplasty and Stents in Canada (TASC I), **229 MP**
- Does low inflation pressure and prolonged coronary dilatation strategy affect restenosis rate? Early and late results, **98 Pr**
- Early experience with the Prostar™ percutaneous vascular closure device in patients following coronary intervention, **96 Pr**
- Early and late follow-up results of primary coronary angioplasty compared to intravenous streptokinase in acute myocardial infarction, **172**
- Evidence for free radical generation following primary coronary angioplasty recanalisation in acute myocardial infarction, **1 Pr**
- Favourable arterial remodeling (defined as a negative absolute loss) after coronary angioplasty. A quantitative angiographic analysis, **222 MP**
- Prognostic significance of CK-MB elevation following ablative new-device angioplasty in native coronary arteries, **248**
- PTCA in allograft coronary disease – is it worthwhile? **245**
- Reduced QT dispersion with repeated ischaemia at angioplasty – evidence of an anti-arrhythmic effect of preconditioning in humans, **144 MP**
- Restenosis after balloon angioplasty: intimal hyperplasia or vessel remodelling? **88 Pr**
- Testing the appropriateness of coronary revascularisation: application of the University of Maryland Revascularisation Appropriateness Scoring System (RAS) to UK angioplasty practice, **221 MP**
- The importance of early quantitative exercise thallium-201 tomography after coronary angioplasty for predicting angina recurrence, **223 MP**
- Time sequence of changes in vessel wall urokinase-type plasminogen activator following experimental angioplasty, **195**
- Perfusion**
- A randomised study of the effects of cardiopulmonary bypass temperature on neuropsychological deficit after coronary artery surgery, **274 MP**
- Attenuation correction in thallium myocardial perfusion imaging, **57 Pr**
- Diagnostic ultrasound intensities may destroy contrast microspheres *in-vivo*: implications for ultrasound perfusion imaging, **50 Pr**
- Myocardial perfusion imaging performed using echo-planar single shot magnetic resonance imaging with a mobile 0.5 Tesla scanner, **225 MP**
- New technologies for echocardiographic myocardial perfusion imaging, **228 MP**
- Solute exchange in the ischaemic myocardium: the voltammetric hydrogen clearance technique and radioactive microspheres, **47 Pr**
- Thallium scans in patients with thyrotoxicosis, **55 Pr**
- Vascular or myocardial abnormality in microvascular angina: thallium and technetium perfusion imaging compared, **54 Pr**
- pH monitoring**, Continuous coronary sinus pH monitoring during dipyridamole stress in patients with angina and hypertrophic cardiomyopathy, **272 JC**
- Phospholemman**, Expression of phospholemman 1-43 induces chloride currents in *Xenopus* oocytes, **6 Pr**
- Physicians**, Audit of physician training in temporary cardiac pacing from District General Hospitals in the North West Region, **209 MP**
- Plasminogen activator inhibitor-1**
- Cyclical mechanical strain induces plasminogen activator inhibitor-1 expression in human vascular smooth muscle cells, **258 MP**
- Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to myocardial infarction in patients undergoing coronary angiography, **257 MP**
- Platelets**
- Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa antibody, **175 JC**
- Coronary artery vein graft platelet activation *in vivo* is inhibited by GSNO, **104 Pr**
- In-vitro* preparation, characterisation and antithrombogenicity of platelet-targeted urokinase immobilised to polymer coated stent wire, **247**



- Peroxyntirite causes the expression of platelet P-selectin but inhibits the internalisation of GPIb, effects that might have important consequences in acute ischaemic syndromes, **162 MPr**
- Platelet activation and deposition in saphenous vein grafts is inhibited *in vitro* by S-nitrosoglutathione, **15 Pr**
- The hypertension and platelet activation of pre-eclampsia are reduced by S-nitrosoglutathione, **256 MPr**
- Polymorphism**
- The fibrinogen gene G-143-A polymorphism influences the acute-phase response of serum fibrinogen to severe exercise, **196**
- The renin-angiotensin system and left ventricular hypertrophy: rat and human studies, **D**
- Positron emission tomography**
- Gated rest 99 Tm MIBI-SPECT in the assessment of myocardial viability: comparison with 13 NH3/18 FDG PET, **56 Pr**
- Positron emission tomography demonstrates normal myocardial perfusion after arterial switch operation in the neonatal period, **227 MPr**
- Positron emission tomography localises insulin resistance to skeletal muscle in premature coronary heart disease, **48 Pr**
- Predictive value of FDG imaging in 502 patients with chronic ischaemic left ventricular dysfunction enrolled in a prospective European multicentre viability study, **226 MPr**
- Post mortem findings**, Post mortem findings in assessing success of out of hospital resuscitation, **206 MPr**
- Postoperative care**, Non-invasive reduction of body water by using air flow kinetics, **112 Pr**
- Postprandial period**
- Insulin mediated vasodilatation causes postprandial hypotension in the elderly, **42 Pr**
- Postprandial worsening of angina: meal composition and timing are important determinants of onset of ischaemia and chest pain, **41 Pr**
- Posture**, Effects of posture on systemic arterial wave intensity in man, **35 Pr**
- Potassium channel blocker**, Comparison of ischaemic preconditioning and a highly selective ATP-dependent potassium channel opener in isolated human atrial muscle, **198**
- Potassium currents**, Differential effects of hypertrophy on regional density of the transient outward current, **5 Pr**
- Pre-eclampsia**, The hypertension and platelet activation of pre-eclampsia are reduced by S-nitrosoglutathione, **256 MPr**
- Preconditioning**
- Arrhythmic preconditioning in patients with variant angina, **73 Pr**
- Comparison of ischaemic preconditioning and a highly selective ATP-dependent potassium channel opener in isolated human atrial muscle, **198**
- Ischaemic preconditioning attenuates myocardial stunning following repetitive exercise, **269 JC**
- Ischaemic preconditioning reduces troponin-T release in patients undergoing cardiac surgery, **240**
- Preconditioning and the extracellular space: implications for ischaemia-induced changes in cell volume, **3 Pr**
- Reduced QT dispersion with repeated ischaemia at angioplasty – evidence of an anti-arrhythmic effect of preconditioning in humans, **144 MPr**
- Prevention**, Cost-efficacy of cholesterol lowering: West of Scotland Coronary Prevention Study versus the Scandinavian Simvastatin Survival Study, **250**
- Prognosis**
- Dobutamine stress echocardiography reliably predicts future cardiac events in patients undergoing diagnostic coronary angiography, **58 Pr**
- Following myocardial infarction and thrombolysis, stress and nitroglycerine enhanced rest TL-201 imaging has superior prognostic value compared to redistribution imaging, **270 JC**
- Is the 'wait and see' strategy for invasive investigation post myocardial infarction flawed? **173**
- Prognosis in patients with chest pain referred for outpatient cardiologic assessment, **128 Pr**
- The prognostic significance of lipoprotein(a) concentrations following myocardial infarction, **249**
- Prognostic markers**, Late potentials in chronic heart failure: correlation with prognostic markers from a multi-centre study of autonomic dysfunction in heart failure, **32 Pr**
- Proliferation**
- Hypoxia alters the chemotactic and proliferative response of vascular smooth muscle cells to platelet-derived growth factor-BB, **21 Pr**
- Role of heparin in the regulation of cardiac myocyte growth, **8 Pr**
- Promoters**, Gene expression after *in vitro* and *in vivo* gene transfer into VSMCs, **191**
- Prostar**, Early experience with the Prostar<sup>TM</sup> percutaneous vascular closure device in patients following coronary intervention, **96 Pr**
- Pulmonary atresia**, Outcome after transcatheter valvotomy for pulmonary valvar atresia and intact septum in neonates, **237 MPr**
- Pulmonary autograft**
- Early results of a prospective randomized trial of homograft versus pulmonary autograft replacement of the aortic valve, **151**
- The pulmonary autograft operation: long term results of the pioneer series, **276 MPr**
- Pulmonary circulation**
- Increased modulation by nitric oxide of dobutamine-induced pulmonary vasodilation during postnatal development in sheep, **22 Pr**
- Is the pulmonary circulation hypersensitive to endothelin-1 in endotoxaemia? **16 Pr**
- Pulmonary hypertension**, Long term results of heterotopic heart transplantation in patients with secondary pulmonary hypertension, **99 Pr**
- Pulmonary stenosis**, An experience of right heart stents in children, **68 Pr**
- QRS evolution**, QRS evolution and ventricular arrhythmias after repair of tetralogy of Fallot: the influence of operative techniques and postoperative physiology, **150**
- QRS morphology**, QRS morphology during AV node reentrant tachycardia, **76 Pr**
- QT dispersion**
- Baroreflex sensitivity and markers of ventricular repolarisation in asymptomatic diabetics, **81 Pr**
- Can the QT interval be used to detect increased dispersion of repolarisation induced by ischaemia? **85 Pr**
- QRS/QT/QT dispersion and symptomatic ventricular arrhythmias after repair of tetralogy of Fallot, **143 MPr**
- Reduced QT dispersion with repeated ischaemia at angioplasty – evidence of an anti-arrhythmic effect of preconditioning in humans, **144 MPr**
- The value of QT dispersion in identifying patients with heart failure due to left ventricular systolic dysfunction, **25 Pr**
- QT interval**
- Abnormal rate adaptation of the QT interval in patients with hypertensive left ventricular hypertrophy, **83**
- Morning increase in QT interval variability: implications for mechanisms underlying the circadian pattern of cardiac risk, **80 Pr**
- The influence of beta-blockade on rate dependent changes of the QT interval in acute myocardial infarction, **84 Pr**
- Quantitative angiography**, Favourable arterial remodeling (defined as a negative absolute loss) after coronary angioplasty. A quantitative angiographic analysis, **222 MPr**
- Radiofrequency ablation**, The learning curve for radiofrequency ablation is more than 160 procedures, **145 MPr**
- Radiofrequency data**, Can radiofrequency data analysis of intravascular ultrasound accurately characterize coronary atherosclerosis? **153**
- Radionuclide ventriculography**, Late ventricular activation identified with radionuclide ventriculography in arrhythmogenic right ventricular dysplasia, **52 Pr**
- Reactive oxygen species**, Myocardium from a chronic coronary artery ligation model has altered responses to reactive oxygen species, **2 Pr**
- Receptor regulation**, Angiotensin II receptor type 1 (AT1R) mRNA is upregulated in atria of patients with end-stage heart failure, **27 Pr**
- Recipient atrium**, Recipient atrial remnant: does it exhibit normal electrophysiology? **77 Pr**
- Reentry**
- Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of canine infarcts that cause ventricular tachycardia, **78 Pr**
- Ventricular tachycardia of arrhythmogenic right ventricular disease – evidence for localised reentry from cardiac mapping, **218**
- Rehabilitation**, Factors affecting uptake of cardiac rehabilitation in Glasgow, **208 MPr**
- Reinnervation**, Functional and clinical significance of sympathetic reinnervation following cardiac transplantation, **107 Pr**
- Remodelling**
- Adventitial changes following coronary artery balloon injury, **14 Pr**
- Favourable arterial remodeling (defined as a negative absolute loss) after coronary angioplasty. A quantitative angiographic analysis, **222 MPr**
- Impaired baroreceptor sensitivity early after myocardial infarction is associated with ventricular dilatation, **133**

- Renal failure**, Should patients receiving renal transplants undergo pre-operative cardiac investigation? 122 **Pr**
- Renin-angiotensin system**, Changes in expression of components of the renin-angiotensin system in post myocardial infarction heart failure and after ACE inhibitor treatment, 40 **Pr**
- Reperfusion**, What do we do when thrombolysis fails? A United Kingdom survey, 265
- Restenosis**  
 Adventitial changes following coronary artery balloon injury, 14 **Pr**  
 Coronary artery stenting reduces late clinical events in restenosis lesions: final results from the Trial of Angioplasty and Stents in Canada (TASC I), 148  
 Do de novo and restenosis lesions react differently to coronary intervention? Angiographic insights from the Trial of Angioplasty and Stents in Canada (TASC I), 229 **MPr**  
 Does low inflation pressure and prolonged coronary dilatation strategy affect restenosis rate? Early and late results, 98 **Pr**  
 Local delivery of the gene for an amphipathic peptide inhibits neointimal hyperplasia, 192  
 Local gene transfer of the antisense to senescent cell-derived inhibitor 1 creates neointima, 194  
 Restenosis after balloon angioplasty: intimal hyperplasia or vessel remodelling? 88 **Pr**  
 The importance of early quantitative exercise thallium-201 tomography after coronary angioplasty for predicting angina recurrence, 223 **MPr**
- Resuscitation**, Post mortem findings in assessing success of out of hospital resuscitation, 206 **MPr**
- Revascularisation**  
 Is the 'wait and see' strategy for invasive investigation post myocardial infarction flawed? 173  
 Revascularisation in ischaemic cardiomyopathy: effects on exercise capacity and ejection fraction, 244  
 Testing the appropriateness of coronary revascularisation: application of the University of Maryland Revascularisation Appropriateness Scoring System (RAS) to UK angioplasty practice, 221 **MPr**
- Risk factors**  
 Cholesterol – whom do we test and whom should we test? 114 **Pr**  
 Fibrinogen as a risk factor for coronary heart disease (CHD) in the eight-year follow-up of men and women in the Scottish Heart Health Study, 121 **Pr**  
 Low levels of coronary heart disease and risk factors in a UK Chinese population, 130 **Pr**  
 Mechanisms of impaired vascular reactivity in insulin dependent diabetes mellitus and hypercholesterolaemia, 251 **MPr**  
 Serum, total cholesterol, HDL-cholesterol and non-fasting triglycerides, and eight-year coronary events in the follow-up of men and women in the Scottish Heart Health Study (SHHS), 120 **Pr**
- Risk stratification**, Intramyocardial conduction abnormalities in idiopathic dilated cardiomyopathy may refine risk assessment, 216
- Ro/La antibodies**, Foetal echocardiographic screening of pregnancies at increased risk for foetal complete heart block, 66 **Pr**
- RR interval**, Abnormal rate adaptation of the QT interval in patients with hypertensive left ventricular hypertrophy, 83
- S-nitrosoglutathione**, The hypertension and platelet activation of pre-eclampsia are reduced by S-nitrosoglutathione, 256 **MPr**
- Saphenous vein**  
 Early response gene expression and vascular cell proliferation in human saphenous vein prepared for coronary bypass grafting, 279 **MPr**  
 Expression of tissue inhibitors of metalloproteinases (TIMPS) in human saphenous vein, 159 **MPr**
- Screening**, Achieving effective use of general practitioner requested echocardiography: should access be open or targeted? 132
- Senescent cell-derived inhibitor 1**, Local gene transfer of the antisense to senescent cell-derived inhibitor 1 creates neointima, 194
- Senning's procedure**, Technetium-sestamibi (MIBI) to estimate left ventricular fibrosis in patients considered for surgical conversion to arterial switch, 69 **Pr**
- Septal rupture**, Post-infarct septal rupture – improvement in surgical outcome in the nineties, 103 **Pr**
- Septic shock (sepsis)**  
 In-situ hybridisation localises myocardial inducible nitric oxide synthase mRNA to non-myocyte cells during septic shock, 4 **Pr**  
 Is the pulmonary circulation hypersensitive to endothelin-1 in endotoxaemia? 16 **Pr**
- Shear stress**, Mechanotransduction through the endothelial cytoskeleton mediates flow- but not agonist-induced nitric oxide release, 168 **MPr**
- Signal averaged electrocardiogram**, Heart rate variability and signal averaged electrocardiography as predictors of clinical deterioration in patients with idiopathic dilated cardiomyopathy, 44 **Pr**
- Signal averaging**  
 Comparison of numerical indices of the wavelet and standard time-domain analysis of signal averaged electrocardiogram in survivors of acute myocardial infarction with and without follow-up events, 140 **MPr**  
 Does the signal averaged P wave predict duration of sinus rhythm after cardioversion, 139 **MPr**  
 Prediction of atrial fibrillation after coronary artery bypass surgery, 138 **MPr**
- Single ventricle**, Univentricular heart with systemic outflow obstruction: the primary Damus procedure as an alternative to pulmonary banding, 238 **MPr**
- Skeletal muscle metabolism**, Abnormalities of skeletal muscle metabolism are present at rest in congestive heart failure: relationship between these abnormalities and symptoms, 37 **Pr**
- Sleep apnoea**, Predictors and prevalence of nocturnal desaturation in patients with maximally treated stable cardiac failure, 43 **Pr**
- Socio-economic group**, The pathway through myocardial infarction – effects of age, sex and socio-economic group, 264
- Sodium channel**, Modulation of oocyte-expressed skeletal muscle sodium channels by NIMA kinase, 7 **Pr**
- Sodium/H<sup>+</sup> exchanger**, Thrombin – more than a thrombogenic mediator: activation of the cardiac sarcolemmal Na<sup>+</sup>/H<sup>+</sup> exchanger via the cloned thrombin receptor, 197
- Solid-state activity monitoring**, Objective assessment of activity in heart disease, 125 **Pr**
- ST depression**, Acute myocardial infarction presenting with primary ST depression: the need for early intervention, 170
- Stellate ganglion blockade**, Complementary role of stellate ganglion blockade and thoracoscopic sympathectomy in the management of intractable angina, 147
- Stent**  
 An experience of right heart stents in children, 68 **Pr**  
 Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIB/IIIA antibody, 175 **JC**  
 Changes in global and regional LV function following successful PTCA of a total coronary occlusion, 243  
 Changing from aggressive anticoagulation to treatment with aspirin alone for coronary stents: the experience of one centre in the UK, 92 **Pr**  
 Coronary artery stenting reduces late clinical events in restenosis lesions: final results from the Trial of Angioplasty and Stents in Canada (TASC I), 148  
 Coronary stenting: cost implications for purchasers, 89 **Pr**  
 Coronary stenting for unstable angina is safe and effective, 86 **Pr**  
 Coronary stenting without anticoagulation or intravascular ultrasound: a retrospective analysis, 231 **MPr**  
 Do de novo and restenosis lesions react differently to coronary intervention? Angiographic insights from the Trial of Angioplasty and Stents in Canada (TASC I), 229 **MPr**  
 Early experience with the Prostar<sup>TM</sup> percutaneous vascular closure device in patients following coronary intervention, 96 **Pr**  
 Early results of the West European stent trial using the ACS Multilink<sup>TM</sup> stent, 230 **MPr**  
 In-vitro preparation, characterisation and antithrombogenicity of platelet-targeted urokinase immobilised to polymer coated stent wire, 247  
 Incomplete expansion of stents despite high-pressure implantation: the role of intravascular ultrasound, 95 **Pr**  
 Intra-coronary stent deployment: is antiplatelet therapy sufficient? 93 **Pr**  
 Intravascular ultrasound and stent implantation: intra- and inter-observer variability, 224 **MPr**  
 Is reduced anticoagulation effective following optimal stent deployment? 90 **Pr**  
 Palmaz Schatz stent deployment without intravascular ultrasound guidance using antiplatelet therapy with aspirin alone, 246
- Streptokinase**  
 Early and late follow-up results of primary coronary angioplasty compared to intravenous streptokinase in acute myocardial infarction, 172  
 Measurement of streptokinase antibodies or inhibitors in blood: comparison of a rapid desk top test panel as conventional antibody and resistance assays, 28 **Pr**
- Stroke**, Cerebral events after cardiac surgery, 273 **MPr**
- Stunned myocardium**, Progressive recovery of tissue perfusion following coronary artery bypass grafting: evidence of 'microvascular stunning' in man, 233 **MPr**



**Substance P**, Effect of intra-arterial substance P on the release of tissue plasminogen activator in the human forearm, 13 Pr

**Subvalvular preservation**, The importance of subvalvular preservation and early operation in mitral valve surgery, 278 MPr

#### **Sudden death**

28-day case fatality of coronary events, and the proportion of out of hospital deaths, in relation to age, sex and previous coronary heart disease (CHD): the Glasgow MONICA project, 203 MPr

A national survey of sudden unexpected cardiac or unexplained death in adults (SADS), 261

**Sympathectomy**, Complementary role of stellate ganglion blockade and thoracoscopic sympathectomy in the management of intractable angina, 147

#### **Syndrome X**

Endothelial function of the brachial artery is not impaired in patients with syndrome X, 252 MPr

Localised endothelial dysfunction in patients with chest pain and normal coronary arteriograms, 253 MPr

**Technetium**, Late ventricular activation identified with radionuclide ventriculography in arrhythmogenic right ventricular dysplasia, 52 Pr

**Technetium imaging**, Vascular or myocardial abnormality in microvascular angina: thallium and technetium perfusion imaging compared, 54 Pr

**Telemedicine**, Low-cost transmission of cardiac angiograms between secondary and tertiary cardiac units, 207 MPr

**Temperature**, A randomised study of the effects of cardiopulmonary bypass temperature on neuropsychological deficit after coronary artery surgery, 274 MPr

#### **Tetralogy of Fallot**

QRS evolution and ventricular arrhythmias after repair of tetralogy of Fallot: the influence of operative techniques and postoperative physiology, 150

QRS/QT/QT dispersion and symptomatic ventricular arrhythmias after repair of tetralogy of Fallot, 143 MPr

#### **Tetrofosmin**

Gated Tc-99m tetrofosmin SPECT in the assessment of left ventricular contractility: a comparison with cine magnetic resonance imaging, 53 Pr

Identification of hibernating myocardium: a comparison of TI-201, Tc-99m tetrofosmin, and dobutamine cine magnetic resonance imaging, 242

#### **Thallium imaging**

Arbutamine blood pool ventriculography: an alternative to exercise thallium scintigraphy? 51 Pr

Attenuation correction in thallium myocardial perfusion imaging, 57 Pr

Following myocardial infarction and thrombolysis, stress and nitroglycerine enhanced rest TL-201 imaging has superior prognostic value compared to redistribution imaging, 270 JC

Identification of hibernating myocardium: a comparison of TI-201, Tc-99m tetrofosmin, and dobutamine cine magnetic resonance imaging, 242

Reverse redistribution of thallium after myocardial infarction indicates low risk, 49 Pr

Thallium scans in patients with thyrotoxicosis, 55 Pr

The importance of early quantitative exercise thallium-201 tomography after coronary angioplasty for predicting angina recurrence, 223 MPr

The role of <sup>18</sup>F-FDG SPET in detection of hibernating myocardium: comparison with rest-redistribution <sup>201</sup>Thallium SPET, 241

Vascular or myocardial abnormality in microvascular angina: thallium and technetium perfusion imaging compared, 54 Pr

**Thermal balloon angioplasty**, Thermal balloon angioplasty of experimental arterial stenoses in lambs: a pilot study, 23 Pr

#### **Three-dimensional echocardiography**

Quantification of regional myocardial dysfunction using three-dimensional echocardiography allows accurate estimation of myocardial infarct mass *in vivo*, 62 Pr

Three-dimensional contrast echocardiography in acute myocardial infarction: *in vivo* quantification of infarct mass, 271 JC

Three-dimensional definition of atrial septal defect by Doppler myocardial imaging, 157

Three-dimensional reconstruction of *in vivo* colour Doppler flow events – initial experience, 156

Two new ultrasound modalities – harmonic imaging and triggered mode – improve delineation of myocardial perfusion defects by three-dimensional contrast echocardiography, 155

**Thrombin**, Thrombin – more than a thrombogenic mediator: activation of the cardiac sarcolemmal Na<sup>+</sup>/H<sup>+</sup> exchanger via the cloned thrombin receptor, 197

**Thrombogenesis**, Left ventricular hypertrophy is associated with abnormal thrombogenesis and endothelial dysfunction, 24 Pr

#### **Thrombolysis**

Call-to-needle times in Grampian: the pivotal role of the general practitioner in achieving early thrombolysis, 205 MPr

Coronary angioplasty is underused in the management of acute myocardial infarction, 91 Pr

Following myocardial infarction and thrombolysis, stress and nitroglycerine enhanced rest TL-201 imaging has superior prognostic value compared to redistribution imaging, 270 JC

Hirudin (<sup>TM</sup>Revasc) vs heparin after thrombolysis in acute myocardial infarction: preliminary results from the TIMI 9B study, 171

Pre-discharge exercise testing in the prediction of cardiac events over 5 yrs following thrombolysis for acute myocardial infarction, 29 Pr

Prehospital versus hospital thrombolysis: an overview of randomised trials, 169

Reverse redistribution of thallium after myocardial infarction indicates low risk, 49 Pr

What do we do when thrombolysis fails? A United Kingdom survey, 265

#### **Thrombosis**

Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIB/IIIA antibody, 175 JC

Intra-coronary stent deployment: is antiplatelet therapy sufficient? 93 Pr

Prothrombotic importance of the Factor V Leiden genotype mutation in acute coronary syndromes, 18 Pr

Spatial and temporal changes in tissue factor protein expression in experimental venous bypass grafts, 165 MPr

**Thyrotoxicosis**, Thallium scans in patients with thyrotoxicosis, 55 Pr

#### **Ticlopidine**

Coronary stenting without anticoagulation or intravascular ultrasound: a retrospective analysis, 231 MPr

Intra-coronary stent deployment: is antiplatelet therapy sufficient? 93 Pr

**Time to thrombolysis**, Direct admission to the coronary care unit by the ambulance service in patients with suspected myocardial infarction, 263

**TIMI-flow grade**, Can the TIMI-flow grade predict the presence of hibernating myocardium? 280 MPr

**Tissue factor**, Spatial and temporal changes in tissue factor protein expression in experimental venous bypass grafts, 165 MPr

**Tissue plasminogen activator**, Effect of intra-arterial substance P on the release of tissue plasminogen activator in the human forearm, 13 Pr

**Total body water**, Non-invasive reduction of body water by using air flow kinetics, 112 Pr

**Total cavopulmonary connection**, Incidence and determinants of arrhythmia following total cavopulmonary connection: a prospective study of 119 cases, 142 MPr

**Total coronary occlusion**, Changes in global and regional LV function following successful PTCA of a total coronary occlusion, 243

**Traction-countertraction pacemaker**, Chronic endocardial pacemaker lead extraction using the 'traction-countertraction' technique, 72 Pr

**Training**, Audit of physician training in temporary cardiac pacing from District General Hospitals in the North West Region, 209 MPr

**Transcatheter valvotomy**, Outcome after transcatheter valvotomy for pulmonary valvar atresia and intact septum in neonates, 237 MPr

**Transforming growth factor-β**, Plasma levels of active transforming growth factor-β are reduced in patients with three vessel coronary artery disease, 259 MPr

#### **Transposition**

Left ventricle mass/volume ratio does not predict early surgical outcome in infants older than 21 days undergoing arterial switch surgery for simple transposition of the great arteries, 70 Pr

Positron emission tomography demonstrates normal myocardial perfusion after arterial switch operation in the neonatal period, 227 MPr

**Trial**, Early results of the West European stent trial using the ACS Multilink<sup>TM</sup> stent, 230 MPr

**Triggered mode ultrasound**, Two new ultrasound modalities – harmonic imaging and triggered mode – improve delineation of myocardial perfusion defects by three-dimensional contrast echocardiography, 155

**Troponin**, Normothermic systemic perfusion does not compromise cold myocardial protection during coronary artery surgery, **106 Pr**

**Troponin-T**  
Admission coagulation activation in patients with unstable angina in relation to cardiac troponin T concentrations, **281 MPr**  
Ischaemic preconditioning reduces troponin-T release in patients undergoing cardiac surgery, **240**

**Tumor necrosis factor  $\alpha$** , The effect of monocyte co-culture on smooth muscle cell proliferation, **19 Pr**

**Ultrafiltration**, Modified ultrafiltration improves cardiac systolic and diastolic function immediately after cardiopulmonary bypass in children, **275 MPr**

**Unexplained death**, A national survey of sudden unexpected cardiac or unexplained death in adults (SADS), **261**

**Univentricular heart**, Univentricular heart with systemic outflow obstruction: the primary Damus procedure as an alternative to pulmonary banding, **238 MPr**

**Urokinase**  
In-vitro preparation, characterisation and antithrombogenicity of platelet-targeted urokinase immobilised to polymer coated stent wire, **247**  
Time sequence of changes in vessel wall urokinase-type plasminogen activator following experimental angioplasty, **195**

**Valve prosthesis**, Remodeling of left ventricular function following aortic valve replacement using stentless valve, **102 Pr**

**Valve resistance**, Left ventricular mass correlates better with valve resistance than effective orifice area in aortic stenosis, **59 Pr**

**Valve surgery**, The pulmonary autograft operation: long term results of the pioneer series, **276 MPr**

**Valves**, Radiographic evaluation of Björk-Shiley Convexo-Concave valves, **178 JC**

**Variability**, Intravascular ultrasound and stent implantation: intra- and interobserver variability, **224 MPr**

**Vascular grafts**  
Aortic root replacement with a zero porosity gelatin-impregnated composite graft, **108 Pr**  
Early response gene expression and vascular cell proliferation in human saphenous vein prepared for coronary bypass grafting, **279 MPr**

**Vascular smooth muscle cells**  
Adenoviral gene transfer of nitric oxide synthase to vascular cells, **193**  
Aquaporin-1 is expressed in rat and human arteries and may play a role in vascular function in health and disease, **268 JC**  
*c-fms* proto-oncogene expression is increased in endothelial and smooth muscle cells following vascular grafting, **161 MPr**  
Cyclical mechanical strain induces plasminogen activator inhibitor-1 expression in human vascular smooth muscle cells, **258 MPr**  
Gene expression after in vitro and in vivo gene transfer into VSMCs, **191**  
Gene expression from the cytomegalovirus immediate early promoter in embryonic, neonatal and adult rat vascular smooth muscle cells, **160 MPr**  
Hypoxia alters the chemotactic and proliferative response of vascular smooth muscle cells to platelet-derived growth factor-BB, **21 Pr**  
The effect of monocyte co-culture on smooth muscle cell proliferation, **19 Pr**  
The expression of  $\beta 1$  integrins by cultured human coronary artery vascular smooth muscle cells, **10 Pr**

**Vasoconstriction**, Localised endothelial dysfunction in patients with chest pain and normal coronary arteriograms, **253 MPr**

**Vein graft**  
Adenoviral gene transfer to venous bypass grafts and native vessels: a comparative study, **163 MPr**  
Coronary artery vein graft platelet activation *in vivo* is inhibited by GSNO, **104 Pr**

Non-restrictive external stenting reduces medial and neointimal thickening in a pig model of arteriovenous bypass grafting, **B**

**Platelet activation and deposition in saphenous vein grafts is inhibited in vitro by S-nitrosoglutathione**, **15 Pr**

**Spatial and temporal changes in tissue factor protein expression in experimental venous bypass grafts**, **165 MPr**

**Venous collaterals**, Systemic venous collaterals after the bidirectional cavopulmonary anastomosis – prevalence and risk factors, **149**

**Ventilation**, The differential effects of negative pressure ventilation (NPV) on cardiac output in children, **177 JC**

**Ventricular arrhythmia**  
Can the QT interval be used to detect increased dispersion of repolarisation induced by ischaemia? **85 Pr**  
Intramyocardial conduction abnormalities in idiopathic dilated cardiomyopathy may refine risk assessment, **216**  
QRS evolution and ventricular arrhythmias after repair of tetralogy of Fallot: the influence of operative techniques and postoperative physiology, **150**

**Ventricular function**, Modified ultrafiltration improves cardiac systolic and diastolic function immediately after cardiopulmonary bypass in children, **275 MPr**

**Ventricular hypertrophy**  
Abnormal rate adaptation of the QT interval in patients with hypertensive left ventricular hypertrophy, **83**  
Differential effects of hypertrophy on regional density of the transient outward current, **5 Pr**  
Endothelin-1 plays a functional role in noradrenaline-induced ventricular hypertrophy *in vivo* and *in vitro*, **C**  
Impaired heart rate variability predicts increased mortality in hypertensive left ventricular hypertrophy, **141 MPr**  
The renin-angiotensin system and left ventricular hypertrophy: rat and human studies, **D**

**Ventricular tachycardia**  
Arrhythmic preconditioning in patients with variant angina, **73 Pr**  
Comparison of numerical indices of the wavelet and standard time-domain analysis of signal averaged electrocardiogram in survivors of acute myocardial infarction with and without follow-up events, **140 MPr**  
Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of canine infarcts that cause ventricular tachycardia, **78 Pr**  
Initial experience with mapping human endocardial activation using a novel non-contact catheter mapping system, **217**  
Is routine pre-discharge testing necessary for patients with implantable defibrillators? **71 Pr**  
QRS/QT/QT dispersion and symptomatic ventricular arrhythmias after repair of tetralogy of Fallot, **143 MPr**  
Stabilisation of refractory ventricular arrhythmias by intra-aortic balloon counterpulsation, **74 Pr**  
Ventricular tachycardia of arrhythmogenic right ventricular disease – evidence for localised reentry from cardiac mapping, **218**

**Ventriculography**, Arbutamine blood pool ventriculography: an alternative to exercise thallium scintigraphy? **51 Pr**

**Vitamin E**  
A randomised controlled trial of vitamin E in patients with coronary disease: the Cambridge Heart Antioxidant Study (CHAOS), **176 JC**  
Anticoagulant effects of vitamin E treatment in patients with coronary disease, **282 MPr**

**Voltammetric hydrogen clearance technique**, Solute exchange in the ischaemic myocardium: the voltammetric hydrogen clearance technique and radioactive microspheres, **47 Pr**

**Water channels**, Aquaporin-1 is expressed in rat and human arteries and may play a role in vascular function in health and disease, **268 JC**

**Wave intensity**, Effects of posture on systemic arterial wave intensity in man, **35 Pr**

